EP4720121A1 - Molécules de liaison à l'antigène immunostimulatrices se liant spécifiquement à bcma - Google Patents

Molécules de liaison à l'antigène immunostimulatrices se liant spécifiquement à bcma

Info

Publication number
EP4720121A1
EP4720121A1 EP24730639.2A EP24730639A EP4720121A1 EP 4720121 A1 EP4720121 A1 EP 4720121A1 EP 24730639 A EP24730639 A EP 24730639A EP 4720121 A1 EP4720121 A1 EP 4720121A1
Authority
EP
European Patent Office
Prior art keywords
seq
amino acid
acid sequence
antigen binding
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24730639.2A
Other languages
German (de)
English (en)
Inventor
Marlene BIEHL
Alexander Christian BUJOTZEK
Alejandro CARPY GUTIERREZ CIRLOS
Jan ECKMANN
Tanja FAUTI
Algirdas GREVYS
Carina HAGE
Christian Klein
Julia Krueger
Stefan Lorenz
Céline MARBAN-DORAN
Pablo Umaña
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of EP4720121A1 publication Critical patent/EP4720121A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • CAR-T cells are one of the promising novel treatment modalities: early data from these agents show significant efficacy, and promise to bring major improvements to the treatment of MM. Nevertheless, as already seen with CAR-T therapies in the treatment of non-Hodgkin lymphoma (NHL), these treatment modalities are associated with similar liabilities to agents already seen for the treatment of NHL - especially early toxicity from cytokine release syndrome and/or associated neurotoxicity as well as limitations with regard to accessibility.
  • NHL non-Hodgkin lymphoma
  • T cell bispecific antibodies offer another promising immunotherapeutic approach by binding and stimulating CD3 independently from antigen presentation on major histocompatibility complex (MHC) class I.
  • MHC major histocompatibility complex
  • T-cells are redirected to TA-positive MM cells to induce their specific lysis.
  • New classes of bispecific antibodies mimicking signal 2 comprise molecules that target a tumor-specific antigen (TA) and a co-stimulatory receptor (e.g. 0X40, GITR, CD137, ICOS or CD28). Combining these bispecific antibodies with the emerging class of TCBs may provide potent “synthetic off-the-shelf CAR T cell-like” antibody therapies to further deepen and prolong the TCB-mediated anti-tumor responses in patients.
  • BCMA B cell maturation antigen
  • TNFRSF17 tumor necrosis factor receptor superfamily 17
  • CAR immunomodulatory drug
  • 4-1BB (CD137), a member of the TNF receptor superfamily, was first identified as an inducible molecule expressed by activated T cells (Kwon and Weissman, 1989, Proc Natl Acad Sci USA 86, 1963-1967). Subsequent studies demonstrated that many other immune cells also express 4-1BB, including NK cells, B cells, NKT cells, monocytes, neutrophils, mast cells, dendritic cells (DCs) and cells of non-hematopoietic origin such as endothelial and smooth muscle cells (Vinay and Kwon, 2011, Cell Mol Immunol 8, 281-284).
  • TCR T-cell receptor
  • B-cell receptor triggering signaling induced through co-stimulatory molecules or receptors of pro-inflammatory cytokines
  • Co-stimulation through the 4-1BB receptor activates multiple signaling cascades within the T cell (both CD4+ and CD8+ subsets), powerfully augmenting T cell activation.
  • agonistic 4-lBB-specific antibodies enhance proliferation of T-cells, stimulate lymphokine secretion and decrease sensitivity of T-lymphocytes to activation-induced cells death (Snell et al., 2011, Immunol Rev 244, 197-217). This mechanism was further advanced as the first proof of concept in cancer immunotherapy.
  • 4-1BB usually exhibits its potency as an anti-tumor agent mainly when administered in combination with other immunomodulatory compounds, chemotherapeutic reagents, tumor-specific vaccination or radiotherapy (Bartkowiak and Curran, 2015, Front Oncol 5, 117).
  • an Fc-competent 4-1BB agonistic Ab (BMS-663513) (NCT00612664) caused a grade 4 hepatitis in the clinic, leading to termination of the trial (Simeone and Ascierto, 2012, J Immunotoxicol 9, 241-247). Therefore, a targeted delivery of an 4-1BB agonist to the tumor side may be an option for eliciting antitumor efficacy and avoiding a systemic toxicity. There is a strong need to provide BCMA-targeted 4-1BB agonists with advantageous properties.
  • the present invention describes new BCMA-targeted 4-1BB agonists which achieve a tumor-dependent T cell activation without a systemic toxicity.
  • the BCMA-4-1BBL antigen binding molecules of the invention were constructed with an IgG fusion protein composed of a split trimeric 4-1BB ligand comprising the amino acid sequence of SEQ ID NO:9 or SEQ ID NOTO (which corresponds to the natural ligand), and a tumor antigen targeting moiety recognizing BCMA fused to a an Fc domain composed of a first and a second subunit capable of stable association comprising one or more amino acid substitution that reduces the binding affinity of the antigen binding molecule to an Fc receptor and/or effector function (silent Fc domain).
  • Fc receptor-mediated cross-linking is thereby abrogated and tumor-specific activation is achieved by cross-linking through binding of the second antigen binding domain capable of specific binding to BCMA.
  • unspecific FcyR mediated crosslinking responsible for Fc- mediated toxicity is replaced by BCMA-targeted MM cell specific crosslinking.
  • the desired mode of action for these molecules is to enhance the effector function of tumor-infiltrating T cells or NK cells upon activation by a tumor-targeted T cell bispecific antibody or ADCC antibody, respectively. As such these molecules are considered to have the potency to treat multiple myeloma.
  • the invention relates to new antigen binding molecules that bind to B cell maturation antigen (BCMA), in particular to new optimized respective humanized BCMA antibodies and to BCMA targeting 4-1BBL trimer-containing antigen binding molecules comprising these BCMA antibodies as well as their use in the treatment of cancer.
  • BCMA B cell maturation antigen
  • the invention further relates to methods of producing these molecules and to methods of using the same.
  • the BCMA targeting 4-1 BBL trimer-containing antigen binding molecules are active in presence of BCMA-expressing tumors, comprise the natural human 4-1BB ligand and should thus impose less safety issues compared to conventional 4-1BB agonistic antibodies or more artificial fusion proteins.
  • the new antigen binding molecules combine an anti-BCMA antigen binding domain with a moiety that is capable of forming a costimulatory 4-1BBL trimer and that is sufficiently stable to be pharmaceutically useful.
  • the immunostimulatory antigen binding molecules of the invention provide a trimeric and thus biologically active human 4- IBB ligand, although one of the trimerizing 4-1BBL ectodomains is located on another polypeptide than the other two 4-1BBL ectodomains of the molecule.
  • an immunostimulatory antigen binding molecule that specifically binds to B cell maturation agent (BCMA), comprising
  • VH BCMA heavy chain variable region
  • VLBCMA light chain variable region
  • VL comprising a light chain complementary determining region CDR-L1 of SEQ ID NO: 4 (RASES VSH4GTHLMH), a CDR-L2 of SEQ ID NO: 5 (AASSLQS) and a CDR-L3 of SEQ ID NO: 6 (QQSIEDPYT); and
  • VL comprising a light chain complementary determining region CDR-L1 of SEQ ID NO: 4 (RASES VSH4GTHLMH), a CDR-L2 of SEQ ID NO: 7 (AASNLES) and a CDR-L3 of SEQ ID NO: 6 (QQSIEDPYT), and
  • VL comprising a light chain complementary determining region CDR-L1 of SEQ ID NO: 4 (RASES VSH4GTHLMH), a CDR-L2 of SEQ ID NO: 8 (AASNLQS) and a CDR- L3 of SEQ ID NO: 6 (QQSIEDPYT),
  • the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of 4-1BBL each comprising the amino acid sequence of SEQ ID NOV or SEQ ID NO: 10 that are connected to each other by a peptide linker, and in that the second polypeptide comprises one ectodomain of 4-1BBL omprising the amino acid sequence of SEQ ID NOV or SEQ ID NO: 10, and
  • an immunostimulatory antigen binding molecule as defined above, wherein the ectodomain of 4-1BBL or a fragment thereof comprises the amino acid sequence of SEQ ID NO:9 or SEQ ID NO: 10.
  • the ectodomain of 4- 1BBL or a fragment thereof comprises the amino acid sequence of SEQ ID NO:9.
  • the immunostimulatory antigen binding molecule comprises three ectodomains of 4-1BBL each comprising the amino acid sequence of SEQ ID NO:9 or SEQ ID NO: 10, particularly the amino acid sequence of SEQ ID NO: 9.
  • an immunostimulatory antigen binding molecule as defined above, wherein the immunostimulatory antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 189 and SEQ ID NO: 190 and in that the second polypeptide comprises the amino acid sequence of SEQ ID NO:9 or SEQ ID NO: 10.
  • the immunostimulatory antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence of SEQ ID NO: 11 and in that the second polypeptide comprises the amino acid sequence of SEQ ID NO:9.
  • an immunostimulatory antigen binding molecule as defined above, wherein the antigen binding domain comprises
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13
  • VLBCMA comprising an amino acid sequence of SEQ ID NO: 15, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13
  • VLBCMA comprising an amino acid sequence of SEQ ID NO: 16.
  • the antibody that specifically binds to BCMA comprises an IgG Fc domain composed of a first and a second subunit.
  • the IgG Fc domain composed of a first and a second subunit is an IgGl Fc domain.
  • the IgG Fc domain is a human Fc domain.
  • the IgG Fc domain comprises a modification promoting the association of the first and the second subunit of the Fc domain.
  • the Fc domain comprises knobs into hole modifications.
  • the first subunit of the Fc domain comprises the amino acid substitutions S354C and T366W (EU numbering) and the second subunit of the Fc domain comprises the amino acid substitutions Y349C, T366S and Y407V (numbering according to Kabat EU index).
  • the IgG Fc domain comprises one or more amino acid substitution that reduces binding to an Fc receptor and/or effector function.
  • the IgG Fc domain is of human IgGl subclass and comprises the amino acid mutations L234A, L235A and P329G (numbering according to Kabat EU index).
  • the immunostimulatory antigen binding molecule as described herein comprises (a) a first polypeptide, comprising (ai) a first ectodomain of 4-1BBL comprising the amino acid sequence of SEQ ID NO:9 or SEQ ID NO: 10, fused at its C-terminus to the N-terminus of the second ectodomain of 4-1BBL or fragment thereof, (aii) a second ectodomain of 4-1BBL comprising the amino acid sequence of SEQ ID NO:9 or SEQ ID NO: 10, fused at its C-terminus to the N-terminus of a CL domain, (aiii) the CL domain, fused at its C-terminus to the N- terminus of one of the subunits (e.g. the first subunit) of the Fc domain, and (aiv) one of the subunits (e.g. the first subunit) of the Fc domain;
  • a second polypeptide comprising (bi) a third ectodomain of 4-1BBL comprising the amino acid sequence of SEQ ID NO:9 or SEQ ID NO: 10, fused at its C-terminus to the N-terminus of a CHI domain, and (bii) the CHI domain;
  • a third polypeptide comprising (ci) the heavy chain of the Fab molecule, fused at its C- terminus to the N-terminus of the other one of the subunits (e.g. the second subunit) of the Fc domain, and (cii) the other one of the subunits (e.g. the second subunit) of the Fc domain; and
  • the immunostimulatory antigen binding molecule comprises a first polypeptide comprising the amino acid sequence of SEQ ID NO:21, a second polypeptide comprising the amino acid sequence of SEQ ID NO:22, a third polypeptide comprising the amino acid sequence of SEQ ID NO:23 and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO:24.
  • the immunostimulatory antigen binding molecule comprises (a) a first polypeptide comprising the amino acid sequence of SEQ ID NO:208, a second polypeptide comprising the amino acid sequence of SEQ ID NO:22, a third polypeptide comprising the amino acid sequence of SEQ ID NO:207 and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO:24.
  • BCMA B cell maturation agent
  • VH comprising a heavy chain complementary determining region CDR-H1 of SEQ ID NO: 26 (GFTFSNAWMD), a CDR-H2 of SEQ ID NO: 27 (QITAKSNNYATYYADSVKG), and a CDR-H3 of SEQ ID NO: 28 (DGYH); and
  • VH comprising a heavy chain complementary determining region CDR-H1 of SEQ ID NO: 26 (GFTFSNAWMD), a CDR-H2 of SEQ ID NO: 29 (QITAKSNNYATYYAAPVKG), and a CDR-H3 of SEQ ID NO: 28 (DGYH); and
  • the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of 4-1BBL each comprising the amino acid sequence of SEQ ID NOV or SEQ ID NO: 10 that are connected to each other by a peptide linker, and in that the second polypeptide comprises one ectodomain of 4-1BBL comprising the amino acid sequence of SEQ ID NOV or SEQ ID NO: 10, and
  • the immunostimulatory antigen binding molecule as defined above, wherein the ectodomain of 4-1BBL or a fragment thereof comprises the amino acid sequence of SEQ ID NOV or SEQ ID NO: 10.
  • the ectodomain of 4- 1BBL or a fragment thereof comprises the amino acid sequence of SEQ ID NOV.
  • the immunostimulatory antigen binding molecule comprises three ectodomains of 4-1BBL each comprising the amino acid sequence of SEQ ID NOV or SEQ ID NO: 10, particularly the amino acid sequence of SEQ ID NOV.
  • the immunostimulatory antigen binding molecule as defined above, wherein the immunostimulatory antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 189 and SEQ ID NO: 190 and in that the second polypeptide comprises the amino acid sequence of SEQ ID NO:9 or SEQ ID NO: 10.
  • the immunostimulatory antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence of SEQ ID NO: 11 and in that the second polypeptide comprises the amino acid sequence of SEQ ID NO:9.
  • an immunostimulatory antigen binding molecule as defined herein before, wherein the antigen binding domain comprises
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:33 (VH2a) and VL BCMA comprising an amino acid sequence of SEQ ID NO:34 (VL2a), or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:35 (VHlb) and VL BCMA comprising an amino acid sequence of SEQ ID NO:36 (VLla).
  • the antigen binding domain comprises a VH BCMA comprising an amino acid sequence of SEQ ID NO:33 (VH2a) and VLBCMA comprising an amino acid sequence of SEQ ID NO:34 (VL2a).
  • the antibody that specifically binds to BCMA comprises an IgG Fc domain.
  • the Fc domain is an IgGl Fc domain.
  • the Fc domain is a human Fc domain.
  • the IgG Fc domain comprises a modification promoting the association of the first and the second subunit of the Fc domain. In one aspect, the IgG Fc domain comprises knobs into hole modifications. In one aspect, the first subunit of the IgG Fc domain comprises the amino acid substitutions S354C and T366W (EU numbering) and the second subunit of the IgG Fc domain comprises the amino acid substitutions Y349C, T366S and Y407V (numbering according to Kabat EU index).
  • the IgG Fc domain comprises one or more amino acid substitution that reduces binding to an Fc receptor and/or effector function.
  • the IgG Fc domain is of human IgGl subclass and comprises the amino acid mutations L234A, L235A and P329G (numbering according to Kabat EU index).
  • the immunostimulatory antigen binding molecule as described herein comprises
  • a first polypeptide comprising (ai) a first ectodomain of 4-1BBL comprising the amino acid sequence of SEQ ID NOV or SEQ ID NO: 10, fused at its C-terminus to the N-terminus of the second ectodomain of 4-1BBL or fragment thereof, (aii) a second ectodomain of 4-1BBL comprising the amino acid sequence of SEQ ID NOV or SEQ ID NO: 10, fused at its C-terminus to the N-terminus of a CL domain, (aiii) the CL domain, fused at its C-terminus to the N- terminus of one of the subunits (e.g.
  • a second polypeptide comprising (bi) a third ectodomain of 4-1BBL comprising the amino acid sequence of SEQ ID NO:9 or SEQ ID NO: 10, fused at its C-terminus to the N-terminus of a CHI domain, and (bii) the CHI domain;
  • a third polypeptide comprising (ci) the heavy chain of the Fab molecule, fused at its C- terminus to the N-terminus of the other one of the subunits (e.g. the second subunit) of the Fc domain, and (cii) the other one of the subunits (e.g. the second subunit) of the Fc domain; and
  • the immunostimulatory antigen binding molecule as described above is a molecule, wherein in the CL domain of the first polypeptide the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat) and the amino acid at position 123 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the CHI domain of the second polypeptide the amino acid at position 147 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to Kabat EU index) and the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to Kabat EU index).
  • the immunostimulatory antigen binding molecule as described herein comprises
  • the immunostimulatory antigen binding molecule as described herein comprises a first polypeptide comprising the amino acid sequence of SEQ ID NO: 21, a second polypeptide comprising the amino acid sequence of SEQ ID NO:22, a third polypeptide comprising the amino acid sequence of SEQ ID NO:37 and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO:38.
  • the invention relates to an antibody that specifically binds to BCMA, wherein the antibody comprises
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13
  • VLBCMA comprising an amino acid sequence of SEQ ID NO: 15, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 16.
  • an antibody that specifically binds to BCMA wherein the antibody comprises
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:33 (VH2a) and VL BCMA comprising an amino acid sequence of SEQ ID NO:34 (VL2a), or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:35 (VHlb) and VL BCMA comprising an amino acid sequence of SEQ ID NO:36 (VLla).
  • the invention further provides a vector, particularly an expression vector, comprising the isolated polynucleotide of the invention and a host cell comprising the isolated nucleic acid or the expression vector of the invention.
  • the host cell is an eukaryotic cell, particularly a mammalian cell.
  • a method of producing an immunostimulatory antigen binding molecule that specifically binds to BCMA as described herein before or an antibody as described herein before comprising the steps of a) culturing the host cell as described above under conditions suitable for the expression of the antigen binding molecule, and optionally b) recovering the antigen binding molecule.
  • the invention also encompasses the immunostimulatory antigen binding molecule that specifically binds to BCMA as produced by the method of the invention.
  • composition comprising an immunostimulatory antigen binding molecule that specifically binds to BCMA as described herein before and at least one pharmaceutically acceptable excipient.
  • pharmaceutical composition comprises an additional therapeutic agent.
  • immunostimulatory antigen binding molecule that specifically binds to BCMA as described herein before, or the pharmaceutical composition comprising the bispecific BCMA antibody, for use as a medicament.
  • the immunostimulatory antigen binding molecule that specifically binds to BCMA as described herein before or the pharmaceutical composition, for use in enhancing (a) T cell activation or (b) T cell effector functions.
  • the immunostimulatory antigen binding molecule that specifically binds to BCMA as described herein before or the pharmaceutical composition, for use in the treatment of a disease.
  • the disease is cancer, in particular multiple myeloma (MM).
  • the immunostimulatory antigen binding molecule that specifically binds to BCMA as described herein before for use in the treatment of cancer wherein the use is for administration in combination with a chemotherapeutic agent, radiation therapy and/ or other agents for use in cancer immunotherapy.
  • the immunostimulatory antigen binding molecule that specifically binds to BCMA as described herein before is for use in the treatment of cancer, wherein the use is for administration in combination with a T-cell activating anti-CD3 bispecific antibody.
  • the T-cell activating anti-CD3 bispecific antibody is an anti- GPRC5D/anti-CD3 antibody.
  • the invention provides a method of inhibiting the growth of tumor cells in an individual comprising administering to the individual an effective amount of the immunostimulatory antigen binding molecule that specifically binds to BCMA as described herein before, or the pharmaceutical composition of the invention, to inhibit the growth of the tumor cells.
  • the invention provides a method of treating or delaying cancer in an individual comprising administering to the individual an effective amount of the immunostimulatory antigen binding molecule that specifically binds to BCMA as described herein before, or the pharmaceutical composition of the invention.
  • the immunostimulatory antigen binding molecule that specifically binds to BCMA as described herein before for the manufacture of a medicament for the treatment of a disease in an individual in need thereof, in particular for the manufacture of a medicament for the treatment of cancer, as well as a method of treating a disease in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising the immunostimulatory antigen binding molecule that specifically binds to BCMA of the invention in a pharmaceutically acceptable form.
  • the disease is cancer.
  • the individual is a mammal, particularly a human.
  • FIG. 1A shows a schematic illustration of the BCMA antibody variants as monovalent hu IgGl PGLALA isotype (“Fc silent”).
  • Fig. IB illustrates schematically the structure of the monovalent BCMA-targeting split trimeric 4-1BBL Fc (kih) P329G LALA fusion antigen binding molecule comprising CH1-CL cross in the arm wherein the two and one 4-1BBL are fused to, respectively.
  • the thick black point stands for the knob-into-hole modification.
  • Certain amino acids are included in the CHI and CL domain of the Fab molecule comprising the BCMA antigen binding domain to allow better pairing with the light chain.
  • Figures 2A and 2B show the dose-dependent binding of various BCMA-4-1BBL antigen binding molecules and the comparator molecule P1AH1062 to cells expressing either human BCMA (Fig. 2A) or human 4-1BB (Fig. 2B).
  • the untargeted 4-1BBL molecule only binds to 4- 1BB expressing cells but not to BCMA expressing cells.
  • Figures 3A and 3B show that all exemplified BCMA-4-1BBL antigen binding molecules have a similar binding behaviour towards BCMA-expressing CHO cells (CHO-huBCMA cells) as well as to human 4- IBB expressing Jurkat reporter cells, whereas the comparator molecule P1AH1062 did bind much less.
  • Figures 3C to 3H show binding of two BCMA-4-1BBL antigen binding molecules Pl AG7400 and Pl AG7397 as well as the BCMA-targeted CD3 T cell engager Alnuctamab, to CHO cells expressing human BCMA with indicated point mutations. Shown is the binding in case no BCMA is present (Fig. 3C) and to human wt BCMA (Fig. 3D) as well as to BCMA variants human BCMA P33S (Fig. 3E), human BCMA P34del (Fig. 3F), human BCMA R27P (Fig. 3G) and human BCMA S3 Odel (Fig. 3H).
  • BCMA-targeted CD3 T cell engager Teclistamab does not bind to two mutated BCMA variants, namely R27P (Fig. 3G) and S30del (Fig. 3H) and Elranatamab only weakly binds to BCMA with the R27P mutation at high concentrations. Neither of the tested molecules bind to BCMA-negative CHOkl cells (Fig. 3C).
  • Figure 4A to 4C show the dose-dependent activation of NFKB in the Jurkat reporter assay when titrated amounts of (600.0-0.02 nM) of BCMA-4-1BBL antigen binding molecules were added and bridging target cells with effector cells. Obtained data are shown as mean ⁇ s.d. of one independent experiment performed in triplicates out of three.
  • Fig. 4A the concentration of BCMA-4-1BBL molecules or its controls is blotted against the units of released light (RLU)
  • Fig. 4B and 4C provide a graphical summary of the ECso values and Emax values as calculated from three independent experiments performed in triplicate and shown together as mean ⁇ s.d.
  • FIGS. 5A and 5B show that the dose-dependent activation of CD8 + T cells through BCMA-4-1BBL antigen binding molecules occurs only in presence of a first signal (TCB) and BCMA expression.
  • the BCMA-expressing MM cell line NCI-H929 (Fig. 5A) was co-cultured with healthy donor PBMCs (ratio of 1 : 1).
  • NCI-H929 BCMAko cells (knock-out cells that do not express BCMA) were used as target cells (Fig. 5B).
  • Co-cultures were treated with GPRC5D-TCB (providing 1st signal) alone or in combination with BCMA-4-1BBL or an untargeted 4-1BBL (neg.
  • Figures 5C to 5H show binding of two BCMA-4-1BBL antigen binding molecules Pl AG7400 and Pl AG7397 to CHO cells expressing human BCMA with indicated point mutations. Shown is the binding in case no BCMA is present (Fig. 5C) and to human wt BCMA (Fig. 5D) as well as to BCMA variants human BCMA R27P (Fig. 5E), human BCMA P34del (Fig. 5F), human BCMA P33S (Fig. 5G) and human BCMA S30del (Fig. 5H).
  • Both molecules displayed a similar concentration-dependent boosting of T cell activation on top of the CD3 IgG- mediated T cell activation (as illustrated by the upregulation of CD25 on CD8 T cells) in presence of either the mutated or the wildtype BCMA expressed on CHO transfectants.
  • FIGS 51 to 5P show that BCMA-4-1BBL (Pl AG7400) was able to boost T cell activation and tumor cell lysis on top of an anti-FcRH5/anti-CD3 bispecific antibody (FcRH5 x CD3).
  • BCMA-4-1BBL was added at a fixed concentration to different concentrations of a FcRH5 x CD3 in a co-culture assay of healthy donor PBMCs in presence of BCMA-expressing MM cell lines.
  • Fig. 51, 5J, 5K and 5L show the increase in frequency of CD 137-positive CD8 T cells in 4 donors, respectively, when BCMA-4-1BBL is added. Lysis of tumor cells is shown in Fig. 5M, 5N, 50 and 5P, respectively. T cell activation and tumor cell lysis were significantly boosted in the combination.
  • FIGS. 6A to 6E show results of an exemplary ex vivo test, using primary MM patients’ bone marrow samples.
  • Tumor Cell Lysis (TCL) was determined by flow cytometry, defining maleimide positive cells with low FSC as dead cells (Fig. 6A).
  • T-cell activation was determined by flow cytometry, assessing the upregulation of CD25 on CD8 (Fig. 6B) or CD4 (Fig. 6C) T cells upon incubation with 1 nM GPRC5D-TCB in absence or presence of the indicated concentrations of BCMA-4-1BBL (P1AG7422) or negative reference molecules for 96 hours.
  • Degranulation was determined by flow cytometry, assessing the upregulation of CD 107a on CD8 (Fig.
  • FIGs 7A to 7E show results of another exemplary ex vivo test, using primary MM patients’ bone marrow samples.
  • Tumor Cell Lysis (TCL) was determined by flow cytometry, defining maleimide positive cells with low FSC as dead cells (Fig. 7A).
  • T-cell activation was determined by flow cytometry, assessing the upregulation of CD25 on CD8 (Figs. 7B and 7C) or CD4 (Figs. 7D and 7E) T cells upon incubation with 1 nM GPRC5D-TCB in absence or presence of the indicated concentrations of BCMA-4-1BBL (Pl AG7400 or Pl AG7409) or negative reference molecules for 96 hours. All data shown refer to single tube measurement per condition.
  • Figures 8A to 8D show results of an ex vivo test, using BM MNCs of primary MM patients’ bone marrow samples. Tumor Cell lysis was determined by flow cytometry, assessing the percent of viable MM PCs upon incubation with 0.025 nM GPRC5D-TCB in absence or presence of 40 nM of BCMA-4-1BBL (Pl AG7400) or reference molecules for 96 hours. All data shown refer to single tube measurement per condition.
  • Figures 9A to 9H depict the results from an in vivo experiment testing the efficacy of GPRC5D x CD3 monotherapy and its combination with BCMA-4-1BBL antigen binding molecules (10 mg/kg and 3 mg/kg Pl AG7409 and 10 mg/kg and 3 mg/kg Pl AG7422) in the NCI-H929 tumor model.
  • Figures 9A to 9F show the tumor growth inhibition in single animals and
  • Fig. 9G shows the tumor volume as Median (+/- IQR) per treatment group. Animals with a terminal tumor load below the size at treatment start were defined as responders.
  • Tumor volume at termination is shown for GPRC5D x CD3 monotherapy group and combinations as Median (+/- IQR) is shown in Fig. 9H.
  • Figures 10A to 10H show the results from an in vivo experiment testing the efficacy of GPRC5D x CD3 monotherapy and its combination with BCMA-4-1BBL antigen binding molecules Pl AG7397 (10 and 20 mg/kg) and Pl AG7400 (10 and 20 mg/kg) in the NCI-H929 tumor model.
  • Tumor growth inhibition is shown in single animals ( Figures 10A to 10F) and as Median (+/- IQR) per treatment group (Fig. 10G). Animals with a terminal tumor load below the size at treatment start were defined as responders.
  • Tumor volume at termination is shown for GPRC5D x CD3 monotherapy and combination groups as Median (+/- IQR) (Fig. 10H)
  • Figures 11A to 11F show the results of an in vivo experiment testing the efficacy of GPRC5D x CD3 monotherapy (0.05 mg/kg) and combination with BCMA-4-1BBL antigen binding molecule Pl AG7400 (40, 4 and 0.4 mg/kg) in the NCI-H929 tumor model.
  • Figures 16A to 16E show the tumor growth inhibition in single animals.
  • Fig. 11A shows the tumor volume as Median (+/- IQR) per treatment group.
  • Figures 11B to 11F show the tumor growth inhibition in single animals. Animals with a terminal tumor load below the size at treatment start were defined as responders.
  • Figure 12 shows a comparison of the plasma concentration-time profiles of BCMA-4- 1BBL antigen binding molecules Pl AG7400, Pl AG7397, Pl AG7409 and Pl AG7422 as measured in HuFcRN transgenic mice (PK study).
  • FIG. 13A to 13D show heatMAPPS representations of the results observed in the MAPPs assay (Example 6.3.1) for the bispecific antibodies P1AG7409 (Fig. 13A), P1AG7422 (Fig.l3B), P1AG7400 (Fig.l3C) and P1AG7397 (Fig.l3D). Clusters found in each domain are highlighted. DETAILED DESCRIPTION OF THE INVENTION
  • antigen binding molecule refers in its broadest sense to a molecule that specifically binds an antigenic determinant.
  • antigen binding molecules are antibodies, multispecific antibodies (e.g., bispecific antibodies), antibody fragments and scaffold antigen binding proteins.
  • the term “antigen binding domain that binds to a tumor-associated antigen” or "moiety capable of specific binding to a tumor-associated antigen” refers to a polypeptide molecule that specifically binds to the tumor-associated antigen BCMA.
  • the antigen binding domain is able to activate signaling through BCMA.
  • the antigen binding domain is able to direct the entity to which it is attached (e.g. the 4- 1BBL trimer) to a BCMA-expressing cell, for example to a specific type of tumor cell.
  • Antigen binding domains capable of specific binding to BCMA include antibodies and fragments thereof as further defined herein.
  • antigen binding domains capable of specific binding to a tumor-associated antigen may include scaffold antigen binding proteins as further defined herein, e.g. binding domains which are based on designed repeat proteins or designed repeat domains (see e.g. WO 2002/020565).
  • an antigen binding domain refers to the part of the molecule that comprises the area which specifically binds to and is complementary to part or all of an antigen.
  • An antigen binding domain capable of specific antigen binding may be provided, for example, by one or more antibody variable domains (also called antibody variable regions).
  • an antigen binding domain capable of specific antigen binding comprises an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH).
  • VL antibody light chain variable region
  • VH antibody heavy chain variable region
  • the "antigen binding domain capable of specific binding to a tumor-associated antigen can also be a Fab fragment or a crossFab fragment.
  • the terms “first”, “second” or “third” with respect to antigen binding domains etc. are used for convenience of distinguishing when there is more than one of each type of moiety. Use of these terms is not intended to confer a specific order or orientation of the moiety unless explicitly so stated.
  • antibody herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, monospecific and multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity.
  • monoclonal antibody refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and/or bind the same epitope, except for possible variant antibodies, e.g. containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts.
  • polyclonal antibody preparations which typically include different antibodies directed against different determinants (epitopes)
  • each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen.
  • bispecific antibody denotes an antibody that has one or more binding sites each of which bind to the same epitope of the same antigen.
  • the term “bispecific” means that the antigen binding molecule is able to specifically bind to at least two distinct antigenic determinants. Typically, a bispecific antigen binding molecule comprises two antigen binding sites, each of which is specific for a different antigenic determinant. However, a bispecific antigen binding molecule may also comprise additional antigen binding sites which bind to further antigenic determinants. In certain aspects, the bispecific antigen binding molecule is capable of simultaneously binding two antigenic determinants, particularly two antigenic determinants expressed on two distinct cells or on the same cell.
  • the term “bispecific” in accordance with the present invention thus may also include a trispecific molecule, e.g. a bispecific molecule comprising a 4-1BBL trimer and two antigen binding domains directed to two different target cell antigens.
  • valent as used within the current application denotes the presence of a specified number of binding sites specific for one distinct antigenic determinant in an antigen binding molecule that are specific for one distinct antigenic determinant.
  • bivalent tetravalent
  • hexavalent denote the presence of two binding sites, four binding sites, and six binding sites specific for a certain antigenic determinant, respectively, in an antigen binding molecule.
  • the bispecific antigen binding molecules according to the invention can be monovalent for a certain antigenic determinant, meaning that they have only one binding site for said antigenic determinant or they can be bivalent or tetravalent for a certain antigenic determinant, meaning that they have two binding sites or four binding sites, respectively, for said antigenic determinant.
  • full length antibody “intact antibody”, and “whole antibody” are used herein interchangeably to refer to an antibody having a structure substantially similar to a native antibody structure.
  • Native antibodies refer to naturally occurring immunoglobulin molecules with varying structures.
  • native IgG-class antibodies are heterotetrameric glycoproteins of about 150,000 daltons, composed of two light chains and two heavy chains that are disulfide-bonded. From N- to C-terminus, each heavy chain has a variable region (VH), also called a variable heavy domain or a heavy chain variable domain, followed by three constant domains (CHI, CH2, and CH3), also called a heavy chain constant region.
  • each light chain has a variable region (VL), also called a variable light domain or a light chain variable domain, followed by a light chain constant domain (CL), also called a light chain constant region.
  • the heavy chain of an antibody may be assigned to one of five types, called a (IgA), 5 (IgD), a (IgE), y (IgG), or p (IgM), some of which may be further divided into subtypes, e.g. yl (IgGl), y2 (IgG2), y3 (IgG3), y4 (IgG4), al (IgAl) and a2 (IgA2).
  • the light chain of an antibody may be assigned to one of two types, called kappa (K) and lambda (X), based on the amino acid sequence of its constant domain.
  • antibody fragment refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds.
  • antibody fragments include but are not limited to Fv, Fab, Fab', Fab’-SH, F(ab')2; diabodies, triabodies, tetrabodies, crossFab fragments; linear antibodies; single-chain antibody molecules (e.g. scFv); and single domain antibodies.
  • scFv single domain antibodies.
  • Diabodies are antibody fragments with two antigen-binding sites that may be bivalent or bispecific, see, for example, EP 404,097; WO 1993/01161; Hudson et al., Nat Med 9, 129-134 (2003); and Hollinger et al., Proc Natl Acad Sci USA 90, 6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., Nat Med 9, 129-134 (2003).
  • Single-domain antibodies are antibody fragments comprising all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody.
  • a single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, MA; see e.g. U.S. Patent No. 6,248,516 Bl).
  • Antibody fragments can be made by various techniques, including but not limited to proteolytic digestion of an intact antibody as well as production by recombinant host cells (e.g. E. coli or phage), as described herein.
  • Fab fragments containing each the heavy- and light-chain variable domains and also the constant domain of the light chain and the first constant domain (CHI) of the heavy chain.
  • Fab fragment or Fab molecule refers to an antibody fragment comprising a light chain fragment comprising a variable light chain (VL) domain and a constant domain of a light chain (CL), and a variable heavy chain (VH) domain and a first constant domain (CHI) of a heavy chain.
  • Fab’ fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CHI domain including one or more cysteins from the antibody hinge region.
  • Fab’-SH are Fab’ fragments in which the cysteine residue(s) of the constant domains bear a free thiol group. Pepsin treatment yields an F(ab')2 fragment that has two antigen-combining sites (two Fab fragments) and a part of the Fc region.
  • a “conventional Fab fragment” is comprised of a VL-CL light chain and a VH-CH1 heavy chain.
  • crossFab fragment or “xFab fragment” or “crossover Fab fragment” refers to a Fab fragment, wherein either the variable regions or the constant regions of the heavy and light chain are exchanged.
  • Two different chain compositions of a crossover Fab molecule are possible and comprised in the bispecific antibodies of the invention: On the one hand, the variable regions of the Fab heavy and light chain are exchanged, i.e. the crossover Fab molecule comprises a peptide chain composed of the light chain variable (VL) domain and the heavy chain constant domain (CHI), and a peptide chain composed of the heavy chain variable domain (VH) and the light chain constant domain (CL).
  • VL light chain variable
  • CHI heavy chain constant domain
  • VH heavy chain variable domain
  • CL light chain constant domain
  • This crossover Fab molecule is also referred to as CrossFab (VLVH).
  • the crossover Fab molecule comprises a peptide chain composed of the heavy chain variable domain (VH) and the light chain constant domain (CL), and a peptide chain composed of the light chain variable domain (VL) and the heavy chain constant domain (CHI).
  • VH heavy chain variable domain
  • CL light chain constant domain
  • CHI heavy chain constant domain
  • a “single chain Fab fragment” or “scFab” is a polypeptide consisting of an antibody heavy chain variable domain (VH), an antibody constant domain 1 (CHI), an antibody light chain variable domain (VL), an antibody light chain constant domain (CL) and a linker, wherein said antibody domains and said linker have one of the following orders in N-terminal to C-terminal direction: a) VH-CH1 -linker- VL-CL, b) VL-CL-linker-VH-CHl, c) VH-CL-linker-VL-CHl or d) VL-CH1 -linker- VH-CL; and wherein said linker is a polypeptide of at least 30 amino acids, preferably between 32 and 50 amino acids.
  • Said single chain Fab fragments are stabilized via the natural disulfide bond between the CL domain and the CHI domain.
  • these single chain Fab molecules might be further stabilized by generation of interchain disulfide bonds via insertion of cysteine residues (e.g. position 44 in the variable heavy chain and position 100 in the variable light chain according to Kabat numbering).
  • a “crossover single chain Fab fragment” or “x-scFab” is a is a polypeptide consisting of an antibody heavy chain variable domain (VH), an antibody constant domain 1 (CHI), an antibody light chain variable domain (VL), an antibody light chain constant domain (CL) and a linker, wherein said antibody domains and said linker have one of the following orders in N- terminal to C-terminal direction: a) VH-CL-linker-VL-CHl and b) VL-CH1 -linker- VH-CL; wherein VH and VL form together an antigen-binding site which binds specifically to an antigen and wherein said linker is a polypeptide of at least 30 amino acids.
  • these x-scFab molecules might be further stabilized by generation of interchain disulfide bonds via insertion of cysteine residues (e.g. position 44 in the variable heavy chain and position 100 in the variable light chain according to Kabat numbering).
  • a “single-chain variable fragment (scFv)” is a fusion protein of the variable regions of the heavy (VH) and light chains (VL) of an antibody, connected with a short linker peptide of ten to about 25 amino acids.
  • the linker is usually rich in glycine for flexibility, as well as serine or threonine for solubility, and can either connect the N-terminus of the VH with the C-terminus of the VL, or vice versa. This protein retains the specificity of the original antibody, despite removal of the constant regions and the introduction of the linker.
  • scFv antibodies are, e.g. described in Houston, J.S., Methods in Enzymol. 203 (1991) 46-96).
  • antibody fragments comprise single chain polypeptides having the characteristics of a VH domain, namely being able to assemble together with a VL domain, or of a VL domain, namely being able to assemble together with a VH domain to a functional antigen binding site and thereby providing the antigen binding property of full length antibodies.
  • fibronectin and designed ankyrin repeat proteins have been used as alternative scaffolds for antigenbinding domains, see, e.g., Gebauer and Skerra, Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 13:245-255 (2009) and Stumpp et al., Darpins: A new generation of protein therapeutics. Drug Discovery Today 13: 695-701 (2008).
  • a scaffold antigen binding protein is selected from the group consisting of CTLA-4 (Evibody), Lipocalins (Anticalin), a Protein A-derived molecule such as Z-domain of Protein A (Affibody), an A-domain (Avimer/Maxibody), a serum transferrin (/ra/z.s-body); a designed ankyrin repeat protein (DARPin), a variable domain of antibody light chain or heavy chain (single-domain antibody, sdAb), a variable domain of antibody heavy chain (nanobody, aVH), VNAR fragments, a fibronectin (AdNectin), a C-type lectin domain (Tetranectin); a variable domain of a new antigen receptor beta-lactamase (VNAR fragments), a human gammacrystallin or ubiquitin (Affilin molecules); a kunitz type domain of human protease inhibitors, microbodies such as the group consisting of CTLA
  • CTLA-4 Cytotoxic T Lymphocyte-associated Antigen 4
  • CTLA-4 is a CD28-family receptor expressed on mainly CD4 + T-cells. Its extracellular domain has a variable domain- like Ig fold. Loops corresponding to CDRs of antibodies can be substituted with heterologous sequence to confer different binding properties.
  • CTLA-4 molecules engineered to have different binding specificities are also known as Evibodies (e.g. US7166697B1). Evibodies are around the same size as the isolated variable region of an antibody (e.g. a domain antibody). For further details, see Journal of Immunological Methods 248 (1-2), 31-45 (2001).
  • Lipocalins are a family of extracellular proteins which transport small hydrophobic molecules such as steroids, bilins, retinoids and lipids. They have a rigid beta-sheet secondary structure with a number of loops at the open end of the conical structure which can be engineered to bind to different target antigens. Anticalins are between 160-180 amino acids in size, and are derived from lipocalins. For further details, see Biochim Biophys Acta 1482: 337-350 (2000), US7250297B1 and US20070224633.
  • An affibody is a scaffold derived from Protein A of Staphylococcus aureus which can be engineered to bind to antigen.
  • the domain consists of a three-helical bundle of approximately 58 amino acids. Libraries have been generated by randomization of surface residues. For further details, see Protein Eng. Des. Sei. 2004, 17, 455-462 and EP 1641818A1. Avimers are multidomain proteins derived from the A-domain scaffold family. The native domains of approximately 35 amino acids adopt a defined disulfide bonded structure. Diversity is generated by shuffling of the natural variation exhibited by the family of A-domains. For further details, see Nature Biotechnology 23(12), 1556 - 1561 (2005) and Expert Opinion on Investigational Drugs 16(6), 909-917 (June 2007). A transferrin is a monomeric serum transport glycoprotein.
  • Transferrins can be engineered to bind different target antigens by insertion of peptide sequences in a permissive surface loop.
  • engineered transferrin scaffolds include the Transbody.
  • Designed Ankyrin Repeat Proteins are derived from Ankyrin which is a family of proteins that mediate attachment of integral membrane proteins to the cytoskeleton.
  • a single ankyrin repeat is a 33 residue motif consisting of two alpha-helices and a beta-turn. They can be engineered to bind different target antigens by randomizing residues in the first alpha-helix and a beta-turn of each repeat.
  • a singledomain antibody is an antibody fragment consisting of a single monomeric variable antibody domain.
  • the first single domains were derived from the variable domain of the antibody heavy chain from camelids (nanobodies or VHH fragments).
  • the term single-domain antibody includes an autonomous human heavy chain variable domain (aVH) or VNAR fragments derived from sharks.
  • Fibronectin is a scaffold which can be engineered to bind to antigen.
  • Adnectins consists of a backbone of the natural amino acid sequence of the 10th domain of the 15 repeating units of human fibronectin type III (FN3). Three loops at one end of the betasandwich can be engineered to enable an Adnectin to specifically recognize a therapeutic target of interest. For further details, see Protein Eng. Des. Sei. 18, 435- 444 (2005), US20080139791, W02005056764 and US6818418B1.
  • Peptide aptamers are combinatorial recognition molecules that consist of a constant scaffold protein, typically thioredoxin (TrxA) which contains a constrained variable peptide loop inserted at the active site. For further details, see Expert Opin. Biol. Ther. 5, 783-797 (2005).
  • Microbodies are derived from naturally occurring microproteins of 25-50 amino acids in length which contain 3-4 cysteine bridges - examples of microproteins include KalataBI and conotoxin and knottins.
  • the microproteins have a loop which can beengineered to include upto 25 amino acids without affecting the overall fold of the microprotein. For further details of engineered knottin domains, see W02008098796.
  • an “antigen binding domain that binds to the same epitope” as a reference molecule refers to an antigen binding domain that blocks binding of the reference molecule to its antigen in a competition assay by 50% or more, and conversely, the reference molecule blocks binding of the antigen binding molecule to its antigen in a competition assay by 50% or more.
  • the term "antigen binding domain” refers to the part of an antigen binding molecule that comprises the area which specifically binds to and is complementary to part or all of an antigen. Where an antigen is large, an antigen binding molecule may only bind to a particular part of the antigen, which part is termed an epitope.
  • An antigen binding domain may be provided by, for example, one or more variable domains (also called variable regions).
  • an antigen binding domain comprises an antibody light chain variable domain (VL) and an antibody heavy chain variable domain (VH).
  • antigenic determinant is synonymous with “antigen” and “epitope,” and refers to a site (e.g. a contiguous stretch of amino acids or a conformational configuration made up of different regions of non-contiguous amino acids) on a polypeptide macromolecule to which an antigen binding moiety binds, forming an antigen binding moiety- antigen complex.
  • Useful antigenic determinants can be found, for example, on the surfaces of tumor cells, on the surfaces of virus-infected cells, on the surfaces of other diseased cells, on the surface of immune cells, free in blood serum, and/or in the extracellular matrix (ECM).
  • ECM extracellular matrix
  • the proteins useful as antigens herein can be any native form the proteins from any vertebrate source, including mammals such as primates (e.g. humans) and rodents (e.g. mice and rats), unless otherwise indicated.
  • the antigen is a human protein.
  • the term encompasses the “full-length”, unprocessed protein as well as any form of the protein that results from processing in the cell.
  • the term also encompasses naturally occurring variants of the protein, e.g. splice variants or allelic variants.
  • ELISA enzyme-linked immunosorbent assay
  • SPR Surface Plasmon Resonance
  • the extent of binding of an antigen binding molecule to an unrelated protein is less than about 10% of the binding of the antigen binding molecule to the antigen as measured, e.g. by SPR.
  • an molecule that binds to the antigen has a dissociation constant (Kd) of ⁇ 1 pM, ⁇ 100 nM, ⁇ 10 nM, ⁇ 1 nM, ⁇ 0.1 nM, ⁇ 0.01 nM, or ⁇ 0.001 nM (e.g. 10' 8 M or less, e.g. from 10' 8 M to 10' 13 M, e.g. from 10' 9 M to 10' 13 M).
  • Binding affinity refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g. an antibody) and its binding partner (e.g. an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity which reflects a 1 : 1 interaction between members of a binding pair (e.g. antibody and antigen).
  • the affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (Kd), which is the ratio of dissociation and association rate constants (koff and kon, respectively).
  • Kd dissociation constant
  • equivalent affinities may comprise different rate constants, as long as the ratio of the rate constants remains the same. Affinity can be measured by common methods known in the art, including those described herein. A particular method for measuring affinity is Surface Plasmon Resonance (SPR).
  • an “activating T cell antigen” as used herein refers to an antigenic determinant expressed on the surface of a T lymphocyte, particularly a cytotoxic T lymphocyte, which is capable of inducing T cell activation upon interaction with an antibody. Specifically, interaction of an antibody with an activating T cell antigen may induce T cell activation by triggering the signaling cascade of the T cell receptor complex.
  • the activating T cell antigen is CD3, particularly the epsilon subunit of CD3 (see UniProt no. P07766 (version 189), NCBI RefSeq no. NP 000724.1, SEQ ID NO: 167 for the human sequence; or UniProt no. Q95LI5 (version 49), NCBI GenBank no. BAB71849.1, SEQ ID NO: 168 for the cynomolgus [Macaca fascicularis] sequence).
  • T cell activation refers to one or more cellular response of a T lymphocyte, particularly a cytotoxic T lymphocyte, selected from proliferation, differentiation, cytokine secretion, cytotoxic effector molecule release, cytotoxic activity, and expression of activation markers. Suitable assays to measure T cell activation are known in the art and described herein.
  • T cell effector functions refers to the activities of T cells that play a key role in the adaptive immune system. T cells are responsible for initiating and coordinating the body’s immune response against foreign invaders, such as viruses or bacteria as well as tumor cells. Effector functions refer to the various activities carried out by T cells to eliminate these offenders, which include releasing cytokines, stimulating other cells, and directly attacking and eliminating infected cells.
  • TAA tumor-associated antigen
  • a target cell for example a cell in a tumor such as a cancer cell, a cell of the tumor stroma, a malignant B lymphocyte or a melanoma cell.
  • the target cell antigen is an antigen on the surface of a tumor cell.
  • TAA is BCMA.
  • BCMA refers to B cell maturation antigen, also termed tumor necrosis factor receptor superfamily member 17 (TNFRS17) or CD269, and is a type III transmembrane protein without a signal-peptide and containing cysteine-rich extracellular domains.
  • Ligands for BCMA include B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), of which APRIL has a higher affinity for BCMA.
  • BAFF B cell activating factor
  • APRIL proliferation-inducing ligand
  • BCMA is preferentially expressed by mature B lymphocytes, with minimal expression in hematopoietic stem cells or non-hematopoietic tissue, and is essential for the survival of long-lived bone marrow plasma cells.
  • BCMA soluble BCMA
  • BAFF transmembrane activator and calcium modulator and cyclophilin ligand interactor
  • BCMA as used herein refers to any BCMA protein from any vertebrate source, including mammals such as primates (e.g. humans) non-human primates (e.g. cynomolgus monkeys) and rodents (e.g. mice and rats), unless otherwise indicated.
  • the amino acid sequence of human BCMA is shown in UniProt (www.uniprot.org) accession no. Q02223 (SEQ ID NO:93).
  • CD28 Cluster of differentiation 28, Tp44 refers to any CD28 protein from any vertebrate source, including mammals such as primates (e.g. humans) non-human primates (e.g. cynomolgus monkeys) and rodents (e.g. mice and rats), unless otherwise indicated.
  • CD28 is expressed on T cells and provides co-stimulatory signals required for T cell activation and survival. T cell stimulation through CD28 in addition to the T-cell receptor (TCR) can provide a potent signal for the production of various interleukins.
  • CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins and is the only B7 receptor constitutively expressed on naive T cells.
  • the amino acid sequence of human CD28 is shown in UniProt (www.uniprot.org) accession no. Pl 0747 (SEQ ID NO: 94).
  • an “agonistic antibody” refers to an antibody that comprises an agonistic function against a given receptor.
  • an agonist ligand factor
  • the tertiary structure of the receptor protein changes, and the receptor is activated (when the receptor is a membrane protein, a cell growth signal or such is usually transducted).
  • the receptor is a dimerforming type, an agonistic antibody can dimerize the receptor at an appropriate distance and angle, thus acting similarly to a ligand.
  • An appropriate anti-receptor antibody can mimic dimerization of receptors performed by ligands, and thus can become an agonistic antibody.
  • a “CD28 agonistic antibody” or “CD28 conventional agonistic antibody” is an antibody that mimics CD28 natural ligands (CD80 or CD86) in their role to enhance T cell activation in presence of a T cell receptor signal (“signal 2”).
  • a T cell needs two signals to become fully activated.
  • signal 1 arises from the interaction of T cell receptor (TCR) molecules with peptide/major histocompatibility complex (MHC) complexes on antigen presenting cells (APCs) and “signal 2” is provided by engagement of a costimulatory receptor, e.g. CD28.
  • a CD28 agonistic antibody is able to costimulate T cells (signal 2).
  • CD28 agonistic antibody is not capable of fully activating T cells without additional stimulation of the TCR.
  • CD28 superagonistic antibodies There is however a subclass of CD28 specific antigen binding molecules, the so-called CD28 superagonistic antibodies.
  • a “CD28 superagonistic antibody” is a CD28 antibody which is capable of fully activating T cells without additional stimulation of the TCR.
  • a CD28 superagonistic anitbody is capable to induce T cell proliferation and cytokine secretion without prior T cell activation (signal 1).
  • variable domain refers to the domain of an antibody heavy or light chain that is involved in binding the antigen binding molecule to antigen.
  • the variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs). See, e.g., Kindt et al., Kuby Immunology, 6th ed., W.H. Freeman and Co., page 91 (2007).
  • a single VH or VL domain may be sufficient to confer antigen-binding specificity.
  • hypervariable region refers to each of the regions of an antigen binding variable domain which are hypervariable in sequence and which determine antigen binding specificity, for example “complementarity determining regions” (“CDRs”).
  • CDRs complementarity determining regions
  • antigen binding domains comprise six CDRs: three in the VH (CDR-H1, CDR-H2, CDR-H3), and three in the VL (CDR-L1, CDR-L2, CDR-L3).
  • Exemplary CDRs herein include:
  • the CDRs are determined according to Kabat et al., supra.
  • the CDR designations can also be determined according to Chothia, supra, McCallum, supra, or any other scientifically accepted nomenclature.
  • Kabat et al. also defined a numbering system for variable region sequences that is applicable to any antibody.
  • One of ordinary skill in the art can unambiguously assign this system of "Kabat numbering" to any variable region sequence, without reliance on any experimental data beyond the sequence itself.
  • Kabat numbering refers to the numbering system set forth by Kabat et al., U.S. Dept, of Health and Human Services, "Sequence of Proteins of Immunological Interest" (1983). Unless otherwise specified, references to the numbering of specific amino acid residue positions in an antibody variable region are according to the Kabat numbering system.
  • affinity matured in the context of antigen binding molecules (e.g., antibodies) refers to an antigen binding molecule that is derived from a reference antigen binding molecule, e.g., by mutation, binds to the same antigen, preferably binds to the same epitope, as the reference antibody; and has a higher affinity for the antigen than that of the reference antigen binding molecule.
  • Affinity maturation generally involves modification of one or more amino acid residues in one or more CDRs of the antigen binding molecule.
  • the affinity matured antigen binding molecule binds to the same epitope as the initial reference antigen binding molecule.
  • FR Framework or "FR” refers to variable domain residues other than hypervariable region (HVR) residues.
  • the FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4. Accordingly, the HVR and FR sequences generally appear in the following sequence in VH (or VL): FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.
  • acceptor human framework for the purposes herein is a framework comprising the amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework, as defined below.
  • An acceptor human framework “derived from” a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereof, or it may contain amino acid sequence changes. In some embodiments, the number of amino acid changes are 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less.
  • the VL acceptor human framework is identical in sequence to the VL human immunoglobulin framework sequence or human consensus framework sequence.
  • chimeric antibody refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species.
  • the “class” of an antibody refers to the type of constant domain or constant region possessed by its heavy chain.
  • the heavy chain constant domains that correspond to the different classes of immunoglobulins are called a, 5, 8, y, and p respectively.
  • a “humanized” antibody refers to a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs.
  • a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non- human antibody, and all or substantially all of the FRs correspond to those of a human antibody.
  • a humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody.
  • a “humanized form” of an antibody, e.g., a non-human antibody refers to an antibody that has undergone humanization.
  • Other forms of "humanized antibodies" encompassed by the present invention are those in which the constant region has been additionally modified or changed from that of the original antibody to generate the properties according to the invention, especially in regard to Clq binding and/or Fc receptor (FcR) binding.
  • a “human” antibody is one which possesses an amino acid sequence which corresponds to that of an antibody produced by a human or a human cell or derived from a non-human source that utilizes human antibody repertoires or other human antibody-encoding sequences.
  • This definition of a human antibody specifically excludes a humanized antibody comprising nonhuman antigen-binding residues.
  • a “human” or “humanized” antibody comprises a constant region of human origin, particularly of the IgG isotype, more particularly of the IgGl isotype, comprising a human CHI, CH2, CH3 and/or CL domain.
  • CL domain denotes the constant part of an antibody light chain polypeptide.
  • exemplary sequences of human constant domains are given in SEQ ID Nos: 95 and 96 (human kappa and lambda CL domains, respectively).
  • CHI domain denotes the part of an antibody heavy chain polypeptide that extends approximately from EU position 118 to EU position 215 (EU numbering system according to Kabat).
  • a CHI domain has the amino acid sequence of ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKV (SEQ ID NO: 97).
  • a segment having the amino acid sequence of EPKSC (SEQ ID NO:98) is following to link the CHI domain to the hinge region.
  • hinge region denotes the part of an antibody heavy chain polypeptide that joins in a wild-type antibody heavy chain the CHI domain and the CH2 domain, e. g. from about position 216 to about position 230 according to the EU number system of Kabat, or from about position 226 to about position 230 according to the EU number system of Kabat.
  • the hinge regions of other IgG subclasses can be determined by aligning with the hinge-region cysteine residues of the IgGl subclass sequence.
  • the hinge region is normally a dimeric molecule consisting of two polypeptides with identical amino acid sequence.
  • the hinge region generally comprises up to 25 amino acid residues and is flexible allowing the associated target binding sites to move independently.
  • the hinge region can be subdivided into three domains: the upper, the middle, and the lower hinge domain (see e.g. Roux, et al., J. Immunol. 161 (1998) 4083).
  • the hinge region has the amino acid sequence DKTHTCPXCP (SEQ ID NO: 99), wherein X is either S or P. In one aspect, the hinge region has the amino acid sequence HTCPXCP (SEQ ID NO: 100), wherein X is either S or P. In one aspect, the hinge region has the amino acid sequence CPXCP (SEQ ID NO: 101), wherein X is either S or P.
  • Fc domain or “Fc region” herein is used to define a C-terminal region of an antibody heavy chain that contains at least a portion of the constant region.
  • the term includes native sequence Fc regions and variant Fc regions.
  • Fc domain may only refer to an IgG CH2 and an IgG CH3 domain.
  • the “CH2 domain” of a human IgG Fc region usually extends from an amino acid residue at about EU position 231 to an amino acid residue at about EU position 340 (EU numbering system according to Kabat).
  • a CH2 domain has the amino acid sequence of APELLGGPSV FLFPPKPKDT LMISRTPEVT CVWDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQESTYRW SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAK (SEQ ID NO: 102).
  • the CH2 domain is unique in that it is not closely paired with another domain. Rather, two N-linked branched carbohydrate chains are interposed between the two CH2 domains of an intact native Fc-region.
  • carbohydrate may provide a substitute for the domaindomain pairing and help stabilize the CH2 domain.
  • a carbohydrate chain is attached to the CH2 domain.
  • the CH2 domain herein may be a native sequence CH2 domain or variant CH2 domain.
  • the “CH3 domain” comprises the stretch of residues C-terminal to a CH2 domain in an Fc region denotes the part of an antibody heavy chain polypeptide that extends approximately from EU position 341 to EU position 446 (EU numbering system according to Kabat).
  • the CH3 domain has the amino acid sequence of GQPREPQVYT LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK (SEQ ID NO: 103).
  • the CH3 region herein may be a native sequence CH3 domain or a variant CH3 domain (e.g.
  • CH3 domain with an introduced “protuberance” (“knob”) in one chain thereof and a corresponding introduced “cavity” (“hole”) in the other chain thereof; see US Patent No. 5,821,333, expressly incorporated herein by reference).
  • Such variant CH3 domains may be used to promote heterodimerization of two non-identical antibody heavy chains as herein described.
  • a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl -terminus of the heavy chain.
  • the C-terminal lysine (Lys447) of the Fc region may or may not be present.
  • EU numbering system also called the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.
  • the “knob-into-hole” technology is described e.g. in US 5,731,168; US 7,695,936; Ridgway et al., Prot Eng 9, 617-621 (1996) and Carter, J Immunol Meth 248, 7-15 (2001).
  • the method involves introducing a protuberance (“knob”) at the interface of a first polypeptide and a corresponding cavity (“hole”) in the interface of a second polypeptide, such that the protuberance can be positioned in the cavity so as to promote heterodimer formation and hinder homodimer formation.
  • Protuberances are constructed by replacing small amino acid side chains from the interface of the first polypeptide with larger side chains (e.g. tyrosine or tryptophan).
  • Compensatory cavities of identical or similar size to the protuberances are created in the interface of the second polypeptide by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine).
  • the protuberance and cavity can be made by altering the nucleic acid encoding the polypeptides, e.g. by site-specific mutagenesis, or by peptide synthesis.
  • a knob modification comprises the amino acid substitution T366W in one of the two subunits of the Fc domain
  • the hole modification comprises the amino acid substitutions T366S, L368A and Y407V in the other one of the two subunits of the Fc domain.
  • the subunit of the Fc domain comprising the knob modification additionally comprises the amino acid substitution S354C
  • the subunit of the Fc domain comprising the hole modification additionally comprises the amino acid substitution Y349C.
  • a "region equivalent to the Fc region of an immunoglobulin" is intended to include naturally occurring allelic variants of the Fc region of an immunoglobulin as well as variants having alterations which produce substitutions, additions, or deletions but which do not decrease substantially the ability of the immunoglobulin to mediate effector functions (such as antibodydependent cellular cytotoxicity).
  • one or more amino acids can be deleted from the N-terminus or C-terminus of the Fc region of an immunoglobulin without substantial loss of biological function.
  • Such variants can be selected according to general rules known in the art so as to have minimal effect on activity (see, e.g., Bowie, J. U. et al., Science 247: 1306-10 (1990)).
  • wild-type Fc domain denotes an amino acid sequence identical to the amino acid sequence of an Fc domain found in nature.
  • Wild-type human Fc domains include a native human IgGl Fc-region (non- A and A allotypes), native human IgG2 Fc-region, native human IgG3 Fc-region, and native human IgG4 Fc-region as well as naturally occurring variants thereof.
  • Wild-type Fc-regions are denoted in SEQ ID NO: 104 (IgGl, Caucasian allotype), SEQ ID NO: 105 (IgGl, afroamerican allotype), SEQ ID NO: 106 (IgG2), SEQ ID NO: 107 (IgG3) and SEQ ID NO: 108 (IgG4).
  • variant (human) Fc domain denotes an amino acid sequence which differs from that of a “wild-type” (human) Fc domain amino acid sequence by virtue of at least one “amino acid mutation”.
  • the variant Fc-region has at least one amino acid mutation compared to a native Fc-region, e.g. from about one to about ten amino acid mutations, and in one aspect from about one to about five amino acid mutations in a native Fc-region.
  • the (variant) Fc-region has at least about 95 % homology with a wild-type Fc-region.
  • a specific variant Fc domain disclosed herein is the human IgGl heavy chain constant region with mutations L234A, L235A and P329G comprising the amino acid sequence of SEQ ID NO: 109.
  • effector functions refers to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype.
  • antibody effector functions include: Clq binding and complement dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), cytokine secretion, immune complex -mediated antigen uptake by antigen presenting cells, down regulation of cell surface receptors (e.g. B cell receptor), and B cell activation.
  • Fc receptor binding dependent effector functions can be mediated by the interaction of the Fc-region of an antibody with Fc receptors (FcRs), which are specialized cell surface receptors on hematopoietic cells.
  • Fc receptors belong to the immunoglobulin superfamily, and have been shown to mediate both the removal of antibody-coated pathogens by phagocytosis of immune complexes, and the lysis of erythrocytes and various other cellular targets (e.g. tumor cells) coated with the corresponding antibody, via antibody dependent cell mediated cytotoxicity (ADCC) (see e.g. Van de Winkel, J.G. and Anderson, C.L., J. Leukoc. Biol. 49 (1991) 511-524).
  • ADCC antibody dependent cell mediated cytotoxicity
  • FcRs are defined by their specificity for immunoglobulin isotypes: Fc receptors for IgG antibodies are referred to as FcyR. Fc receptor binding is described e.g. in Ravetch, J.V. and Kinet, J.P., Annu. Rev. Immunol. 9 (1991) 457-492; Capel, P.J., et al., Immunomethods 4 (1994) 25-34; de Haas, M., et al., J. Lab. Clin. Med. 126 (1995) 330-341; and Gessner, J.E., et al., Ann. Hematol. 76 (1998) 231-248.
  • FcyR Fc-region of IgG antibodies
  • FcyRI binds monomeric IgG with high affinity and is expressed on macrophages, monocytes, neutrophils and eosinophils.
  • Modification in the Fc-region IgG at least at one of the amino acid residues E233-G236, P238, D265, N297, A327 and P329 (numbering according to EU index of Kabat) reduce binding to FcyRI.
  • FcyRIIA is found on many cells involved in killing (e.g. macrophages, monocytes, neutrophils) and seems able to activate the killing process.
  • FcyRIIB seems to play a role in inhibitory processes and is found on B cells, macrophages and on mast cells and eosinophils. On B-cells it seems to function to suppress further immunoglobulin production and isotype switching to, for example, the IgE class.
  • FcyRIIB acts to inhibit phagocytosis as mediated through FcyRIIA.
  • the B-form may help to suppress activation of these cells through IgE binding to its separate receptor.
  • Reduced binding for FcyRIIA is found e.g. for antibodies comprising an IgG Fc-region with mutations at least at one of the amino acid residues E233- G236, P238, D265, N297, A327, P329, D270, Q295, A327, R292, and K414 (numbering according to EU index of Kabat).
  • FcyRIII (CD16) binds IgG with medium to low affinity and exists as two types.
  • FcyRIIIA is found on NK cells, macrophages, eosinophils and some monocytes and T cells and mediates ADCC.
  • FcyRIIIB is highly expressed on neutrophils. Reduced binding to FcyRIIIA is found e.g.
  • antibodies comprising an IgG Fc-region with mutation at least at one of the amino acid residues E233-G236, P238, D265, N297, A327, P329, D270, Q295, A327, S239, E269, E293, Y296, V303, A327, K338 and D376 (numbering according to EU index of Kabat).
  • ADCC antibody-dependent cellular cytotoxicity
  • the target cells are cells to which antibodies or derivatives thereof comprising an Fc region specifically bind, generally via the protein part that is N-terminal to the Fc region.
  • reduced ADCC is defined as either a reduction in the number of target cells that are lysed in a given time, at a given concentration of antibody in the medium surrounding the target cells, by the mechanism of ADCC defined above, and/or an increase in the concentration of antibody in the medium surrounding the target cells, required to achieve the lysis of a given number of target cells in a given time, by the mechanism of ADCC.
  • the reduction in ADCC is relative to the ADCC mediated by the same antibody produced by the same type of host cells, using the same standard production, purification, formulation and storage methods (which are known to those skilled in the art), but that has not been engineered.
  • the reduction in ADCC mediated by an antibody comprising in its Fc domain an amino acid substitution that reduces ADCC is relative to the ADCC mediated by the same antibody without this amino acid substitution in the Fc domain.
  • Suitable assays to measure ADCC are well known in the art (see e.g. PCT publication no. WO 2006/082515 or PCT publication no. WO 2012/130831).
  • the capacity of the antibody to induce the initial steps mediating ADCC is investigated by measuring their binding to Fey receptors expressing cells, such as cells, recombinantly expressing FcyRI and/or FcyRIIA or NK cells (expressing essentially FcyRIIIA). In particular, binding to FcyR on NK cells is measured.
  • an “activating Fc receptor” is an Fc receptor that following engagement by an Fc region of an antibody elicits signaling events that stimulate the receptor-bearing cell to perform effector functions.
  • Activating Fc receptors include FcyRIIIa (CD16a), FcyRI (CD64), FcyRIIa (CD32), and FcaRI (CD89).
  • a particular activating Fc receptor is human FcyRIIIa (SEQ ID NO: 110, UniProt accession no. P08637, version 141).
  • Ectodomain is the domain of a membrane protein that extends into the extracellular space (i.e. the space outside the target cell). Ectodomains are usually the parts of proteins that initiate contact with surfaces, which leads to signal transduction.
  • peptide linker refers to a peptide comprising one or more amino acids, typically about 2 to 20 amino acids.
  • Peptide linkers are known in the art or are described herein.
  • Suitable, non-immunogenic linker peptides are, for example, (G4S) n , (SG4)n or G4(SG4) n peptide linkers, wherein “n” is generally a number between 1 and 5, typically between 2 and 4, in particular 2, i.e.
  • GGGGS GGGGSGGGG (SEQ ID NO: 111), GGGGSGGGG (SEQ ID NO: 112), GGGGSGGGGS (SEQ ID NO: 113), SGGGGSGGGG (SEQ ID NO: 114) and GGGGS GGGGSGGGG (SEQ ID NO: 115), but also include the sequences GSPGSSSSGS (SEQ ID NO: 116), (G4S) 3 (SEQ ID NO: 117), (G4S) 4 (SEQ ID NO: 118), GSGSGSGS (SEQ ID NO: 119), GSGSGNGS (SEQ ID NO: 120), GGSGSGSG (SEQ ID NO: 121), GGSGSG (SEQ ID NO: 122), GGSG (SEQ ID NO: 123), GGSGNGSG (SEQ ID NO: 124), GGNGSGSG (SEQ ID NO: 125) and GGNGSG (SEQ ID NO: 126).
  • Peptide linkers of particular interest are (G4S) (SEQ ID NO: 111), (G 4 S) 2 , GGGGSGGGG (SEQ ID NO: 112) or GGGGSGGGGS (SEQ ID NO: 113), (G4S) 3 (SEQ ID NO: 117), and (G4S) 4 (SEQ ID NO: 118).
  • amino acid denotes the group of naturally occurring carboxy a-amino acids comprising alanine (three letter code: ala, one letter code: A), arginine (arg, R), asparagine (asn, N), aspartic acid (asp, D), cysteine (cys, C), glutamine (gin, Q), glutamic acid (glu, E), glycine (gly, G), histidine (his, H), isoleucine (ile, I), leucine (leu, L), lysine (lys, K), methionine (met, M), phenylalanine (phe, F), proline (pro, P), serine (ser, S), threonine (thr, T), tryptophan (trp, W), tyrosine (tyr, Y), and valine (val, V).
  • alanine three letter code: ala, one letter code: A
  • arginine arg, R
  • fused or “connected” is meant that the components (e.g. a polypeptide and an ectodomain of said TNF ligand family member) are linked by peptide bonds, either directly or via one or more peptide linkers.
  • Percent (%) amino acid sequence identity with respect to a reference polypeptide (protein) sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN. SAWI or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
  • % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2.
  • the ALIGN- 2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087.
  • the ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, California, or may be compiled from the source code.
  • the ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
  • the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B is calculated as follows: 100 times the fraction X/Y, where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program’s alignment of A and B, and where Y is the total number of amino acid residues in B.
  • amino acid sequence variants of the BCMA antibodies or immunostimulatory antigen binding molecules provided herein are contemplated.
  • Amino acid sequence variants of the BCMA antibodies or immunostimulatory antigen binding molecules may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the molecules, or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of residues within the amino acid sequences of the antigen binding molecule.
  • Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, e.g., antigen-binding.
  • Sites of interest for substitutional mutagenesis include the CDRs and Framework (FRs). Conservative substitutions are provided in Table B under the heading “Preferred Substitutions” and further described below in reference to amino acid side chain classes (1) to (6). Amino acid substitutions may be introduced into the molecule of interest and the products screened for a desired activity, e.g., retained/improved antigen binding, decreased immunogenicity, or improved ADCC or CDC.
  • Amino acids may be grouped according to common side-chain properties:
  • Non-conservative substitutions will entail exchanging a member of one of these classes for another class.
  • amino acid sequence variants includes substantial variants wherein there are amino acid substitutions in one or more hypervariable region residues of a parent antigen binding molecule (e.g. a humanized or human antibody).
  • a parent antigen binding molecule e.g. a humanized or human antibody.
  • the resulting variant(s) selected for further study will have modifications (e.g., improvements) in certain biological properties (e.g., increased affinity, reduced immunogenicity) relative to the parent antigen binding molecule and/or will have substantially retained certain biological properties of the parent antigen binding molecule.
  • An exemplary substitutional variant is an affinity matured antibody, which may be conveniently generated, e.g., using phage display-based affinity maturation techniques such as those described herein.
  • one or more CDR residues are mutated and the variant antigen binding molecules displayed on phage and screened for a particular biological activity (e.g. binding affinity).
  • substitutions, insertions, or deletions may occur within one or more CDRs so long as such alterations do not substantially reduce the ability of the antigen binding molecule to bind antigen.
  • conservative alterations e.g., conservative substitutions as provided herein
  • a useful method for identification of residues or regions of an antibody that may be targeted for mutagenesis is called "alanine scanning mutagenesis" as described by Cunningham and Wells (1989) Science, 244: 1081-1085.
  • a residue or group of target residues e.g., charged residues such as Arg, Asp, His, Lys, and Glu
  • a neutral or negatively charged amino acid e.g., alanine or polyalanine
  • Further substitutions may be introduced at the amino acid locations demonstrating functional sensitivity to the initial substitutions.
  • a crystal structure of an antigen-antigen binding molecule complex to identify contact points between the antibody and antigen. Such contact residues and neighboring residues may be targeted or eliminated as candidates for substitution.
  • Variants may be screened to determine whether they contain the desired properties.
  • Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues.
  • Examples of insertions include immunostimulatory antigen binding molecules with a fusion to the N- or C-terminus to a polypeptide which increases the serum half-life of the immunostimulatory antigen binding molecule.
  • the immunostimulatory antigen binding molecules provided herein are altered to increase or decrease the extent to which the antibody is glycosylated. Glycosylation variants of the molecules may be conveniently obtained by altering the amino acid sequence such that one or more glycosylation sites is created or removed. Where the agonistic ICOS- binding molecule comprises an Fc domain, the carbohydrate attached thereto may be altered. Native antibodies produced by mammalian cells typically comprise a branched, biantennary oligosaccharide that is generally attached by an N-linkage to Asn297 of the CH2 domain of the Fc region. See, e.g., Wright et al. TIBTECH 15:26-32 (1997).
  • the oligosaccharide may include various carbohydrates, e.g., mannose, N-acetyl glucosamine (GlcNAc), galactose, and sialic acid, as well as a fucose attached to a GlcNAc in the “stem” of the biantennary oligosaccharide structure.
  • modifications of the oligosaccharide in BCMA antibodies or bispecific BCMA antibodies may be made in order to create variants with certain improved properties.
  • variants of BCMA antibodies or bispecific BCMA antibodies are provided having a carbohydrate structure that lacks fucose attached (directly or indirectly) to an Fc region.
  • Such fucosylation variants may have improved ADCC function, see e.g. US Patent Publication Nos. US 2003/0157108 (Presta, L.) or US 2004/0093621 (Kyowa Hakko Kogyo Co., Ltd).
  • Further variants of the BCMA antibodies or bispecific BCMA antibodies include those with bisected oligosaccharides, e.g., in which a biantennary oligosaccharide attached to the Fc region is bisected by GlcNAc.
  • Such variants may have reduced fucosylation and/or improved ADCC function., see for example WO 2003/011878 (Jean-Mairet et al.); US Patent No.
  • cysteine engineered variants of the immunostimulatory antigen binding molecules described herein e.g., “thioMAbs,” in which one or more residues of the molecule are substituted with cysteine residues.
  • the substituted residues occur at accessible sites of the molecule.
  • reactive thiol groups are thereby positioned at accessible sites of the antibody and may be used to conjugate the immunostimulatory antigen binding molecule to other moieties, such as drug moieties or linker-drug moieties, to create an immunoconjugate.
  • any one or more of the following residues may be substituted with cysteine: V205 (Kabat numbering) of the light chain; Al 18 (EU numbering) of the heavy chain; and S400 (EU numbering) of the heavy chain Fc region.
  • Cysteine engineered antigen binding molecules may be generated as described, e.g., in U.S. Patent No. 7,521,541.
  • the immunostimulatory antigen binding molecules provided herein may be further modified to contain additional non-proteinaceous moieties that are known in the art and readily available.
  • the moieties suitable for derivatization of the antigen binding molecule include but are not limited to water soluble polymers.
  • Non-limiting examples of water soluble polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1, 3-dioxolane, poly-1, 3, 6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random copolymers), and dextran or poly(n-vinyl pyrrolidone)polyethylene glycol, propropylene glycol homopolymers, prolypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof.
  • PEG polyethylene glycol
  • copolymers of ethylene glycol/propylene glycol carboxymethylcellulose
  • dextran polyvinyl alcohol
  • Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water.
  • the polymer may be of any molecular weight, and may be branched or unbranched.
  • the number of polymers attached to the antibody may vary, and if more than one polymer is attached, they can be the same or different molecules. In general, the number and/or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular properties or functions of the antibody to be improved, whether the bispecific antibody derivative will be used in a therapy under defined conditions, etc.
  • conjugates of an antibody and non-proteinaceous moiety that may be selectively heated by exposure to radiation are provided.
  • the non-proteinaceous moiety is a carbon nanotube (Kam, N.W. et al., Proc. Natl. Acad. Sci. USA 102 (2005) 11600-11605).
  • the radiation may be of any wavelength, and includes, but is not limited to, wavelengths that do not harm ordinary cells, but which heat the non-proteinaceous moiety to a temperature at which cells proximal to the antibody-non-proteinaceous moiety are killed.
  • immunoconjugates of the BCMA antibodies or bispecific BCMA antibodies provided herein may be obtained.
  • An “immunoconjugate” is an antigen binding molecule conjugated to one or more heterologous molecule(s), for instance a small molecule agent.
  • polynucleotide refers to an isolated nucleic acid molecule or construct, e.g. messenger RNA (mRNA), virally-derived RNA, or plasmid DNA (pDNA).
  • a polynucleotide may comprise a conventional phosphodiester bond or a non-conventional bond (e.g. an amide bond, such as found in peptide nucleic acids (PNA).
  • PNA peptide nucleic acids
  • nucleic acid molecule refers to any one or more nucleic acid segments, e.g. DNA or RNA fragments, present in a polynucleotide. Each nucleotide is composed of a base, specifically a purine- or pyrimidine base (i.e.
  • nucleic acid molecule is described by the sequence of bases, whereby said bases represent the primary structure (linear structure) of a nucleic acid molecule.
  • sequence of bases is typically represented from 5’ to 3’.
  • nucleic acid molecule encompasses deoxyribonucleic acid (DNA) including e.g., complementary DNA (cDNA) and genomic DNA, ribonucleic acid (RNA), in particular messenger RNA (mRNA), synthetic forms of DNA or RNA, and mixed polymers comprising two or more of these molecules.
  • DNA deoxyribonucleic acid
  • cDNA complementary DNA
  • RNA ribonucleic acid
  • mRNA messenger RNA
  • the nucleic acid molecule may be linear or circular.
  • nucleic acid molecule includes both, sense and antisense strands, as well as single stranded and double stranded forms.
  • the herein described nucleic acid molecule can contain naturally occurring or non-naturally occurring nucleotides.
  • nucleic acid molecules also encompass DNA and RNA molecules which are suitable as a vector for direct expression of an antibody of the invention in vitro and/or in vivo, e.g., in a host or patient.
  • DNA e.g., cDNA
  • RNA e.g., mRNA
  • mRNA can be chemically modified to enhance the stability of the RNA vector and/or expression of the encoded molecule so that mRNA can be injected into a subject to generate the antibody in vivo (see e.g., Stadler et al. (2017) Nature Medicine 23:815-817, or EP 2 101 823 Bl).
  • isolated nucleic acid molecule or polynucleotide is meant a nucleic acid molecule, DNA or RNA, which has been removed from its native environment.
  • a recombinant polynucleotide encoding a polypeptide contained in a vector is considered isolated for the purposes of the present invention.
  • Further examples of an isolated polynucleotide include recombinant polynucleotides maintained in heterologous host cells or purified (partially or substantially) polynucleotides in solution.
  • An isolated polynucleotide includes a polynucleotide molecule contained in cells that ordinarily contain the polynucleotide molecule, but the polynucleotide molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.
  • Isolated RNA molecules include in vivo or in vitro RNA transcripts, as well as positive and negative strand forms, and double-stranded forms. Isolated polynucleotides or nucleic acids according to the present disclosure further include such molecules produced synthetically.
  • a polynucleotide or a nucleic acid may be or may include a regulatory element such as a promoter, ribosome binding site, or a transcription terminator.
  • nucleic acid or polynucleotide having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence.
  • a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence.
  • These alterations of the reference sequence may occur at the 5’ or 3’ terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.
  • any particular polynucleotide sequence is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs, such as the ones discussed above for polypeptides (e.g. ALIGN-2).
  • expression cassette refers to a polynucleotide generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a target cell.
  • the recombinant expression cassette can be incorporated into a plasmid, chromosome, mitochondrial DNA, plastid DNA, virus, or nucleic acid fragment.
  • the recombinant expression cassette portion of an expression vector includes, among other sequences, a nucleic acid sequence to be transcribed and a promoter.
  • the expression cassette as disclosed herein comprises polynucleotide sequences that encode the immunostimulatory antigen binding molecule or fragments thereof.
  • vector or "expression vector” is synonymous with "expression construct” and refers to a DNA molecule that is used to introduce and direct the expression of a specific gene to which it is operably associated in a target cell.
  • the term includes the vector as a self-replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced.
  • the expression vector of the present invention comprises an expression cassette. Expression vectors allow transcription of large amounts of stable mRNA. Once the expression vector is inside the target cell, the ribonucleic acid molecule or protein that is encoded by the gene is produced by the cellular transcription and/or translation machinery.
  • the expression vector as disclosed herein comprises an expression cassette that comprises polynucleotide sequences that encode an immunostimulatory antigen binding molecule or fragments thereof.
  • host cell refers to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells.
  • Host cells include “transformants” and “transformed cells,” which include the primary transformed cell and progeny derived therefrom without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to a parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein.
  • a host cell is any type of cellular system that can be used to generate the bispecific antigen binding molecules of the present invention.
  • Host cells include cultured cells, e.g.
  • mammalian cultured cells such as CHO cells, BHK cells, NSO cells, SP2/0 cells, YO myeloma cells, P3X63 mouse myeloma cells, PER cells, PER.C6 cells or hybridoma cells, yeast cells, insect cells, and plant cells, to name only a few, but also cells comprised within a transgenic animal, transgenic plant or cultured plant or animal tissue.
  • an “effective amount” of an agent refers to the amount that is necessary to result in a physiological change in the cell or tissue to which it is administered.
  • a “therapeutically effective amount” of an agent refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.
  • a therapeutically effective amount of an agent for example eliminates, decreases, delays, minimizes or prevents adverse effects of a disease.
  • mammals include, but are not limited to, domesticated animals (e.g. cows, sheep, cats, dogs, and horses), primates (e.g. humans and nonhuman primates such as monkeys), rabbits, and rodents (e.g. mice and rats). Particularly, the individual or subject is a human.
  • domesticated animals e.g. cows, sheep, cats, dogs, and horses
  • primates e.g. humans and nonhuman primates such as monkeys
  • rabbits e.g. mice and rats
  • rodents e.g. mice and rats
  • composition refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.
  • a “pharmaceutically acceptable excipient” refers to an ingredient in a pharmaceutical composition, other than an active ingredient, which is nontoxic to a subject.
  • a pharmaceutically acceptable excipient includes, but is not limited to, a buffer, a stabilizer, or a preservative.
  • package insert is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and/or warnings concerning the use of such therapeutic products.
  • treatment and grammatical variations thereof such as “treat” or “treating” refers to clinical intervention in an attempt to alter the natural course of the individual being treated, and can be performed either for prophylaxis or during the course of clinical pathology.
  • Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis.
  • the molecules of the invention are used to delay development of a disease or to slow the progression of a disease.
  • the term “therapy” refers to any protocol, method and/or agent that can be used in the prevention, management, treatment and/or amelioration of a disease (or symptom related thereto) or cancer.
  • the terms “therapies” and “therapy” refer to a biological therapy, supportive therapy, and/or other therapies useful in the prevention, management, treatment and/or amelioration of a disease or cancer known to one of skill in the art such as a physician.
  • combination treatment or “co-administration” as noted herein encompasses combined administration (where two or more therapeutic agents are included in the same or separate formulations), and separate administration, in which case, administration of an antibody as reported herein can occur prior to, simultaneously, and/or following, administration of the additional therapeutic agent or agents, preferably an antibody or antibodies.
  • cancer refers to or describes the physiological condition in mammals that is typically characterized by unregulated cell growth/proliferation.
  • cancer refers to proliferative diseases, such as carcinoma, lymphomas (e.g., Hodgkin’s and nonHodgkin’s lymphoma), blastoma, sarcoma, and leukemia.
  • cancer includes lymphocytic leukemias, lung cancer, non-small cell lung (NSCL) cancer, bronchi oloalviolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal
  • the cancer is a solid tumor.
  • the cancer is a haematological cancer, particularly leukemia, most particularly acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML).
  • ALL acute lymphoblastic leukemia
  • AML acute myelogenous leukemia
  • the term cancer refers to any canceer in which BCMA is expressed. More preferably, the cancer is multiple myeloma (MM).
  • novel antibodies and/or antibody fragments that specifically bind to B cell maturation antigen (BCMA).
  • novel antibodies and/or antibody fragments that specifically bind to the extracellular domain of human BCMA comprising the amino acid sequence of SEQ ID NO: 127. Thus, these antibodies specifically bind to human BCMA.
  • These antibodies are able to bind to human BCMA and to cynomolgus BCMA. Thus, they also bind to the extracellular domain of cynomolgus BCMA comprising the amino acid sequence of SEQ ID NO: 129.
  • the new antibodies are also able to bind to mutated human BCMA variants hu BCMA R27P (SEQ ID NO:203), Hu BCMA_S30del (SEQ ID NO:204), hu BCMA_P33S (SEQ ID NO:205) and hu BCMA_P34del (SEQ ID NO:206). They are therefore not affected by point mutations in the ECD of BCMA and do not lose the therapeutic activity as has been observed with other BCMA-targeted molecules such as Elranatamab and Teclistamab ((Lee et al., Nature Medicine 2023, 29, 2295-2306).
  • the new antibodies are further characterized in that they are producable in high amounts and with high titers, that they show high thermal stability (as measured by the aggregation temperature T agg ), or in that they possess a high degree of humanness and may therefore be less immunogenic in the human body.
  • the percentage of humanness of the VH and VL sequences as compared to the human germline sequences can be determined by the methods described in Abhinandan, K. R. and Martin, Andrew C. R. 2007, J. Mol. Biol. 2007, 369, 852-862.
  • VH BCMA heavy chain variable region
  • VH BCMA heavy chain variable region comprising a heavy chain complementary determining region CDR-H1 of SEQ ID NO: 1 (GYTFTNYWMH), a CDR-H2 of SEQ ID NO: 2 (IH4PNSGSTNYNEKFQG), and a CDR-H3 of SEQ ID NO: 3 (GIYDYPFAY), and
  • VLBCMA light chain variable region
  • VL comprising a light chain complementary determining region CDR-L1 of SEQ ID NO: 4 (RASES VSIHGTHLMH), a CDR-L2 of SEQ ID NO: 5 (AASSLQS) and a CDR-L3 of SEQ ID NO: 6 (QQSIEDPYT); or
  • VL comprising a light chain complementary determining region CDR-L1 of SEQ ID NO: 4 (RASES VSIHGTHLMH), a CDR-L2 of SEQ ID NO: 7 (AASNLES) and a CDR-L3 of SEQ ID NO: 6 (QQSIEDPYT), or
  • VL comprising a light chain complementary determining region CDR-L1 of SEQ ID NO: 4 (RASES VSIHGTHLMH), a CDR-L2 of SEQ ID NO: 8 (AASNLQS) and a CDR-L3 of SEQ ID NO: 6 (QQSIEDPYT).
  • a BCMA antibody (or an antigen binding domain that specifically binds to BCMA), wherein said antibody comprises a VH BCMA comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 13 (VHla) and SEQ ID NO: 14 (VHlb), and/or a VLBCMA comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 15 (VLlf) , SEQ ID NO: 16 (VLla), SEQ ID NO: 17 (VLlb), SEQ ID NO: 18 (VLlc), SEQ ID NO: 19 (VLld), and SEQ ID NO:20 (VLle).
  • VH BCMA comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 13 (VHla) and SEQ ID NO: 14 (VHlb)
  • VLBCMA comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 15 (VLlf) , SEQ ID NO: 16 (VLla), SEQ ID
  • BCMA antibody or an antigen binding domain that specifically binds to BCMA, wherein said antibody (or antigen binding domain) comprises
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13
  • VLBCMA comprising an amino acid sequence of SEQ ID NO: 15, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 16;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 17, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 18;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 19, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and VLBCMA comprising an amino acid sequence of SEQ ID NO:20;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 130, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 131;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 14 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 15, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 14 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 16;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 14
  • VLBCMA comprising an amino acid sequence of SEQ ID NO: 17, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 14 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 18;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 14 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 19, or (n) a VH BCMA comprising an amino acid sequence of SEQ ID NO: 14 and VLBCMA comprising an amino acid sequence of SEQ ID NO:20; or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 14 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 130, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 14
  • VLBCMA comprising an amino acid sequence of SEQ ID NO: 131.
  • the BCMA antibody (or the antigen binding domain that specifically binds to BCMA) comprises
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13
  • VLBCMA comprising an amino acid sequence of SEQ ID NO: 15, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 16;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 17, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 18;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 19, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and VLBCMA comprising an amino acid sequence of SEQ ID NO:20;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 130, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13
  • VLBCMA comprising an amino acid sequence of SEQ ID NO: 131.
  • the BCMA antibody (or the antigen binding domain that specifically binds to BCMA) comprises
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 14 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 15, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 14 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 16;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 14
  • VLBCMA comprising an amino acid sequence of SEQ ID NO: 17, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 14 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 18;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 14
  • VLBCMA comprising an amino acid sequence of SEQ ID NO: 19, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 14 and VLBCMA comprising an amino acid sequence of SEQ ID NO:20; or (o) a VH BCMA comprising an amino acid sequence of SEQ ID NO: 14 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 130, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 14
  • VLBCMA comprising an amino acid sequence of SEQ ID NO: 131.
  • BCMA antibody or an antigen binding domain that specifically binds to BCMA, wherein said antibody (or antigen binding domain) comprises
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and a VLBCMA comprising an amino acid sequence of SEQ ID NO: 15, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13
  • VLBCMA comprising an amino acid sequence of SEQ ID NO: 16.
  • the BCMA antibody (or the antigen binding domain that specifically binds to BCMA) comprises a VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and a VLBCMA comprising an amino acid sequence of SEQ ID NO: 15.
  • VH BCMA heavy chain variable region
  • VH comprising a heavy chain complementary determining region CDR-H1 of SEQ ID NO: 26 (GFTFSNAWMD), a CDR-H2 of SEQ ID NO: 27 (QITAKSNNYATYYADSVKG), and a CDR-H3 of SEQ ID NO: 28 (DGYH), and
  • VH comprising a heavy chain complementary determining region CDR-H1 of SEQ ID NO: 26 (GFTFSNAWMD), a CDR-H2 of SEQ ID NO: 29 (QITAKSNNYATYYAAPVKG), and a CDR-H3 of SEQ ID NO: 29 (DGYH), and
  • VLBCMA light chain variable region
  • RASEDIRNGLA light chain complementary determining region CDR-L1 of SEQ ID NO: 30
  • NANSLHT NANSLHT
  • EDTSKYPYT a light chain variable region comprising a light chain complementary determining region CDR-L1 of SEQ ID NO: 30 (RASEDIRNGLA), a CDR-L2 of SEQ ID NO: 31 (NANSLHT) and a CDR-L3 of SEQ ID NO: 32 (EDTSKYPYT).
  • a BCMA antibody (or an antigen binding domain that specifically binds to BCMA), wherein said antibody (or antigen binding domain) comprises a heavy chain variable region (VHBCMA) comprising a CDR-H1 of SEQ ID NO: 26 (GFTFSNAWMD), a CDR-H2 of SEQ ID NO: 27 (QITAKSNNYATYYADSVKG), and a CDR-H3 of SEQ ID NO: 28 (DGYH), and a light chain variable region (VLBCMA) comprising a CDR-L1 of SEQ ID NO: 30 (RASEDIRNGLA), a CDR-L2 of SEQ ID NO: 31 (NANSLHT) and a CDR-L3 of SEQ ID NO: 32 (EDTSKYPYT).
  • VHBCMA heavy chain variable region
  • RASEDIRNGLA RASEDIRNGLA
  • NANSLHT NANSLHT
  • EDTSKYPYT CDR-L3 of SEQ ID NO: 32
  • a BCMA antibody (or an antigen binding domain that specifically binds to BCMA), wherein said antibody (or antigen binding domain) comprises a heavy chain variable region (VHBCMA) comprising a CDR-H1 of SEQ ID NO: 26 (GFTFSNAWMD), a CDR-H2 of SEQ ID NO: 29 (QITAKSNNYATYYAAPVKG), and a CDR-H3 of SEQ ID NO: 28 (DGYH), and a light chain variable region (VLBCMA) comprising a CDR-L1 of SEQ ID NO: 30 (RASEDIRNGLA), a CDR-L2 of SEQ ID NO: 31 (NANSLHT) and a CDR-L3 of SEQ ID NO: 32 (EDTSKYPYT).
  • VHBCMA heavy chain variable region
  • RASEDIRNGLA RASEDIRNGLA
  • NANSLHT NANSLHT
  • EDTSKYPYT CDR-L3 of SEQ ID NO: 32
  • a BCMA antibody (or an antigen binding domain that specifically binds to BCMA), wherein said antibody (or antigen binding domain) comprises a VH BCMA comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 33 (VH2a), SEQ ID NO: 35 (VHlb), SEQ ID NO:53 (VHla), SEQ ID NO:54 (VHla_Y292D), SEQ ID NO 55 (VHlc hu CDR2) and SEQ ID NO:56 (VHla_W197Y), and/or the V L BCMA comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 34 (VL2a), SEQ ID NO:36 (VLla), SEQ ID NO:57 (VLla_L2_GL), SEQ ID NO:58 (VL2a_L2_GL), SEQ ID NO:59 (VLla_Ll_pGL), SEQ ID NO:60 (VLla_N651A), SEQ ID NO:
  • a BCMA antibody (or an antigen binding domain that specifically binds to BCMA), wherein said antibody (or antigen binding domain) comprises a VH BCMA comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 33 (VH2a) and SEQ ID NO: 35 (VHlb), and/or the VL BCMA comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 34 (VL2a) and SEQ ID NO:36 (VLla).
  • BCMA antibody or an antigen binding domain that specifically binds to BCMA, wherein said antibody (or antigen binding domain) comprises
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:33 and a VL BCMA comprising an amino acid sequence of SEQ ID NO:34, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:35 and a VL BCMA comprising an amino acid sequence of SEQ ID NO:36;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:53 and VLBCMA comprising an amino acid sequence of SEQ ID NO:57, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:54 and VLBCMA comprising an amino acid sequence of SEQ ID NO:36;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:54 and VLBCMA comprising an amino acid sequence of SEQ ID NO:57, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:54 and VLBCMA comprising an amino acid sequence of SEQ ID NO:63;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:54 and VLBCMA comprising an amino acid sequence of SEQ ID NO:34, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:35 and VLBCMA comprising an amino acid sequence of SEQ ID NO:59;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:35 and VLBCMA comprising an amino acid sequence of SEQ ID NO:60
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:35 and VLBCMA comprising an amino acid sequence of SEQ ID NO:61
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:35 and VLBCMA comprising an amino acid sequence of SEQ ID NO:63, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:35 and VLBCMA comprising an amino acid sequence of SEQ ID NO:34;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:33 and VLBCMA comprising an amino acid sequence of SEQ ID NO:36, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:33 and VLBCMA comprising an amino acid sequence of SEQ ID NO:59;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:33 and VLBCMA comprising an amino acid sequence of SEQ ID NO:63.
  • BCMA antibody or an antigen binding domain that specifically binds to BCMA, wherein said antibody (or antigen binding domain) comprises
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:33 and a VLBCMA comprising an amino acid sequence of SEQ ID NO:34, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:35
  • VLBCMA comprising an amino acid sequence of SEQ ID NO:36.
  • the BCMA antibody comprises a VH BCMA comprising an amino acid sequence of SEQ ID NO:33 and a VLBCMA comprising an amino acid sequence of SEQ ID NO:34.
  • the antibody that specifically binds to BCMA is a full-length antibody, in particular of human IgGl subclass. In one particular aspect, it comprises the amino acid mutations L234A, L235A and P329G (numbering according to Kabat EU index).
  • Immunostimulatory antigen binding molecules comprising the new BCMA antibodies
  • the patent application provides new BCMA targeting 4-1BBL antigen binding molecules that comprise three 4-1 BB ligands or fragments thereof that are fused to the antigen binding molecule whereby two of the 4-1 BB ligands or fragments thereof are fused to each other via a linker and one 4- IBB ligand is present on a different chain of the molecule (split 4-1BBL trimer).
  • These BCMA targeting 4-1BBL antigen binding molecules possess advantageous properties such as excellent producibility, stability, binding affinity, biological activity, targeting efficiency, reduced toxicity, an extended dosage range that can be given to a patient and thereby a possibly an enhanced efficacy can be observed.
  • the new BCMA targeting 4-1BBL antigen binding molecules comprise an Fc domain composed of a first and a second subunit capable of stable association comprising one or more amino acid substitution that reduces the binding affinity of the antigen binding molecule to an Fc receptor and/or effector function (Fc silent) and thus unspecific cross-linking via Fc receptors is avoided. Instead, they comprise specific antigen binding domain capable of specific binding to BCMA which causes cross-linking at the tumor site.
  • the inventors have found that based on their binding properties the BCMA antigen binding domains as described herein have advantageous properties that makes them more usable in this format as other BCMA antigen binding domains.
  • a 4-1BBL antigen binding molecule comprising BCMA antibody PR was less able to induce T cell activation compared to the 4-1BBL antigen binding molecules comprising the new BCMA antibodies described herein. It has been found that the a 4-1BBL antigen binding molecules comprising these BCMA antigen binding domains possess an improved functionality and ability to increase T cell activation, particularly in the presence of T-cell activating anti-CD3 bispecific antibodies. Thus, an enhanced tumor-specific T cell activation is achieved.
  • an immunostimulatory antigen binding molecule that specifically binds to B cell maturation agent (BCMA), comprising a) an antigen binding domain comprising
  • VH BCMA heavy chain variable region
  • VH BCMA heavy chain variable region comprising a heavy chain complementary determining region CDR-H1 of SEQ ID NO: 1 (GYTFTNYWMH), a CDR-H2 of SEQ ID NO: 2 (IIHPNSGSTNYNEKFQG), and a CDR-H3 of SEQ ID NO: 3 (GIYDYPFAY), and
  • VLBCMA light chain variable region
  • VL comprising a light chain complementary determining region CDR-L1 of SEQ ID NO: 4 (RASES VSH4GTHLMH), a CDR-L2 of SEQ ID NO: 5 (AASSLQS) and a CDR-L3 of SEQ ID NO: 6 (QQSIEDPYT); and
  • VL comprising a light chain complementary determining region CDR-L1 of SEQ ID NO: 4 (RASES VSIHGTHLMH), a CDR-L2 of SEQ ID NO: 7 (AASNLES) and a CDR-L3 of SEQ ID NO: 6 (QQSIEDPYT), and
  • VL comprising a light chain complementary determining region CDR-L1 of SEQ ID NO: 4 (RASES VSIHGTHLMH), a CDR-L2 of SEQ ID NO: 8 (AASNLQS) and a CDR- L3 of SEQ ID NO: 6 (QQSIEDPYT),
  • the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of 4-1 BBL or a fragment thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises one ectodomain of 4-1BBL or a fragment thereof, and
  • an immunostimulatory antigen binding molecule as defined above, wherein the ectodomain of 4-1BBL or a fragment thereof comprises the amino acid sequence of SEQ ID NO:9 or SEQ ID NO: 10.
  • the ectodomain of 4- 1BBL or a fragment thereof comprises the amino acid sequence of SEQ ID NO:9.
  • the immunostimulatory antigen binding molecule comprises three ectodomains of 4-1BBL each comprising the amino acid sequence of SEQ ID NO:9 or SEQ ID NO: 10, particularly the amino acid sequence of SEQ ID NO: 9.
  • an immunostimulatory antigen binding molecule as defined above, wherein the immunostimulatory antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 189 and SEQ ID NO: 190 and in that the second polypeptide comprises the amino acid sequence of SEQ ID NO:9 or SEQ ID NO: 10.
  • the immunostimulatory antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence of SEQ ID NO: 11 and in that the second polypeptide comprises the amino acid sequence of SEQ ID NO:9.
  • the peptide linker that connects the ectodomains of 4-1BBL or a fragment thereof with each other comprises the amino acid sequence of SEQ ID NO: 112 or SEQ ID NO:113. In one particular aspect, the peptide linker comprises the amino acid sequence of SEQ ID NO:112.
  • an immunostimulatory antigen binding molecule as defined above, wherein said antigen binding molecule comprises a VH BCMA comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 13 (VHla) and SEQ ID NO: 14 (VHlb), and/or a VL BCMA comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 15 (VLlf) , SEQ ID NO: 16 (VLla), SEQ ID NO: 17 (VLlb), SEQ ID NO: 18 (VLlc), SEQ ID NO: 19 (VLld), and SEQ ID NO:20 (VLle).
  • VH BCMA comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 13 (VHla) and SEQ ID NO: 14 (VHlb
  • VL BCMA comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 15 (VLlf) , SEQ ID NO: 16 (VLla), SEQ ID NO: 17 (
  • an immunostimulatory antigen binding molecule as defined above, wherein said antigen binding molecule comprises
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13
  • VLBCMA comprising an amino acid sequence of SEQ ID NO: 15, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 16;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 17, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 18;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 19, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and VLBCMA comprising an amino acid sequence of SEQ ID NO:20;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 130
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 131; or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 14 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 15, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 14 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 16;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 14
  • VLBCMA comprising an amino acid sequence of SEQ ID NO: 17, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 14 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 18;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 14
  • VLBCMA comprising an amino acid sequence of SEQ ID NO: 19, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 14 and VLBCMA comprising an amino acid sequence of SEQ ID NO:20;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 14 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 130, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 14
  • VLBCMA comprising an amino acid sequence of SEQ ID NO: 131.
  • the immunostimulatory antigen binding molecule as defined above comprises
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13
  • VLBCMA comprising an amino acid sequence of SEQ ID NO: 15, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 16;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 17, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 18;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 19, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and VLBCMA comprising an amino acid sequence of SEQ ID NO:20;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 130, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13
  • VLBCMA comprising an amino acid sequence of SEQ ID NO: 131.
  • the immunostimulatory antigen binding molecule as defined above comprises (i) a VH BCMA comprising an amino acid sequence of SEQ ID NO: 14 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 15, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 14 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 16;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 14
  • VLBCMA comprising an amino acid sequence of SEQ ID NO: 17, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 14 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 18;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 14
  • VLBCMA comprising an amino acid sequence of SEQ ID NO: 19, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 14 and VLBCMA comprising an amino acid sequence of SEQ ID NO:20;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 14 and VLBCMA comprising an amino acid sequence of SEQ ID NO: 130, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 14
  • VLBCMA comprising an amino acid sequence of SEQ ID NO: 131.
  • an immunostimulatory antigen binding molecule as defined above, wherein said antigen binding molecule comprises
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and a VL BCMA comprising an amino acid sequence of SEQ ID NO: 15, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13
  • VL BCMA comprising an amino acid sequence of SEQ ID NO: 16.
  • the immunostimulatory antigen binding molecule comprises a VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and a VL BCMA comprising an amino acid sequence of SEQ ID NO: 15.
  • the antigen binding domain is a Fab molecule.
  • the immunostimulatory antigen binding molecule as defined above comprises an Fc domain composed of a first and a second subunit.
  • the Fc domain composed of a first and a second subunit is an IgG, particularly an IgGl Fc domain.
  • the Fc domain is a human Fc domain.
  • the Fc domain comprises a modification promoting the association of the first and the second subunit of the Fc domain. In one aspect, the Fc domain comprises knobs into hole modifications. In one aspect, the first subunit of the Fc domain comprises the amino acid substitutions S354C and T366W (EU numbering) and the second subunit of the Fc domain comprises the amino acid substitutions Y349C, T366S and Y407V (numbering according to Kabat EU index).
  • the immunostimulatory antigen binding molecule as described herein comprises (a) a first polypeptide, comprising (ai) a first ectodomain of 4-1BBL or fragment thereof, fused at its C-terminus to the N-terminus of the second ectodomain of 4-1 BBL or fragment thereof, (aii) a second ectodomain of 4-1BBL or fragment thereof, fused at its C-terminus to the N-terminus of a CL domain, (aiii) the CL domain, fused at its C-terminus to the N-terminus of one of the subunits (e.g. the first subunit) of the Fc domain, and (aiv) one of the subunits (e.g. the first subunit) of the Fc domain;
  • a second polypeptide comprising (bi) a third ectodomain of 4-1BBL or fragment thereof, fused at its C-terminus to the N-terminus of a CHI domain, and (bii) the CHI domain;
  • a third polypeptide comprising (ci) the heavy chain of the Fab molecule, fused at its C- terminus to the N-terminus of the other one of the subunits (e.g. the second subunit) of the Fc domain, and (cii) the other one of the subunits (e.g. the second subunit) of the Fc domain; and
  • immunostimulatory antigen binding molecule as described above is a molecule, wherein n the CL domain of the first polypeptide the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat) and the amino acid at position 123 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the CHI domain of the second polypeptide the amino acid at position 147 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to Kabat EU index) and the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to Kabat EU index).
  • the immunostimulatory antigen binding molecule as described herein comprises a polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 21, a peptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 22, a polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 23, and a polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 24.
  • the immunostimulatory antigen binding molecule as described herein comprises a polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 21, a polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 22, a polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 23, and a polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 25.
  • the immunostimulatory antigen binding molecule as described herein comprises
  • the immunostimulatory antigen binding molecule comprises a first polypeptide comprising the amino acid sequence of SEQ ID NO:21, a second polypeptide comprising the amino acid sequence of SEQ ID NO:22, a third polypeptide comprising the amino acid sequence of SEQ ID NO:23 and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO:24.
  • the immunostimulatory antigen binding molecule comprises (a) a first polypeptide comprising the amino acid sequence of SEQ ID NO:208, a second polypeptide comprising the amino acid sequence of SEQ ID NO:22, a third polypeptide comprising the amino acid sequence of SEQ ID NO:207 and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO:24.
  • the immunostimulatory antigen binding molecule consists of (a) a first polypeptide comprising the amino acid sequence of SEQ ID NO:208, a second polypeptide comprising the amino acid sequence of SEQ ID NO:22, a third polypeptide comprising the amino acid sequence of SEQ ID NO:207 and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO:24.
  • BCMA B cell maturation agent
  • VLBCMA heavy chain variable region
  • VH comprising a heavy chain complementary determining region CDR-H1 of SEQ ID NO: 26 (GFTFSNAWMD), a CDR-H2 of SEQ ID NO: 27 (QITAKSNNYATYYADSVKG), and a CDR-H3 of SEQ ID NO: 28 (DGYH); and
  • VH comprising a heavy chain complementary determining region CDR-H1 of SEQ ID NO: 26 (GFTFSNAWMD), a CDR-H2 of SEQ ID NO: 29 (QITAKSNNYATYYAAPVKG), and a CDR-H3 of SEQ ID NO: 28 (DGYH); and
  • VLBCMA light chain variable region
  • the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of 4-1 BBL or a fragment thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises one ectodomain of 4-1BBL or a fragment thereof, and
  • the immunostimulatory antigen binding molecule as defined above, wherein the ectodomain of 4-1BBL or a fragment thereof comprises the amino acid sequence of SEQ ID NO:9 or SEQ ID NO: 10.
  • the ectodomain of 4- 1BBL or a fragment thereof comprises the amino acid sequence of SEQ ID NO:9.
  • the immunostimulatory antigen binding molecule comprises three ectodomains of 4-1BBL each comprising the amino acid sequence of SEQ ID NO:9 or SEQ ID NO: 10, particularly the amino acid sequence of SEQ ID NO: 9.
  • the immunostimulatory antigen binding molecule as defined above, wherein the immunostimulatory antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 189 and SEQ ID NO: 190 and in that the second polypeptide comprises the amino acid sequence of SEQ ID NO:9 or SEQ ID NO: 10.
  • the immunostimulatory antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence of SEQ ID NO: 11 and in that the second polypeptide comprises the amino acid sequence of SEQ ID NO:9.
  • the peptide linker that connects the ectodomains of 4-1BBL or a fragment thereof with each other comprises the amino acid sequence of SEQ ID NO: 112 or SEQ ID NO:113. In one particular aspect, the peptide linker comprises the amino acid sequence of SEQ ID NO:112.
  • an immunostimulatory antigen binding molecule as defined herein before, wherein said antigen binding molecule comprises a VH BCMA comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 33 (VH2a), SEQ ID NO: 35 (VHlb), SEQ ID NO:53 (VHla), SEQ ID NO:54 (VHla_Y292D), SEQ ID NO:55 (VHlc hu CDR2) and SEQ ID NO:56 (VHla_W197Y), and/or the VL BCMA comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 34 (VL2a), SEQ ID NO:36 (VLla), SEQ ID NO:57 (VLla_L2_GL), SEQ ID NO:58 (VL2a_L2_GL), SEQ ID NO:59 (VLla_Ll_pGL), SEQ ID NO:60 (VLla_N651A), SEQ ID NO:61 (VLla_
  • an immunostimulatory antigen binding molecule as described above, wherein said antigen binding molecule comprises a VH BCMA comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 33 (VH2a) and SEQ ID NO: 35 (VHlb), and/or the VL BCMA comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 34 (VL2a) and SEQ ID NO:36 (VLla).
  • an immunostimulatory antigen binding molecule wherein said antigen binding molecule comprises
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:33 and a VLBCMA comprising an amino acid sequence of SEQ ID NO:34
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:35 and a VLBCMA comprising an amino acid sequence of SEQ ID NO:36
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:53 and VLBCMA comprising an amino acid sequence of SEQ ID NO:57, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:54 and VLBCMA comprising an amino acid sequence of SEQ ID NO:36;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:54 and VLBCMA comprising an amino acid sequence of SEQ ID NO:57, or
  • VHBCMA comprising an amino acid sequence of SEQ ID NO:54 and VLBCMA comprising an amino acid sequence of SEQ ID NO:63;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:54 and VLBCMA comprising an amino acid sequence of SEQ ID NO:34, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:35 and VLBCMA comprising an amino acid sequence of SEQ ID NO:59;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:35 and VLBCMA comprising an amino acid sequence of SEQ ID NO:60, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:35 and VLBCMA comprising an amino acid sequence of SEQ ID NO:61;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:35 and VLBCMA comprising an amino acid sequence of SEQ ID NO:63, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:35 and VLBCMA comprising an amino acid sequence of SEQ ID NO:34;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:33 and VLBCMA comprising an amino acid sequence of SEQ ID NO:36, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:33 and VLBCMA comprising an amino acid sequence of SEQ ID NO:59;
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:33 and VLBCMA comprising an amino acid sequence of SEQ ID NO:63.
  • an immunostimulatory antigen binding molecule as described above, wherein said antigen binding molecule comprises
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:33 and a VLBCMA comprising an amino acid sequence of SEQ ID NO:34, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:35
  • VLBCMA comprising an amino acid sequence of SEQ ID NO:36.
  • the immunostimulatory antigen binding molecule comprises a VH BCMA comprising an amino acid sequence of SEQ ID NO:33 and a VLBCMA comprising an amino acid sequence of SEQ ID NO:34.
  • the antigen binding domain is a Fab molecule.
  • the antigen binding molecule that specifically binds to BCMA comprises an Fc domain composed of a first and a second subunit.
  • the Fc domain composed of a first and a second subunit is an IgG, particularly an IgGl Fc domain.
  • the Fc domain is a human Fc domain.
  • the Fc domain comprises a modification promoting the association of the first and the second subunit of the Fc domain. In one aspect, the Fc domain comprises knobs into hole modifications. In one aspect, the first subunit of the Fc domain comprises the amino acid substitutions S354C and T366W (EU numbering) and the second subunit of the Fc domain comprises the amino acid substitutions Y349C, T366S and Y407V (numbering according to Kabat EU index).
  • the immunostimulatory antigen binding molecule as described herein comprises
  • a first polypeptide comprising (ai) a first ectodomain of 4-1BBL or fragment thereof, fused at its C-terminus to the N-terminus of the second ectodomain of 4-1 BBL or fragment thereof, (aii) a second ectodomain of 4-1BBL or fragment thereof, fused at its C-terminus to the N-terminus of a CL domain, (aiii) the CL domain, fused at its C-terminus to the N-terminus of one of the subunits (e.g. the first subunit) of the Fc domain, and (aiv) one of the subunits (e.g. the first subunit) of the Fc domain;
  • a second polypeptide comprising (bi) a third ectodomain of 4-1BBL or fragment thereof, fused at its C-terminus to the N-terminus of a CHI domain, and (bii) the CHI domain;
  • a third polypeptide comprising (ci) the heavy chain of the Fab molecule, fused at its C- terminus to the N-terminus of the other one of the subunits (e.g. the second subunit) of the Fc domain, and (cii) the other one of the subunits (e.g. the second subunit) of the Fc domain; and
  • immunostimulatory antigen binding molecule as described above is a molecule, wherein the CL domain of the first polypeptide the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat) and the amino acid at position 123 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the CHI domain of the second polypeptide the amino acid at position 147 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to Kabat EU index) and the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to Kabat EU index).
  • the immunostimulatory antigen binding molecule as described herein comprises a polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 21, a polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 22, a polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 37, and a polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 38.
  • the immunostimulatory antigen binding molecule as described herein comprises a polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 21, a polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 22, a polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 39, and a polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 40.
  • the immunostimulatory antigen binding molecule as described herein comprises
  • the immunostimulatory antigen binding molecule as described herein comprises a first polypeptide comprising the amino acid sequence of SEQ ID NO: 21, a second polypeptide comprising the amino acid sequence of SEQ ID NO:22, a third polypeptide comprising the amino acid sequence of SEQ ID NO:37 and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 38.
  • the immunostimulatory antigen binding molecule comprises a Fc domain.
  • the Fc domain is an IgG, particularly an IgGl Fc domain.
  • the Fc domain is a human Fc domain, particularly a human IgGl Fc domain.
  • the Fc domain comprises one or more amino acid substitution that reduces binding to an Fc receptor and/or effector function. In one particular aspect, it comprises the amino acid mutations L234A, L235A and P329G (numbering according to Kabat EU index).
  • the Fc domain of the immunostimulatory antigen binding molecule described herein consists of a pair of polypeptide chains comprising heavy chain domains of an immunoglobulin molecule.
  • the Fc domain of an immunoglobulin G (IgG) molecule is a dimer, each subunit of which comprises the CH2 and CH3 IgG heavy chain constant domains.
  • the two subunits of the Fc domain are capable of stable association with each other.
  • the Fc domain confers favorable pharmacokinetic properties to the antigen binding molecules of the invention, including a long serum half-life which contributes to good accumulation in the target tissue and a favorable tissue-blood distribution ratio. On the other side, it may, however, lead to undesirable targeting of the antigen binding molecules to cells expressing Fc receptors rather than to the preferred antigen-bearing cells.
  • the Fc domain of the immunostimulatory antigen binding molecule that binds to BCMA exhibits reduced binding affinity to an Fc receptor and/or reduced effector function, as compared to a native IgGl Fc domain.
  • the Fc domain does not substantially bind to an Fc receptor and/or does not induce effector function.
  • the Fc receptor is an Fey receptor.
  • the Fc receptor is a human Fc receptor.
  • the Fc receptor is an activating human Fey receptor, more specifically human FcyRIIIa, FcyRI or FcyRIIa, most specifically human FcyRIIIa.
  • the Fc domain does not induce effector function.
  • the reduced effector function can include, but is not limited to, one or more of the following: reduced complement dependent cytotoxicity (CDC), reduced antibody-dependent cell-mediated cytotoxicity (ADCC), reduced antibody-dependent cellular phagocytosis (ADCP), reduced cytokine secretion, reduced immune complex-mediated antigen uptake by antigen- presenting cells, reduced binding to NK cells, reduced binding to macrophages, reduced binding to monocytes, reduced binding to polymorphonuclear cells, reduced direct signaling inducing apoptosis, reduced dendritic cell maturation, or reduced T cell priming.
  • CDC complement dependent cytotoxicity
  • ADCC reduced antibody-dependent cell-mediated cytotoxicity
  • ADCP reduced antibody-dependent cellular phagocytosis
  • cytokine secretion reduced immune complex-mediated antigen uptake by antigen- presenting cells
  • reduced binding to NK cells reduced binding to macrophages
  • monocytes reduced binding to monocytes
  • polymorphonuclear cells reduced direct signaling induc
  • one or more amino acid modifications may be introduced into the Fc region of an antigen binding molecule provided herein, thereby generating an Fc region variant.
  • the Fc region variant may comprise a human Fc region sequence (e.g., a human IgGl, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification (e.g. a substitution) at one or more amino acid positions.
  • an immunostimulatory antigen binding molecule that specifically binds to BCMA, wherein the Fc region comprises one or more amino acid substitution that reduces binding to an Fc receptor, in particular towards Fey receptor.
  • an immunostimulatory antigen binding molecule that specifically binds to BCMA, wherein the Fc region comprises one or more amino acid substitution and wherein the ADCC induced by the antigen binding molecule is reduced to 0-20% of the ADCC induced by an antibody comprising the wild-type human IgGl Fc region.
  • the Fc domain of the antigen binding molecule described herein comprises one or more amino acid mutation that reduces the binding affinity of the Fc domain to an Fc receptor and/or effector function.
  • the same one or more amino acid mutation is present in each of the two subunits of the Fc domain.
  • the Fc domain comprises an amino acid substitution at a position of E233, L234, L235, N297, P331 and P329 (EU numbering).
  • the Fc domain comprises amino acid substitutions at positions 234 and 235 (EU numbering) and/or 329 (EU numbering) of the IgG heavy chains.
  • an immunostimulatory antigen binding molecule that specifically binds to BCMA which comprises an Fc domain with the amino acid substitutions L234A, L235A and P329G (“P329G LALA”, EU numbering) in the IgG heavy chains.
  • the amino acid substitutions L234A and L235A refer to the so-called LALA mutation.
  • the “P329G LALA” combination of amino acid substitutions almost completely abolishes Fey receptor binding of a human IgGl Fc domain and is described in International Patent Appl. Publ. No. WO 2012/130831 Al which also describes methods of preparing such mutant Fc domains and methods for determining its properties such as Fc receptor binding or effector functions.
  • Fc domains with reduced Fc receptor binding and/or effector function also include those with substitution of one or more of Fc domain residues 238, 265, 269, 270, 297, 327 and 329 (U.S. Patent No. 6,737,056).
  • Such Fc mutants include Fc mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297 and 327, including the so-called “DANA” Fc mutant with substitution of residues 265 and 297 to alanine (US Patent No. 7,332,581).
  • the Fc domain is an IgG4 Fc domain.
  • IgG4 antibodies exhibit reduced binding affinity to Fc receptors and reduced effector functions as compared to IgGl antibodies.
  • the Fc domain is an IgG4 Fc domain comprising an amino acid substitution at position S228 (Kabat numbering), particularly the amino acid substitution S228P.
  • the Fc domain is an IgG4 Fc domain comprising amino acid substitutions L235E and S228P and P329G (EU numbering).
  • IgG4 Fc domain mutants and their Fey receptor binding properties are also described in WO 2012/130831.
  • Mutant Fc domains can be prepared by amino acid deletion, substitution, insertion or modification using genetic or chemical methods well known in the art. Genetic methods may include site-specific mutagenesis of the encoding DNA sequence, PCR, gene synthesis, and the like. The correct nucleotide changes can be verified for example by sequencing.
  • Binding to Fc receptors can be easily determined e.g. by ELISA, or by Surface Plasmon Resonance (SPR) using standard instrumentation such as a BIAcore instrument (GE Healthcare), and Fc receptors such as may be obtained by recombinant expression.
  • binding affinity of Fc domains or cell activating antibodies comprising an Fc domain for Fc receptors may be evaluated using cell lines known to express particular Fc receptors, such as human NK cells expressing Fey Illa receptor.
  • Effector function of an Fc domain, or antigen binding molecules as described herein comprising an Fc domain can be measured by methods known in the art.
  • a suitable assay for measuring ADCC is described herein.
  • Other examples of in vitro assays to assess ADCC activity of a molecule of interest are described in U.S. Patent No. 5,500,362; Hellstrom et al. Proc Natl Acad Sci USA 83, 7059-7063 (1986) and Hellstrom et al., Proc Natl Acad Sci USA 82, 1499- 1502 (1985); U.S. Patent No. 5,821,337; Bruggemann et al., J Exp Med 166, 1351-1361 (1987).
  • non-radioactive assays methods may be employed (see, for example, ACT!TM nonradioactive cytotoxicity assay for flow cytometry (CellTechnology, Inc. Mountain View, CA); and CytoTox 96® non-radioactive cytotoxicity assay (Promega, Madison, WI)).
  • Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells.
  • PBMC peripheral blood mononuclear cells
  • NK Natural Killer
  • ADCC activity of the molecule of interest may be assessed in vivo, e.g. in an animal model such as that disclosed in Clynes et al., Proc Natl Acad Sci USA 95, 652-656 (1998).
  • binding of the Fc domain to a complement component, specifically to Clq is reduced. Accordingly, in some aspects wherein the Fc domain is engineered to have reduced effector function, said reduced effector function includes reduced CDC.
  • Clq binding assays may be carried out to determine whether the bispecific antibodies of the invention are able to bind Clq and hence has CDC activity. See e.g., Clq and C3c binding ELISA in WO 2006/029879 and WO 2005/100402.
  • a CDC assay may be performed (see, for example, Gazzano-Santoro et al., J Immunol Methods 202, 163 (1996); Cragg et al., Blood 101, 1045-1052 (2003); and Cragg and Glennie, Blood 103, 2738-2743 (2004)).
  • the Fc domain exhibiting reduced binding affinity to an Fc receptor and/or reduced effector function, as compared to a native IgGl Fc domain is a human IgGl Fc domain comprising the amino acid substitutions L234A, L235A and optionally P329G, or a human IgG4 Fc domain comprising the amino acid substitutions S228P, L235E and optionally P329G (numberings according to Kabat EU index). More particularly, it is a human IgGl Fc domain comprising the amino acid substitutions L234A, L235A and P329G (numbering according to Kabat EU index).
  • the immunostimulatory antigen binding molecule that specifically binds to BCMA comprises different antigen-binding sites, fused to one or the other of the two subunits of the Fc domain, thus the two subunits of the Fc domain may be comprised in two non-identical polypeptide chains. Recombinant co-expression of these polypeptides and subsequent dimerization leads to several possible combinations of the two polypeptides. To improve the yield and purity of the bispecific antigen binding molecules disclosed herein in recombinant production, it will thus be advantageous to introduce in the Fc domain of the antibody described herein a modification promoting the association of the desired polypeptides.
  • said modification is a so-called “knob-into-hole” modification, comprising a “knob” modification in one of the two subunits of the Fc domain and a “hole” modification in the other one of the two subunits of the Fc domain.
  • an immunostimulatory antigen binding molecule that specifically binds to BCMA, wherein the antibody comprises a Fc domain composed of a first and a second subunit capable of stable association comprising one or more amino acid substitution that reduces the binding affinity of the antigen binding molecule to an Fc receptor and/or effector function, wherein the first subunit of the Fc domain comprises knobs and the second subunit of the Fc domain comprises holes according to the knobs into holes method.
  • the first subunit of the Fc domain comprises the amino acid substitutions S354C and T366W (EU numbering) and the second subunit of the Fc domain comprises the amino acid substitutions Y349C, T366S and Y407V (numbering according to Kabat EU index).
  • the method involves introducing a protuberance (“knob”) at the interface of a first polypeptide and a corresponding cavity (“hole”) in the interface of a second polypeptide, such that the protuberance can be positioned in the cavity so as to promote heterodimer formation and hinder homodimer formation.
  • Protuberances are constructed by replacing small amino acid side chains from the interface of the first polypeptide with larger side chains (e.g. tyrosine or tryptophan).
  • Compensatory cavities of identical or similar size to the protuberances are created in the interface of the second polypeptide by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine).
  • an amino acid residue is replaced with an amino acid residue having a larger side chain volume, thereby generating a protuberance within the CH3 domain of the first subunit which is positionable in a cavity within the CH3 domain of the second subunit, and in the CH3 domain of the second subunit of the Fc domain an amino acid residue is replaced with an amino acid residue having a smaller side chain volume, thereby generating a cavity within the CH3 domain of the second subunit within which the protuberance within the CH3 domain of the first subunit is positionable.
  • the protuberance and cavity can be made by altering the nucleic acid encoding the polypeptides, e.g. by site-specific mutagenesis, or by peptide synthesis.
  • the threonine residue at position 366 is replaced with a tryptophan residue (T366W)
  • T366W tryptophan residue
  • Y407V valine residue
  • the threonine residue at position 366 is replaced with a serine residue (T366S) and the leucine residue at position 368 is replaced with an alanine residue (L368A).
  • the serine residue at position 354 is replaced with a cysteine residue (S354C)
  • the tyrosine residue at position 349 is replaced by a cysteine residue (Y349C).
  • the first subunit of the Fc domain comprises the amino acid substitutions S354C and T366W (EU numbering) and the second subunit of the Fc domain comprises the amino acid substitutions Y349C, T366S and Y407V (numbering according to Kabat EU index).
  • a modification promoting association of the first and the second subunit of the Fc domain comprises a modification mediating electrostatic steering effects, e.g. as described in PCT publication WO 2009/089004.
  • this method involves replacement of one or more amino acid residues at the interface of the two Fc domain subunits by charged amino acid residues so that homodimer formation becomes electrostatically unfavorable but heterodimerization electrostatically favorable.
  • the C-terminus of the heavy chain of the antibody as reported herein can be a complete C- terminus ending with the amino acid residues PGK.
  • the C-terminus of the heavy chain can be a shortened C-terminus in which one or two of the C terminal amino acid residues have been removed.
  • the C-terminus of the heavy chain is a shortened C-terminus ending P.
  • the C-terminus of the heavy chain is a shortened C-terminus ending PG.
  • an antigen binding molecule comprising a heavy chain including a C-terminal CH3 domain as specified herein comprises the C -terminal glycine-lysine dipeptide (G446 and K447, numbering according to Kabat EU index).
  • an antigen binding molecule comprising a heavy chain including a C-terminal CH3 domain comprises a C-terminal glycine residue (G446, numbering according to Kabat EU index). Modifications in the Fab domains
  • an immunostimulatory antigen binding molecule that specifically binds to BCMA characterized by monovalent binding to BCMA comprising (a) a first antigen binding domain capable of specific binding to BCMA, (b) a first and a second polypeptide that are linked to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of 4-1BBL or a fragment thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises one ectodomain of 4-1BBL or a fragment thereof, and (c) a Fc domain composed of a first and a second subunit capable of stable association comprising one or more amino acid substitution that reduces the binding affinity of the antigen binding molecule to an Fc receptor and/or effector function, wherein the two ectodomains of 4-1BBL and the one ectodomain of 4- 1BBL are fused, optionally via a peptide link
  • Multispecific antibodies with a domain replacement/exchange in one binding arm are described in detail in W02009/080252 and Schaefer, W. et al, PNAS, 108 (2011) 11187-1191. They clearly reduce the byproducts caused by the mismatch of a light chain against a first antigen with the wrong heavy chain against the second antigen (compared to approaches without such domain exchange).
  • the immunostimulatory antigen binding molecule that specifically binds to BCMA contains different charged amino acid substitutions (so-called “charged residues”). These modifications are introduced in the crossed or non-crossed CHI and CL domains.
  • the invention relates to an immunostimulatory antigen binding molecule that specifically binds to BCMA, wherein in the CL domain of the Fab molecule that binds to BCMA the amino acid at position 123 (EU numbering) has been replaced by arginine (R) and the amino acid at position 124 (EU numbering) has been substituted by lysine (K) and wherein in one of the CHI domains the amino acids at position 147 (EU numbering) and at position 213 (EU numbering) have been substituted by glutamic acid (E).
  • the amino acid at position 123 (EU numbering) has been replaced by arginine (R) and the amino acid at position 124 (EU numbering) has been substituted by lysine (K) and in the CHI domain of the Fab molecule capable of specific binding to BCMA the amino acids at position 147 (EU numbering) and at position 213 (EU numbering) have been substituted by glutamic acid (E).
  • the invention further provides isolated polynucleotides encoding a BCMA antibody or an immunostimulatory antigen binding molecule that specifically binds to BCMA as described herein.
  • the one or more isolated polynucleotides encoding the BCMA antibody or the immunostimulatory antigen binding molecule that specifically binds to BCMA may be expressed as a single polynucleotide that encodes the entire antigen binding molecule or as multiple (e.g., two or more) polynucleotides that are co-expressed.
  • Polypeptides encoded by polynucleotides that are co-expressed may associate through, e.g., disulfide bonds or other means to form a functional antigen binding molecule.
  • the light chain portion of an immunoglobulin may be encoded by a separate polynucleotide from the heavy chain portion of the immunoglobulin. When co-expressed, the heavy chain polypeptides will associate with the light chain polypeptides to form the immunoglobulin.
  • the isolated polynucleotide encodes the entire immunostimulatory antigen binding molecule that specifically binds to BCMA as described herein.
  • the isolated polynucleotide encodes a polypeptide comprised in the immunostimulatory antigen binding molecule that specifically binds to BCMA as described herein.
  • the polynucleotide or nucleic acid is DNA.
  • a polynucleotide of the present invention is RNA, for example, in the form of messenger RNA (mRNA). RNA of the present invention may be single stranded or double stranded.
  • BCMA antibodies or immunostimulatory antigen binding molecules that specifically binds to BCMA as described herein may be obtained, for example, by solid-state peptide synthesis (e.g. Merrifield solid phase synthesis) or recombinant production.
  • solid-state peptide synthesis e.g. Merrifield solid phase synthesis
  • polypeptide fragments thereof e.g., as described above
  • polynucleotide may be readily isolated and sequenced using conventional procedures.
  • a vector preferably an expression vector, comprising one or more of the polynucleotides as described herein.
  • Methods which are well known to those skilled in the art can be used to construct expression vectors containing the coding sequence of the antibody (fragment) along with appropriate transcriptional/translational control signals. These methods include in vitro recombinant DNA techniques, synthetic techniques and in vivo recombination/genetic recombination. See, for example, the techniques described in Maniatis et al., MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory, N.Y.
  • the expression vector can be part of a plasmid, virus, or may be a nucleic acid fragment.
  • the expression vector includes an expression cassette into which the polynucleotide encoding the antibody or polypeptide fragments thereof (i.e. the coding region) is cloned in operable association with a promoter and/or other transcription or translation control elements.
  • a "coding region" is a portion of nucleic acid which consists of codons translated into amino acids.
  • a "stop codon" (TAG, TGA, or TAA) is not translated into an amino acid, it may be considered to be part of a coding region, if present, but any flanking sequences, for example promoters, ribosome binding sites, transcriptional terminators, introns, 5' and 3' untranslated regions, and the like, are not part of a coding region.
  • Two or more coding regions can be present in a single polynucleotide construct, e.g. on a single vector, or in separate polynucleotide constructs, e.g. on separate (different) vectors.
  • any vector may contain a single coding region, or may comprise two or more coding regions, e.g.
  • a vector of the present invention may encode one or more polypeptides, which are post- or co-translationally separated into the final proteins via proteolytic cleavage.
  • a vector, polynucleotide, or nucleic acid of the invention may encode heterologous coding regions, either fused or unfused to a polynucleotide encoding the antibody of the invention or polypeptide fragments thereof, or variants or derivatives thereof.
  • Heterologous coding regions include without limitation specialized elements or motifs, such as a secretory signal peptide or a heterologous functional domain. An operable association is when a coding region for a gene product, e.g.
  • a polypeptide is associated with one or more regulatory sequences in such a way as to place expression of the gene product under the influence or control of the regulatory sequence(s).
  • Two DNA fragments (such as a polypeptide coding region and a promoter associated therewith) are "operably associated” if induction of promoter function results in the transcription of mRNA encoding the desired gene product and if the nature of the linkage between the two DNA fragments does not interfere with the ability of the expression regulatory sequences to direct the expression of the gene product or interfere with the ability of the DNA template to be transcribed.
  • a promoter region would be operably associated with a nucleic acid encoding a polypeptide if the promoter was capable of effecting transcription of that nucleic acid.
  • the promoter may be a cell specific promoter that directs substantial transcription of the DNA only in predetermined cells.
  • Other transcription control elements besides a promoter, for example enhancers, operators, repressors, and transcription termination signals, can be operably associated with the polynucleotide to direct cell-specific transcription.
  • transcription control regions which function in vertebrate cells, such as, but not limited to, promoter and enhancer segments from cytomegaloviruses (e.g. the immediate early promoter, in conjunction with intron-A), simian virus 40 (e.g. the early promoter), and retroviruses (such as, e.g. Rous sarcoma virus).
  • transcription control regions include those derived from vertebrate genes such as actin, heat shock protein, bovine growth hormone and rabbit a-globin, as well as other sequences capable of controlling gene expression in eukaryotic cells.
  • tissue-specific promoters and enhancers as well as inducible promoters (e.g. promoters inducible tetracyclins).
  • inducible promoters e.g. promoters inducible tetracyclins
  • translation control elements include, but are not limited to ribosome binding sites, translation initiation and termination codons, and elements derived from viral systems (particularly an internal ribosome entry site, or IRES, also referred to as a CITE sequence).
  • the expression cassette may also include other features such as an origin of replication, and/or chromosome integration elements such as retroviral long terminal repeats (LTRs), or adeno-associated viral (AAV) inverted terminal repeats (ITRs).
  • LTRs retroviral long terminal repeats
  • AAV adeno-associated viral inverted terminal repeats
  • Polynucleotide and nucleic acid coding regions as described herein may be associated with additional coding regions which encode secretory or signal peptides, which direct the secretion of a polypeptide encoded by a polynucleotide of the present invention.
  • DNA encoding a signal sequence may be placed upstream of the nucleic acid encoding an antibody as described herein or polypeptide fragments thereof.
  • proteins secreted by mammalian cells have a signal peptide or secretory leader sequence which is cleaved from the mature protein once export of the growing protein chain across the rough endoplasmic reticulum has been initiated.
  • polypeptides secreted by vertebrate cells generally have a signal peptide fused to the N-terminus of the polypeptide, which is cleaved from the translated polypeptide to produce a secreted or "mature" form of the polypeptide.
  • the native signal peptide e.g. an immunoglobulin heavy chain or light chain signal peptide is used, or a functional derivative of that sequence that retains the ability to direct the secretion of the polypeptide that is operably associated with it.
  • a heterologous mammalian signal peptide, or a functional derivative thereof may be used.
  • the wild-type leader sequence may be substituted with the leader sequence of human tissue plasminogen activator (TP A) or mouse P-glucuronidase.
  • DNA encoding a short protein sequence that could be used to facilitate later purification (e.g. a histidine tag) or assist in labeling the antibody as described herein may be included within or at the ends of the polynucleotide encoding the antibody as described herein or polypeptide fragments thereof.
  • a host cell comprising one or more polynucleotides as described herein.
  • a host cell comprising one or more vectors as described herein.
  • the polynucleotides and vectors may incorporate any of the features, singly or in combination, described herein in relation to polynucleotides and vectors, respectively.
  • a host cell comprises (e.g. has been transformed or transfected with) a vector comprising a polynucleotide that encodes (part of) an antibody as disclosed herein.
  • the term "host cell” refers to any kind of cellular system which can be engineered to generate the fusion proteins of the invention or fragments thereof.
  • Host cells suitable for replicating and for supporting expression of antigen binding molecules are well known in the art. Such cells may be transfected or transduced as appropriate with the particular expression vector and large quantities of vector containing cells can be grown for seeding large scale fermenters to obtain sufficient quantities of the antibody for clinical applications.
  • Suitable host cells include prokaryotic microorganisms, such as E. coli, or various eukaryotic cells, such as Chinese hamster ovary cells (CHO), insect cells, or the like.
  • polypeptides may be produced in bacteria in particular when glycosylation is not needed. After expression, the polypeptide may be isolated from the bacterial cell paste in a soluble fraction and can be further purified.
  • eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for polypeptide-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been “humanized”, resulting in the production of a polypeptide with a partially or fully human glycosylation pattern. See Gemgross, Nat Biotech 22, 1409-1414 (2004), and Li et al., Nat Biotech 24, 210-215 (2006).
  • Suitable host cells for the expression of (glycosylated) polypeptides are also derived from multicellular organisms (invertebrates and vertebrates).
  • invertebrate cells include plant and insect cells. Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells. Plant cell cultures can also be utilized as hosts. See e.g. US Patent Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIESTM technology for producing antibodies in transgenic plants). Vertebrate cells may also be used as hosts.
  • mammalian cell lines that are adapted to grow in suspension may be useful.
  • useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293T cells as described, e.g., in Graham et al., J Gen Virol 36, 59 (1977)), baby hamster kidney cells (BHK), mouse sertoli cells (TM4 cells as described, e.g., in Mather, Biol Reprod 23, 243-251 (1980)), monkey kidney cells (CV1), African green monkey kidney cells (VERO-76), human cervical carcinoma cells (HELA), canine kidney cells (MDCK), buffalo rat liver cells (BRL 3 A), human lung cells (W138), human liver cells (Hep G2), mouse mammary tumor cells (MMT 060562), TRI cells (as described, e.g., in Mather et al., Annals N.Y.
  • MRC 5 cells MRC 5 cells
  • FS4 cells Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including dhfr- CHO cells (Urlaub et al., Proc Natl Acad Sci USA 77, 4216 (1980)); and myeloma cell lines such as YO, NS0, P3X63 and Sp2/0.
  • CHO Chinese hamster ovary
  • dhfr- CHO cells Urlaub et al., Proc Natl Acad Sci USA 77, 4216 (1980)
  • myeloma cell lines such as YO, NS0, P3X63 and Sp2/0.
  • Host cells include cultured cells, e.g., mammalian cultured cells, yeast cells, insect cells, bacterial cells and plant cells, to name only a few, but also cells comprised within a transgenic animal, transgenic plant or cultured plant or animal tissue.
  • the host cell is a eukaryotic cell, preferably a mammalian cell, such as a Chinese Hamster Ovary (CHO) cell, a human embryonic kidney (HEK) cell or a lymphoid cell (e.g., Y0, NSO, Sp20 cell). Standard technologies are known in the art to express foreign genes in these systems.
  • Cells expressing a polypeptide comprising either the heavy or the light chain of an immunoglobulin may be engineered so as to also express the other of the immunoglobulin chains such that the expressed product is an immunoglobulin that has both a heavy and a light chain.
  • a method of producing an immunostimulatory antigen binding molecule that specifically binds to BCMA or polypeptide fragments thereof comprises culturing a host cell comprising polynucleotides encoding the antibody or polypeptide fragments thereof, as provided herein, under conditions suitable for expression of the antibody or polypeptide fragments thereof, and recovering the antibody as described herein or polypeptide fragments thereof from the host cell (or host cell culture medium).
  • the antigen binding domain capable of specific binding to BCMA e.g. a Fab fragment
  • the immunostimulatory antigen binding molecule that specifically binds to BCMA comprises at least an immunoglobulin variable region capable of binding to an antigen.
  • Variable regions can form part of and be derived from naturally or non-naturally occurring antibodies and fragments thereof. Methods to produce polyclonal antibodies and monoclonal antibodies are well known in the art (see e.g. Harlow and Lane, "Antibodies, a laboratory manual", Cold Spring Harbor Laboratory, 1988).
  • Non-naturally occurring antibodies can be constructed using solid phase-peptide synthesis, can be produced recombinantly (e.g. as described in U.S. patent No. 4,186,567) or can be obtained, for example, by screening combinatorial libraries comprising variable heavy chains and variable light chains (see e.g. U.S. Patent. No. 5,969,108 to McCafferty).
  • Non-limiting immunoglobulins useful can be of murine, primate, or human origin. If the antibody is intended for human use, a chimeric form of immunoglobulin may be used wherein the constant regions of the immunoglobulin are from a human.
  • a humanized or fully human form of the immunoglobulin can also be prepared in accordance with methods well known in the art (see e. g. U.S. Patent No. 5,565,332 to Winter). Humanization may be achieved by various methods including, but not limited to (a) grafting the non-human (e.g., donor antibody) CDRs onto human (e.g.
  • recipient antibody framework and constant regions with or without retention of critical framework residues (e.g. those that are important for retaining good antigen binding affinity or antibody functions), (b) grafting only the non-human specificity-determining regions (SDRs or a-CDRs; the residues critical for the antibody-antigen interaction) onto human framework and constant regions, or (c) transplanting the entire non-human variable domains, but "cloaking" them with a human-like section by replacement of surface residues.
  • critical framework residues e.g. those that are important for retaining good antigen binding affinity or antibody functions
  • Particular immunoglobulins according to the invention are human immunoglobulins.
  • Human antibodies and human variable regions can be produced using various techniques known in the art. Human antibodies are described generally in van Dijk and van de Winkel, Curr Opin Pharmacol 5, 368-74 (2001) and Lonberg, Curr Opin Immunol 20, 450-459 (2008). Human variable regions can form part of and be derived from human monoclonal antibodies made by the hybridoma method (see e.g. Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)).
  • Human antibodies and human variable regions may also be prepared by administering an immunogen to a transgenic animal that has been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigenic challenge (see e.g. Lonberg, Nat Biotech 23, 1117-1125 (2005). Human antibodies and human variable regions may also be generated by isolating Fv clone variable region sequences selected from human-derived phage display libraries (see e.g., Hoogenboom et al.
  • Phage typically display antibody fragments, either as single-chain Fv (scFv) fragments or as Fab fragments.
  • the antigen binding domains comprised in the antigen binding molecules described herein are engineered to have enhanced binding affinity according to, for example, the methods disclosed in PCT publication WO 2012/020006 (see Examples relating to affinity maturation) or U.S. Pat. Appl. Publ. No. 2004/0132066.
  • the ability of the antibodies of the invention to bind to a specific antigenic determinant can be measured either through an enzyme- linked immunosorbent assay (ELISA) or other techniques familiar to one of skill in the art, e.g. surface plasmon resonance technique (Liljeblad, et al., Glyco J 17, 323-329 (2000)), and traditional binding assays (Heeley, Endocr Res 28, 217-229 (2002)).
  • ELISA enzyme- linked immunosorbent assay
  • Competition assays may be used to identify an antigen binding molecule that competes with a reference antibody for binding to a particular antigen.
  • a competing antigen binding molecule binds to the same epitope (e.g. a linear or a conformational epitope) that is bound by the reference antigen binding molecule.
  • epitope e.g. a linear or a conformational epitope
  • Detailed exemplary methods for mapping an epitope to which an antigen binding molecule binds are provided in Morris (1996) “Epitope Mapping Protocols”, in Methods in Molecular Biology vol. 66 (Humana Press, Totowa, NJ).
  • immobilized antigen is incubated in a solution comprising a first labeled antigen binding molecule that binds to the antigen and a second unlabeled antigen binding molecule that is being tested for its ability to compete with the first antigen binding molecule for binding to the antigen.
  • the second antigen binding molecule may be present in a hybridoma supernatant.
  • immobilized antigen is incubated in a solution comprising the first labeled antigen binding molecule but not the second unlabeled antigen binding molecule. After incubation under conditions permissive for binding of the first antibody to the antigen, excess unbound antibody is removed, and the amount of label associated with immobilized antigen is measured.
  • Antigen binding molecules that specifically bind to BCMA prepared as described herein may be purified by art-known techniques such as high performance liquid chromatography, ion exchange chromatography, gel electrophoresis, affinity chromatography, size exclusion chromatography, and the like.
  • the actual conditions used to purify a particular protein will depend, in part, on factors such as net charge, hydrophobicity, hydrophilicity etc., and will be apparent to those having skill in the art.
  • affinity chromatography purification an antibody, ligand, receptor or antigen can be used to which the antigen binding molecule binds.
  • a matrix with protein A or protein G may be used.
  • Sequential Protein A or G affinity chromatography and size exclusion chromatography can be used to isolate an antigen binding molecule essentially as described in the Examples.
  • the purity of the antibody or fragments thereof can be determined by any of a variety of well-known analytical methods including gel electrophoresis, high pressure liquid chromatography, and the like.
  • the bispecific antibody expressed as described in the Examples was shown to be intact and properly assembled as demonstrated by reducing and non-reducing SDS-PAGE.
  • BCMA antibody or the immunostimulatory antigen binding molecule that specifically binds to BCMA provided herein may be identified, screened for, or characterized for its physical/chemical properties and/or biological activities by various assays known in the art. 1. Affinity assays
  • the affinity of the antigen binding molecule provided herein for the corresponding target can be determined in accordance with the methods set forth in the Examples by surface plasmon resonance (SPR), using standard instrumentation such as a Proteon instrument (Bio-rad), and receptors or target proteins such as may be obtained by recombinant expression.
  • the affinity of the antigen binding molecule for the target cell antigen can also be determined by surface plasmon resonance (SPR), using standard instrumentation such as a Proteon instrument (Biorad), and receptors or target proteins such as may be obtained by recombinant expression.
  • KD is measured by surface plasmon resonance using a Proteon ® machine (Bio-Rad) at 25 °C.
  • Binding of the antibody or the immunostimulatory antigen binding molecule that specifically binds to BCMA provided herein to the corresponding receptor expressing cells may be evaluated using cell lines expressing the particular receptor or target antigen, for example by flow cytometry (FACS).
  • FACS flow cytometry
  • CHO-K1 cell lines expressing BCMA extracellular domain and non-truncating mutants thereof are used in the binding assay.
  • Jurkat-NFkB-luc2_4-lBB cells were used to demonstrate the binding of the antigen binding molecules to 4-1BBL.
  • assays are provided for identifying the biological activity of the BCMA-4- 1BBL antigen binding molecule.
  • Biological activity may include, e.g. T cell proliferation and cytokine secretion as measured with the methods as described in Example 4.
  • Antigen binding molecules having such biological activity in vivo and/or in vitro are also provided.
  • the invention provides pharmaceutical compositions comprising any of the immunostimulatory antigen binding molecules that specifically bind to BCMA provided herein, e.g., for use in any of the below therapeutic methods.
  • a pharmaceutical composition comprises an immunostimulatory antigen binding molecule that specifically binds to BCMA provided herein and at least one pharmaceutically acceptable excipient.
  • a pharmaceutical composition comprises an immunostimulatory antigen binding molecule that specifically binds to BCMA provided herein and at least one additional therapeutic agent, e.g., as described below.
  • Pharmaceutical compositions as disclosed herein comprise a therapeutically effective amount of one or more antigen binding molecules dissolved or dispersed in a pharmaceutically acceptable excipient.
  • compositions that are generally non-toxic to recipients at the dosages and concentrations employed, i.e. do not produce an adverse, allergic or other untoward reaction when administered to an animal, such as, for example, a human, as appropriate.
  • the preparation of a pharmaceutical composition that contains at least one immunostimulatory antigen binding molecule that specifically binds to BCMA and optionally an additional active ingredient will be known to those of skill in the art in light of the present disclosure, as exemplified by Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, incorporated herein by reference.
  • the compositions are lyophilized formulations or aqueous solutions.
  • pharmaceutically acceptable excipient includes any and all solvents, buffers, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g. antibacterial agents, antifungal agents), isotonic agents, salts, stabilizers and combinations thereof, as would be known to one of ordinary skill in the art.
  • Parenteral compositions include those designed for administration by injection, e.g. subcutaneous, intradermal, intralesional, intravenous, intraarterial intramuscular, intrathecal or intraperitoneal injection.
  • the 4-1 BBL trimer-containing antigen binding molecules may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiological saline buffer.
  • the solution may contain formulation agents such as suspending, stabilizing and/or dispersing agents.
  • the immunostimulatory antigen binding molecule that specifically binds to BCMA may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
  • Sterile injectable solutions are prepared by incorporating the fusion proteins of the invention in the required amount in the appropriate solvent with various of the other ingredients enumerated below, as required. Sterility may be readily accomplished, e.g., by filtration through sterile filtration membranes. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and/or the other ingredients. In the case of sterile powders for the preparation of sterile injectable solutions, suspensions or emulsion, the preferred methods of preparation are vacuum-drying or freeze- drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered liquid medium thereof.
  • the liquid medium should be suitably buffered if necessary and the liquid diluent first rendered isotonic prior to injection with sufficient saline or glucose.
  • the composition must be stable under the conditions of manufacture and storage, and preserved against the contaminating action of microorganisms, such as bacteria and fungi. It will be appreciated that endotoxin contamination should be kept minimally at a safe level, for example, less than 0.5 ng/mg protein.
  • Suitable pharmaceutically acceptable excipients include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monos
  • Aqueous injection suspensions may contain compounds which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, dextran, or the like.
  • the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
  • suspensions of the active compounds may be prepared as appropriate oily injection suspensions.
  • Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl cleats or triglycerides, or liposomes.
  • Active ingredients may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules) or in macroemulsions.
  • colloidal drug delivery systems for example, liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules
  • Sustained-release preparations may be prepared.
  • sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the polypeptide, which matrices are in the form of shaped articles, e.g. films, or microcapsules.
  • prolonged absorption of an injectable composition can be brought about by the use in the compositions of agents delaying absorption, such as, for example, aluminum monostearate, gelatin or combinations thereof.
  • Exemplary pharmaceutically acceptable excipients herein further include interstitial drug dispersion agents such as soluble neutral-active hyaluronidase glycoproteins (sHASEGP), for example, human soluble PH-20 hyaluronidase glycoproteins, such as rHuPH20 (HYLENEX®, Baxter International, Inc.).
  • sHASEGP soluble neutral-active hyaluronidase glycoproteins
  • rHuPH20 HYLENEX®, Baxter International, Inc.
  • Certain exemplary sHASEGPs and methods of use, including rHuPH20 are described in US Patent Publication Nos. 2005/0260186 and 2006/0104968.
  • a sHASEGP is combined with one or more additional glycosaminoglycanases such as chondroitinases.
  • Exemplary lyophilized antibody formulations are described in US Patent No. 6,267,958.
  • Aqueous antibody formulations include those described in US Patent No. 6,171,586 and W02006/044908, the latter formulations including a histidine-acetate buffer.
  • the immunostimulatory antigen binding molecule that specifically binds to BCMA may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • the immunostimulatory antigen binding molecule that specifically binds to BCMA may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • compositions comprising the immunostimulatory antigen binding molecule that specifically binds to BCMA may be manufactured by means of conventional mixing, dissolving, emulsifying, encapsulating, entrapping or lyophilizing processes.
  • Pharmaceutical compositions may be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries which facilitate processing of the proteins into preparations that can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
  • the immunostimulatory antigen binding molecule that specifically binds to BCMA may be formulated into a composition in a free acid or base, neutral or salt form.
  • Pharmaceutically acceptable salts are salts that substantially retain the biological activity of the free acid or base.
  • salts formed with the free carboxyl groups can also be derived from inorganic bases such as for example, sodium, potassium, ammonium, calcium or ferric hydroxides; or such organic bases as isopropylamine, trimethylamine, histidine or procaine. Pharmaceutical salts tend to be more soluble in aqueous and other protic solvents than are the corresponding free base forms.
  • composition herein may also contain more than one active ingredient as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other.
  • active ingredients are suitably present in combination in amounts that are effective for the purpose intended.
  • the formulations to be used for in vivo administration are generally sterile. Sterility may be readily accomplished, e.g., by filtration through sterile filtration membranes.
  • immunostimulatory antigen binding molecule that specifically binds to BCMA provided herein may be used in therapeutic methods, either alone or in combination.
  • an immunostimulatory antigen binding molecule that specifically binds to BCMA for use as a medicament is provided.
  • an antigen binding molecule that specifically binds to BCMA and 4- IBB for use in treating cancer is provided.
  • an immunostimulatory antigen binding molecule that specifically binds to BCMA for use in treating hematologic malignancies is provided.
  • the term “hematologic malignancies” includes diseases selected from the group consisting of multiple myeloma (MM), chronic lymphocytic leukemia, acute B-lymphoblastic leukemia, non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma, but also acute myeloid leukemia and acute lymphoblastic leukemia.
  • an antigen binding molecule that specifically binds to BCMA and 4- IBB for use in treating multiple myeloma (MM) is provided.
  • an immunostimulatory antigen binding molecule that specifically binds to BCMA for use in a method of treatment is provided.
  • an immunostimulatory antigen binding molecule that specifically binds to BCMA for use in a method of treating an individual having cancer comprising administering to the individual an effective amount of the immunostimulatory antigen binding molecule that specifically binds to BCMA.
  • the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent.
  • the immunostimulatory antigen binding molecule that specifically binds to BCMA as described herein is for use in inhibiting the growth of BCMA-expressing cancer cells.
  • an immunostimulatory antigen binding molecule that specifically binds to BCMA for use in a method of treatment is provided.
  • an immunostimulatory antigen binding molecule that specifically binds to BCMA for use in a method of treating an individual having cancer comprising administering to the individual an effective amount of the immunostimulatory antigen binding molecule that specifically binds to BCMA.
  • an immunostimulatory antigen binding molecule that specifically binds to BCMA for use in a method of treating an individual having BCMA- expressing cancer, in particular hematologic malignancies selected from the group consisting of multiple myeloma (MM), chronic lymphocytic leukemia, acute B-lymphoblastic leukemia, nonHodgkin lymphoma (NHL), Hodgkin lymphoma, acute myeloid leukemia and acute lymphoblastic leukemia, comprising administering to the individual an effective amount of the immunostimulatory antigen binding molecule that specifically binds to BCMA.
  • the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent.
  • the medicament is for treatment of cancer, particularly BCMA-expressing cancer.
  • the medicament is for use in a method of treating cancer comprising administering to an individual having cancer an effective amount of said medicament.
  • the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, e.g., as described below.
  • the medicament is for treatment of BCMA-expressing cancer.
  • the medicament is for use in a method of treating cancer, in particular BCMA-expressing cancer, comprising administering to an individual having cancer an effective amount of the medicament.
  • a method for treating a cancer, in particular BCMA- expressing cancer comprises administering to an individual having cancer an effective amount of an immunostimulatory antigen binding molecule that specifically binds to BCMA.
  • the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, as described below.
  • An “individual” according to any of the above aspects may be a human.
  • a pharmaceutical formulation comprising any of the immunostimulatory antigen binding molecules that specifically bind to BCMA as reported herein, e.g., for use in any of the above therapeutic methods.
  • a pharmaceutical formulation comprises an immunostimulatory antigen binding molecule that specifically binds to BCMA as reported herein and a pharmaceutically acceptable carrier.
  • a pharmaceutical formulation comprises an immunostimulatory antigen binding molecule that specifically binds to BCMA as reported herein and at least one additional therapeutic agent.
  • An immunostimulatory antigen binding molecule that specifically binds to BCMA as reported herein can be used either alone or in combination with other agents in a therapy.
  • an immunostimulatory antigen binding molecule that specifically binds to BCMA as reported herein may be co-administered with at least one additional therapeutic agent.
  • an immunostimulatory antigen binding molecule that specifically binds to BCMA as described herein for use in cancer immunotherapy is provided.
  • an immunostimulatory antigen binding molecule that specifically binds to BCMA for use in a method of cancer immunotherapy is provided.
  • An “individual” according to any of the above aspects is preferably a human.
  • combination therapies noted above encompass combined administration (where two or more therapeutic agents are included in the same or separate formulations), and separate administration, in which case, administration of the antibody as reported herein can occur prior to, simultaneously, and/or following, administration of the additional therapeutic agent or agents.
  • administration of the immunostimulatory antigen binding molecule that specifically binds to BCMA and administration of an additional therapeutic agent occur within about one month, or within about one, two or three weeks, or within about one, two, three, four, five, or six days, of each other.
  • An antigen binding molecule as reported herein can be administered by any suitable means, including parenteral, intrapulmonary, and intranasal, and, if desired for local treatment, intralesional administration.
  • Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. Dosing can be by any suitable route, e.g. by injections, such as intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic.
  • Various dosing schedules including but not limited to single or multiple administrations over various time-points, bolus administration, and pulse infusion are contemplated herein.
  • Immunostimulatory antigen binding molecules that specifically bind to BCMA as described herein would be formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
  • the immunostimulatory antigen binding molecule that specifically binds to BCMA needs not be, but is optionally formulated with one or more agents currently used to prevent or treat the disorder in question. The effective amount of such other agents depends on the amount of antibody present in the formulation, the type of disorder or treatment, and other factors discussed above. These are generally used in the same dosages and with administration routes as described herein, or about from 1 to 99% of the dosages described herein, or in any dosage and by any route that is empirically/ clinically determined to be appropriate.
  • an immunostimulatory antigen binding molecule that specifically binds to BCMA as described herein when used alone or in combination with one or more other additional therapeutic agents, will depend on the type of disease to be treated, the type of antibody, the severity and course of the disease, whether the antibody is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody, and the discretion of the attending physician.
  • the immunostimulatory antigen binding molecule that specifically binds to BCMA is suitably administered to the patient at one time or over a series of treatments. Depending on the type and severity of the disease, about 1 pg/kg to 15 mg/kg (e.g.
  • 0.5 mg/kg - 10 mg/kg) of the immunostimulatory antigen binding molecule that specifically binds to BCMA can be an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion.
  • One typical daily dosage might range from about 1 pg/kg to 100 mg/kg or more, depending on the factors mentioned above.
  • the treatment would generally be sustained until a desired suppression of disease symptoms occurs.
  • One exemplary dosage of the antigen binding molecule would be in the range from about 0.05 mg/kg to about 10 mg/kg.
  • one or more doses of about 0.5 mg/kg, 2.0 mg/kg, 4.0 mg/kg or 10 mg/kg (or any combination thereof) may be administered to the patient.
  • Such doses may be administered intermittently, e.g. every week or every three weeks (e.g. such that the patient receives from about two to about twenty, or e.g. about six doses of the antibody).
  • An initial higher loading dose, followed by one or more lower doses may be administered.
  • other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.
  • the immunostimulatory antigen binding molecule that specifically binds to BCMA may be administered in combination with one or more other agents in therapy.
  • an antigen binding molecule as described herein may be co-administered with at least one additional therapeutic agent.
  • therapeutic agent encompasses any agent that can be administered for treating a symptom or disease in an individual in need of such treatment.
  • additional therapeutic agent may comprise any active ingredients suitable for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other.
  • an additional therapeutic agent is another anti -cancer agent, for example a microtubule disruptor, an antimetabolite, a topoisomerase inhibitor, a DNA intercalator, an alkylating agent, a hormonal therapy, a kinase inhibitor, a receptor antagonist, an activator of tumor cell apoptosis, or an anti angiogenic agent.
  • an additional therapeutic agent is an immunomodulatory agent, a cytostatic agent, an inhibitor of cell adhesion, a cytotoxic or cytostatic agent, an activator of cell apoptosis, or an agent that increases the sensitivity of cells to apoptotic inducers.
  • immunostimulatory antigen binding molecules that specifically bind to BCMA as disclosed herein or pharmaceutical compositions comprising them for use in the treatment of cancer, wherein the bispecific antibody is administered in combination with a chemotherapeutic agent, radiation and/ or other agents for use in cancer immunotherapy.
  • Such other agents are suitably present in combination in amounts that are effective for the purpose intended.
  • the effective amount of such other agents depends on the amount of fusion protein used, the type of disorder or treatment, and other factors discussed above.
  • the bispecific antigen binding molecule or antibody of the invention are generally used in the same dosages and with administration routes as described herein, or about from 1 to 99% of the dosages described herein, or in any dosage and by any route that is empirically/clinically determined to be appropriate.
  • combination therapies noted above encompass combined administration (where two or more therapeutic agents are included in the same or separate compositions), and separate administration, in which case, administration of the bispecific antigen binding molecule or antibody of the invention can occur prior to, simultaneously, and/or following, administration of the additional therapeutic agent and/or adjuvant.
  • an immunostimulatory antigen binding molecule that specifically binds to BCMA as described herein for use in the treatment of cancer, in particular BCMA-expressing cancer, wherein the bispecific antigen binding molecule is administered in combination with another immunomodulator.
  • immunomodulator refers to any substance including a monoclonal antibody that effects the immune system.
  • the molecules of the -n- inventions can be considered immunomodulators.
  • Immunomodulators can be used as anti- neoplastic agents for the treatment of cancer.
  • immunomodulators include, but are not limited to anti-CTLA4 antibodies (e.g. ipilimumab), anti-PDl antibodies (e.g.
  • combination therapies noted above encompass combined administration (where two or more therapeutic agents are included in the same or separate compositions), and separate administration, in which case, administration of the bispecific antigen binding molecule can occur prior to, simultaneously, and/or following, administration of the additional therapeutic agent and/or adjuvant.
  • the immunostimulatory antigen binding molecules that specifically bind to BCMA may be administered in combination with T-cell activating anti-CD3 bispecific antibodies.
  • the T-cell activating anti-CD3 bispecific antibodies are specific for a tumor- associated antigen, for example GPRC5D, CD38 or BCMA.
  • the T-cell activating anti-CD3 bispecific antibody is an anti-GPRC5D/anti-CD3 bispecific antibody.
  • the anti-GPRC5D/anti-CD3 bispecific antibody comprises at least one antigen binding domain capable of specific binding to GPRC5D which comprises a heavy chain variable region (VHGPRC5D) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 140, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 141, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 142, and a light chain variable region (VLGPRC5D) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 143, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 144, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 145.
  • VHGPRC5D heavy chain variable region
  • VLGPRC5D light chain variable region
  • the anti-GPRC5D/anti- CD3 bispecific antibody comprises at least one antigen binding domain capable of specific binding to GPRC5D which comprises a heavy chain variable region (VHGPRC5D) comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 146, SEQ ID NO: 148, SEQ ID NO: 149 and SEQ ID NO: 150 and a light chain variable region (VLGPRC5D) comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 147, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154 and SEQ ID NO: 155.
  • VHGPRC5D heavy chain variable region
  • VLGPRC5D light chain variable region
  • the anti-GPRC5D/anti-CD3 bispecific antibody comprises at least one antigen binding domain capable of specific binding to GPRC5D which comprises a heavy chain variable region (VHGPRC5D) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 146, and a light chain variable region (VLGPRC5D) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 147.
  • VHGPRC5D heavy chain variable region
  • VLGPRC5D light chain variable region
  • the antigen binding domain capable of specific binding to GPRC5D comprises a heavy chain variable region (VHGPRC5D) comprising the amino acid sequence of SEQ ID NO: 146 and a light chain variable region (VLGPRC5D) comprising the amino acid sequence of SEQ ID NO: 147.
  • VHGPRC5D heavy chain variable region
  • VLGPRC5D light chain variable region
  • the anti-GPRC5D/anti-CD3 bispecific antibody comprises at least one antigen binding domain capable of specific binding to GPRC5D which comprises a heavy chain variable region (VHGPRC5D) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 156, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 157, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 158, and a light chain variable region (VLGPRC5D) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 159, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 160, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 161.
  • VHGPRC5D heavy chain variable region
  • VLGPRC5D light chain variable region
  • the anti-GPRC5D/anti- CD3 bispecific antibody comprises at least one antigen binding domain capable of specific binding to GPRC5D which comprises a heavy chain variable region (VHGPRC5D) comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166 and SEQ ID NO: 167 and a light chain variable region (VLGPRC5D) comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171 and SEQ ID NO: 172.
  • the anti-GPRC5D/anti-CD3 bispecific antibody comprises at least one antigen binding domain capable of specific binding to GPRC5D which comprises
  • VHGPRC5D heavy chain variable region
  • VLGPRC5D light chain variable region
  • VHGPRC5D heavy chain variable region
  • VLGPRC5D light chain variable region
  • VHGPRC5D heavy chain variable region
  • VLGPRC5D light chain variable region
  • VHGPRC5D heavy chain variable region
  • VLGPRC5D light chain variable region
  • VHGPRC5D heavy chain variable region
  • VLGPRC5D light chain variable region
  • the anti-GPRC5D/anti-CD3 bispecific antibody comprises an antigen binding domain capable of specific binding to CD3 which comprises a heavy chain variable region (VHCD3) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 173, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 174, and (iii) CDR- H3 comprising the amino acid sequence of SEQ ID NO: 175, and a light chain variable region (VLCD3) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 176, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 177, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 178.
  • VHCD3 heavy chain variable region
  • VLCD3 light chain variable region
  • the anti-GPRC5D/anti-CD3 bispecific antibody comprises an antigen binding domain capable of specific binding to CD3 which comprises a heavy chain variable region (VHCD3) comprising an amino acid sequence of SEQ ID NO: 179 and a light chain variable region (VLCD3) comprising an amino acid sequence of SEQ ID NO: 180.
  • VHCD3 heavy chain variable region
  • VLCD3 light chain variable region
  • the anti-GPRC5D/anti-CD3 bispecific antibody comprises an antigen binding domain capable of specific binding to CD3 which comprises a heavy chain variable region (VHCD3) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 181, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 182, and (iii) CORED comprising the amino acid sequence of SEQ ID NO: 183, and a light chain variable region (VLCD3) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 184, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 185, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 186.
  • VHCD3 heavy chain variable region
  • the anti-GPRC5D/anti-CD3 bispecific antibody comprises an antigen binding domain capable of specific binding to CD3 which comprises a heavy chain variable region (VHCD3) comprising an amino acid sequence of SEQ ID NO: 187 and a light chain variable region (VLCD3) comprising an amino acid sequence of SEQ ID NO: 188.
  • VHCD3 heavy chain variable region
  • VLCD3 light chain variable region
  • the anti-GPRC5D/anti-CD3 bispecific antibody comprises an antigen binding domain capable of specific binding to CD3 which comprises a heavy chain variable region (VHCD3) comprising an amino acid sequence of SEQ ID NO: 179 and a light chain variable region (VLCD3) comprising an amino acid sequence of SEQ ID NO: 180, and two antigen binding domains capable of specifically binding to GPRC5D, wherein the antigen binding domains capable of specifically binding to GPRC5D each comprise a heavy chain variable region (VHGPRC5D) comprising the amino acid sequence of SEQ ID NO: 146 and a light chain variable region (VLGPRC5D) comprising the amino acid sequence of SEQ ID NO: 147.
  • VHCD3 heavy chain variable region
  • VLCD3 light chain variable region
  • the anti-GPRC5D/anti-CD3 bispecific antibody comprises a polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 132, two polypeptides that are at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 133, a polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 134, and a polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 135.
  • the bispecific antibody comprises a polypeptide sequence of SEQ ID NO: 132, two polypeptide sequences of SEQ ID NO: 133, a polypeptide sequence of SEQ ID NO: 134 and a polypeptide sequence of SEQ ID NO: 135 (GPRC5D CD3 TCB).
  • the anti- GPRC5D/anti-CD3 bispecific antibody is forimtamig.
  • the anti-GPRC5D/anti-CD3 bispecific antibody comprises a polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 136, a polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 137, a polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 138, and a polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 139.
  • the bispecific antibody comprises a polypeptide sequence of SEQ ID NO: 136, a polypeptide sequence of SEQ ID NO: 137, a polypeptide sequence of SEQ ID NO: 138 and a polypeptide sequence of SEQ ID NO: 139 (GPRC5D CD3 1+1 bispecific antibody).
  • the T-cell activating anti-CD3 bispecific antibody is an anti- BCMA/anti-CD3 bispecific antibody.
  • the anti-BCMA/anti-CD3 bispecific antibody is in the 2+1 format.
  • the anti-BCMA/anti-CD3 bispecific antibody comprises an amino acid sequence of SEQ ID NO: 191, two amino acid sequences of SEQ ID NO: 192, an amino acid sequence of SEQ ID NO: 193 and amino acid sequence of SEQ ID NO: 194.
  • the anti-BCMA/anti-CD3 bispecific antibody is in the 1+1 format.
  • the anti-BCMA/anti-CD3 bispecific antibody comprises an amino acid sequence of SEQ ID NO: 195, an amino acid sequence of SEQ ID NO: 196, an amino acid sequence of SEQ ID NO: 197 and amino acid sequence of SEQ ID NO: 198. In one aspect, the anti-BCMA/anti-CD3 bispecific antibody comprises an amino acid sequence of SEQ ID NO: 199, an amino acid sequence of SEQ ID NO: 200, an amino acid sequence of SEQ ID NO: 201 and amino acid sequence of SEQ ID NO: 202.
  • Such combination therapies noted above encompass combined administration (where two or more therapeutic agents are included in the same or separate formulations), and separate administration, in which case, administration of the therapeutic agent can occur prior to, simultaneously, and/or following, administration of an additional therapeutic agent or agents.
  • administration of the therapeutic agent and administration of an additional therapeutic agent occur within about one month, or within about one, two or three weeks, or within about one, two, three, four, five, or six days, of each other.
  • an article of manufacture containing materials useful for the treatment, prevention and/or diagnosis of the disorders described above comprises a container and a label or package insert on or associated with the container.
  • Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc.
  • the containers may be formed from a variety of materials such as glass or plastic.
  • the container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper that is pierceable by a hypodermic injection needle).
  • At least one active agent in the composition is an immunostimulatory antigen binding molecule that specifically binds to BCMA as disclosed herein.
  • the label or package insert indicates that the composition is used for treating the condition of choice.
  • the article of manufacture may comprise (a) a first container with a composition contained therein, wherein the composition comprises an immunostimulatory antigen binding molecule that specifically binds to BCMA; and (b) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent.
  • the article of manufacture in this embodiment of the invention may further comprise a package insert indicating that the compositions can be used to treat a particular condition.
  • the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
  • BWFI bacteriostatic water for injection
  • phosphate-buffered saline such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution.
  • BWFI bacteriostatic water for injection
  • phosphate-buffered saline such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution.
  • BWFI bacteriostatic water for injection
  • Ringer's solution such as phosphate
  • An immunostimulatory antigen binding molecule that specifically binds to B cell maturation agent (BCMA), comprising (a) an antigen binding domain comprising
  • VH BCMA heavy chain variable region
  • VH BCMA heavy chain variable region comprising a heavy chain complementary determining region CDR-H1 of SEQ ID NO: 1 (GYTFTNYWMH), a CDR-H2 of SEQ ID NO: 2 (IH4PNSGSTNYNEKFQG), and a CDR-H3 of SEQ ID NO: 3 (GIYDYPFAY), and
  • VL BCMA light chain variable region
  • VL comprising a light chain complementary determining region CDR-L1 of SEQ ID NO: 4 (RASES VSIHGTHLMH), a CDR-L2 of SEQ ID NO: 5 (AASSLQS) and a CDR-L3 of SEQ ID NO: 6 (QQSIEDPYT);
  • VL comprising a light chain complementary determining region CDR-L1 of SEQ ID NO: 4 (RASES VSIHGTHLMH), a CDR-L2 of SEQ ID NO: 7 (AASNLES) and a CDR-L3 of SEQ ID NO: 6 (QQSIEDPYT), and
  • VL comprising a light chain complementary determining region CDR-L1 of SEQ ID NO: 4 (RASES VSIHGTHLMH), a CDR-L2 of SEQ ID NO: 8 (AASNLQS) and a CDR-L3 of SEQ ID NO: 6 (QQSIEDPYT),
  • the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of 4-1BBL or a fragment thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises one ectodomain of 4-1BBL or a fragment thereof, and
  • immunostimulatory antigen binding molecule of para 1 wherein the ectodomain of 4-1BBL or a fragment thereof comprises the amino acid sequence of SEQ ID NO:9 or SEQ ID NOTO.
  • immunostimulatory antigen binding molecule of any one of paras 1 to 3, wherein the antigen binding domain comprises
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13
  • VL BCMA comprising an amino acid sequence of SEQ ID NO: 15, or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO: 13 and VL BCMA comprising an amino acid sequence of SEQ ID NO: 16.
  • immunostimulatory antigen binding molecule of any one of paras 1 to 5, wherein the Fc domain composed of a first and a second subunit is an IgG, particularly an IgGl Fc domain.
  • the immunostimulatory antigen binding molecule of para 8 wherein the first subunit of the Fc domain comprises the amino acid substitutions S354C and T366W (EU numbering) and the second subunit of the Fc domain comprises the amino acid substitutions Y349C, T366S and Y407V (numbering according to Kabat EU index).
  • immunostimulatory antigen binding molecule of any one of paras 1 to 10, wherein the Fc domain is of human IgGl subclass and comprises the amino acid mutations L234A, L235A and P329G (numbering according to Kabat EU index).
  • immunostimulatory antigen binding molecule of any one of paras 1 to 11, comprising
  • a first polypeptide comprising (ai) a first ectodomain of 4-1BBL or fragment thereof, fused at its C-terminus to the N-terminus of the second ectodomain of 4-1BBL or fragment thereof, (aii) a second ectodomain of 4-1BBL or fragment thereof, fused at its C-terminus to the N-terminus of a CL domain, (aiii) the CL domain, fused at its C-terminus to the N-terminus of one of the subunits (e.g. the first subunit) of the Fc domain, and (aiv) one of the subunits (e.g. the first subunit) of the Fc domain;
  • a second polypeptide comprising (bi) a third ectodomain of 4-1BBL or fragment thereof, fused at its C-terminus to the N-terminus of a CHI domain, and (bii) the CHI domain;
  • a third polypeptide comprising (ci) the heavy chain of the Fab molecule, fused at its C- terminus to the N-terminus of the other one of the subunits (e.g. the second subunit) of the Fc domain, and (cii) the other one of the subunits (e.g. the second subunit) of the Fc domain; and (d) a fourth polypeptide, comprising the light chain of the Fab molecule.
  • VL BCMA heavy chain variable region
  • VH comprising a heavy chain complementary determining region CDR-H1 of SEQ ID NO: 26 (GFTFSNAWMD), a CDR-H2 of SEQ ID NO: 27 (QITAKSNNYATYYADSVKG), and a CDR-H3 of SEQ ID NO: 28 (DGYH); and
  • VH comprising a heavy chain complementary determining region CDR-H1 of SEQ ID NO: 26 (GFTFSNAWMD), a CDR-H2 of SEQ ID NO: 29 (QITAKSNNYATYYAAPVKG), and a CDR-H3 of SEQ ID NO: 28 (DGYH); and
  • VL BCMA light chain variable region
  • RASED IRNGLA light chain complementary determining region CDR-L1 of SEQ ID NO: 30
  • NANSLHT NANSLHT
  • EDTSKYPYT a light chain variable region
  • the antigen binding molecule is characterized in that the first polypeptide comprises two ectodomains of 4-1BBL or a fragment thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises one ectodomain of 4-1BBL or a fragment thereof, and
  • the immunostimulatory antigen binding molecule of paras 15 or 16 wherein the immunostimulatory antigen binding molecule is characterized in that the first polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO:12, SEQ ID NO: 189 and SEQ ID NO: 190 and in that the second polypeptide comprises the amino acid sequence of SEQ ID NO:9 or SEQ ID NOTO.
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:33 (VH2a) and VL BCMA comprising an amino acid sequence of SEQ ID NO:34 (VL2a), or
  • VH BCMA comprising an amino acid sequence of SEQ ID NO:35 (VHlb) and VL BCMA comprising an amino acid sequence of SEQ ID NO:36 (VLla).
  • the immunostimulatory antigen binding molecule of para 22 wherein the first subunit of the Fc domain comprises the amino acid substitutions S354C and T366W (EU numbering) and the second subunit of the Fc domain comprises the amino acid substitutions Y349C, T366S and Y407V (numbering according to Kabat EU index).
  • 24. The immunostimulatory antigen binding molecule of any one of paras 15 to 23, wherein the Fc domain comprises one or more amino acid substitution that reduces binding to an Fc receptor and/or effector function.
  • a first polypeptide comprising (ai) a first ectodomain of 4-1BBL or fragment thereof, fused at its C-terminus to the N-terminus of the second ectodomain of 4-1BBL or fragment thereof, (aii) a second ectodomain of 4-1BBL or fragment thereof, fused at its C-terminus to the N-terminus of a CL domain, (aiii) the CL domain, fused at its C-terminus to the N-terminus of one of the subunits (e.g. the first subunit) of the Fc domain, and (aiv) one of the subunits (e.g. the first subunit) of the Fc domain;
  • a second polypeptide comprising (bi) a third ectodomain of 4-1BBL or fragment thereof, fused at its C-terminus to the N-terminus of a CHI domain, and (bii) the CHI domain;
  • a third polypeptide comprising (ci) the heavy chain of the Fab molecule, fused at its C- terminus to the N-terminus of the other one of the subunits (e.g. the second subunit) of the Fc domain, and (cii) the other one of the subunits (e.g. the second subunit) of the Fc domain; and
  • One or more vector, particularly expression vector, comprising the polynucleotide(s) of claim 29.
  • a host cell comprising the polynucleotide(s) of para 29 or the vector(s) of para 30.
  • a method of producing an immunostimulatory antigen binding molecule that specifically binds to BCMA comprising the steps of a) culturing the host cell of para 31 under conditions suitable for the expression of the immunostimulatory antigen binding molecule and optionally b) recovering the immunostimulatory antigen binding molecule.
  • a pharmaceutical composition comprising the immunostimulatory antigen binding molecule of any one of paras 1 to 28 or 33 and at least one pharmaceutically acceptable excipient.
  • the immunostimulatory antigen binding molecule or the pharmaceutical composition for use of para 40 wherein the T-cell activating anti-CD3 bispecific antibody is an anti- GPRC5D/anti-CD3 antibody.
  • a method of treating a disease, particularly cancer, in an individual comprising administering to said individual an effective amount of the immunostimulatory antigen binding molecule of paras 1 to 28 or 33, or the pharmaceutical composition of claim 34.
  • the method of para 43 further comprising administration in combination with a chemotherapeutic agent, radiation therapy and/ or other agents for use in cancer immunotherapy, particularly in combination with a T-cell activating anti-CD3 bispecific antibody.
  • DNA sequencing DNA sequences were determined by double strand sequencing.
  • Desired gene segments were either generated by PCR using appropriate templates or were synthesized at Geneart AG (Regensburg, Germany) or Genscript (New Jersey, USA) from synthetic oligonucleotides and PCR products by automated gene synthesis.
  • the gene segments flanked by singular restriction endonuclease cleavage sites were cloned into standard cloning / sequencing vectors.
  • the plasmid DNA was purified from transformed bacteria and concentration determined by UV spectroscopy.
  • the DNA sequence of the subcloned gene fragments was confirmed by DNA sequencing.
  • Gene segments were designed with suitable restriction sites to allow subcloning into the respective expression vectors. All constructs were designed with a 5 ’-end DNA sequence coding for a leader peptide which targets proteins for secretion in eukaryotic cells.
  • IgG and bispecific antibodies The DNA sequences encoding the variable heavy and light chain regions of the BCMA antibodies were cloned into mammalian expression vectors using conventional cloning techniques. The antibodies described herein were produced using shaking flasks with FedBatch mode. The recombinant production was performed by transient transfection of Expi293TM Cells in a defined, serum-free medium. For transfection ExpiFectamineTM 293 Transfection Kit was used (Gibco). Cell culture supernatants were harvested 7-12 days after transfection.
  • Quantification of protein titer The protein titer of supernatant samples was determined by affinity chromatography using a POROS A 20 pm column, 2.1 x 30 mm (Life Technologies, Carlsbad, CA, USA) on a High Performance Liquid Chromatography system (Ultimate 3000 HPLC system, Thermo Scientific, Waltham, MA, USA). The supernatant was loaded onto the column equilibrated with 0.2 M Na2HPO4, pH 7.4, followed by elution with 0.1 M citric acid, 0.2 M NaCl, pH 2.5. Titers were quantified by measuring absorption at 280 nm, and subsequently calculating the protein concentration by comparing the elution peak area (under the curve) of the analyte with a reference standard curve.
  • Proteins were purified from cell culture supernatants referring to standard protocols.
  • Fc containing proteins were purified from cell culture supernatants by Protein A-affinity chromatography (equilibration buffer: 20 mM sodium citrate, 20 mM sodium phosphate, pH 7.5 or PBS; elution buffer: 20 mM, 25 mM or 50 mM sodium citrate, pH 3.0). Elution was achieved at pH 3.0 followed by immediate pH neutralization of the sample.
  • the protein was concentrated by centrifugation (Millipore Amicon® ULTRA-15, #UFC903096), and aggregated protein was separated from monomeric protein by size exclusion chromatography in 20 mM histidine, 140 mM sodium chloride, pH 6.0.
  • the concentrations of purified proteins were determined by measuring the absorption at 280 nm using the mass extinction coefficient calculated on the basis of the amino acid sequence according to Pace, et al., Protein Science, 1995, 4, 2411-1423. Purity and molecular weight of the proteins were analyzed by CE-SDS in the presence and absence of a reducing agent using a LabChipGXII or LabChip GX Touch (Perkin Elmer).
  • VH/VL CrossMabs VH/VL CrossMabs
  • ESI-MS electrospray ionization mass spectrometry
  • the VH/VL CrossMabs were deglycosylated with N-Glycosidase F in a phosphate or Tris buffer at 37°C for up to 17 h at a protein concentration of 1 mg/ml.
  • the plasmin or limited LysC (Roche) digestions were performed with 100 pg deglycosylated VH/VL CrossMabs in a Tris buffer pH 8 at room temperature for 120 hours and at 37°C for 40 min, respectively. Prior to mass spectrometry the samples were desalted via HPLC on a Sephadex G25 column (GE Healthcare). The total mass was determined via ESLMS on a maXis 4G UHR-QTOF MS system (Bruker Daltonik) equipped with a TriVersa NanoMate source (Advion).
  • Binding of the generated antibodies to the respective antigens is investigated by surface plasmon resonance using a BIACORE instrument (GE Healthcare Biosciences AB, Uppsala, Sweden). Briefly, for affinity measurements Goat- Anti -Human IgG, HR 109-005-098 antibodies are immobilized on a CM5 chip via amine coupling for presentation of the antibodies against the respective antigen. Binding is measured in HBS buffer (HBS-P (10 mM HEPES, 150 mM NaCl, 0.005% Tween 20, ph 7.4), 25°C (or alternatively at 37°C).
  • HBS buffer HBS-P (10 mM HEPES, 150 mM NaCl, 0.005% Tween 20, ph 7.4
  • Antigen (R&D Systems or in house purified) was added in various concentrations in solution. Association was measured by an antigen injection of 80 seconds to 3 minutes; dissociation was measured by washing the chip surface with HBS buffer for 3 - 10 minutes and a KD value was estimated using a 1 : 1 Langmuir binding model. Negative control data (e.g. buffer curves) are subtracted from sample curves for correction of system intrinsic baseline drift and for noise signal reduction. The respective Biacore Evaluation Software is used for analysis of sensorgrams and for calculation of affinity data.
  • Anti-BCMA antibody E04 is disclosed in WO 2012/163805 and has the VH domain of SEQ ID NO:41 and the VL domain of SEQ ID NO:42. Optimized variants thereof were created as described in the following.
  • a suitable human acceptor framework during the humanization, a combination of two methodologies was used. On the one hand, a classical approach was taken by querying a BLASTp database of human V- and J-region sequences for the murine input sequences (cropped to the variable part).
  • Selective criteria for the choice of human acceptor framework were sequence homology, same or similar CDR lengths, and the estimated frequency of the human germline, but also the conservation of certain amino acids at the VH-VL domain interface.
  • the CDRs of the murine input sequences were grafted onto the human acceptor framework regions.
  • Each amino acid difference between these initial CDR grafts and the parental antibody was rated for possible impact on the structural integrity of the respective variable region, and “back mutations” towards the parental sequence were introduced whenever deemed appropriate.
  • the structural assessment was based on Fv region homology models of both the parental antibody and the humanization variants, created with an in-house antibody structure homology modeling protocol implemented using the BIO VIA Discovery Studio Environment, version 17R2.
  • “forward mutations” were included, i.e., amino acid exchanges that change the original amino acid occurring at a given CDR position of the parental binder to the amino acid found at the equivalent position of the human acceptor germline. The aim is to increase the overall human character of the humanization variants (beyond the framework regions) to further reduce the immunogenicity risk.
  • the acceptor framework was chosen as described in Table 1 below:
  • Acceptor framework Post-CDR3 framework regions were adapted from human IGHJ germline IGHJ4*01 (YFDYWGQGTLVTVSS, SEQ ID NO: 41) and human IGKJ germline IGKJ4*01 (LTFGGGTKVEIK, SEQ ID NO:42). The part relevant for the acceptor framework is indicated as underlined.
  • Table 2 List of Variants -I l l-
  • forward mutations with f e.g., bS49A refers to a back mutation (human germline amino acid to parental antibody amino acid) from serine to alanine at position 49. All residue indices are given in Kabat numbering.
  • the NetMHCIIpan 4.0 predictor (Reynisson B et. al: NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data, Nucl. Acids Res., 48(W1): W449-W454 (2020)) was employed.
  • the thresholds for strong and weak binding 15mer peptides were set to a percentile rank of 1 and 5, respectively. Binding 15mer peptides with a percentile rank above 5 were not considered. Likewise, all binding 15mer peptides with a 9mer core peptide occurring in 10 or more human V-region germlines were not considered.
  • the germline sequences were obtained from the IMGT database (Giudicelli, V. et al.: IMGT/LIGM-DB, the IMGT® comprehensive database of immunoglobulin and T cell receptor nucleotide sequences. Nucl. Acids Res., 34(S1):D781-D784 (2006)). As many of the predicted 15mer binders are sharing the same 9mer core peptide, Table 3 below also details the number of unique 9mer cores present in the respective sequence and predicted to bind in the percentile rank range ⁇ 5.
  • the resulting VH domains of the humanized BCMA antibodies can be found in Table 4 below and the resulting VL domains of the humanized BCMA antibodies are listed in Table 5 below.
  • the humanized amino acid sequences for heavy and light chain variable domains of E04 humanized variants were fused to a one-armed human IgGl backbone/human CH1-Hinge-CH2- CH3 with an effector silent Fc domain (P329G; L234A, L235A) to abrogate binding to Fey receptors according to the method described in WO 2012/130831 Al and into a light chain.
  • an effector silent Fc domain P329G; L234A, L235A
  • the amino acid sequences were backtranslated in to DNA and the resulting cDNA were synthesized (GeneArt or Twist Biosciences) and then cloned into heavy chain expression vectors as fusion proteins with human IgGl backbones expression vectors as fusion proteins to human C-kappa.
  • Light chain (LC) and heavy chain (HC) plasmids were then co-transfected into HEK293 cells and purified after 7 days from supernatants by standard methods for antibody purification.
  • Anti-BCMA antibody 54 is disclosed in WO 2013/072415 and has the VH domain of SEQ ID NO:47 and the VL domain of SEQ ID NO:48.
  • BCMA-54 is a humanized antibody with 84.8% identity to the most similar human HV germline (IGHV3-15*01) and 83.2% identity to the most similar human KV germline (IGKV1-6*O1). Even though the variable region of BCMA-54 is based on framework regions of human origin, there are several positions in these regions which are not corresponding to the human germline amino acid. Examples for this include the positions VH-16 (Ala), VH-44 (Arg), VH-84 (Lys), VL-22 (Ala), VL-83 (Glu), and VL-95 (He).
  • Post-CDR3 framework regions were adapted from human IGHJ germline IGHJ1*O1 (AEYFOHWGQGTLVTVSS, SEQ ID NO:49) and human IGKJ germline IGKJ2*01 (YTF GQGTK LE IK, SEQ ID NO:50).
  • the part relevant for the acceptor framework is indicated as underlined.
  • forward mutations with f e.g., bS49A refers to a back mutation (human germline amino acid to parental antibody amino acid) from serine to alanine at position 49. All residue indices are given in Kabat numbering..
  • T-cell Epitope Prediction To assess the occurrence of potential T-cell epitopes in the humanized sequences, the NetMHCIIpan 4.0 predictor (Reynisson B et. al: NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data, Nucl. Acids Res., 48(W1): W449-W454 (2020)) was employed.
  • the thresholds for strong and weak binding 15mer peptides were set to a percentile rank of 1 and 5, respectively. Binding 15mer peptides with a percentile rank above 5 were not considered. Likewise, all binding 15mer peptides with a 9mer core peptide occurring in 10 or more human V-region germlines were not considered.
  • the germline sequences were obtained from the IMGT database (Giudicelli, V. et al.: IMGT/LIGM-DB, the IMGT® comprehensive database of immunoglobulin and T cell receptor nucleotide sequences. Nucl. Acids Res., 34(S1):D781-D784 (2006)). As many of the predicted 15mer binders are sharing the same 9mer core peptide, Table 8 below also details the number of unique 9mer cores present in the respective sequence and predicted to bind in the percentile rank range ⁇ 5.
  • the resulting VH domains of the humanized BCMA antibodies can be found in Table 9 below and the resulting VL domains of the humanized BCMA antibodies are listed in Table 10 below.
  • the humanized amino acid sequences for heavy and light chain variable domains of E04 humanized variants were fused to a one-armed human IgGl backbone/human CH1-Hinge-CH2- CH3 with an effector silent Fc domain (P329G; L234A, L235A) to abrogate binding to Fey receptors according to the method described in WO 2012/130831 Al and containing a knob mutation according to Knobs-into-Holes technology and into a light chain.
  • a human Fc containing an effector silent Fc domain was used for the right assembly of the one-armed IgGl .
  • the amino acid sequences were backtranslated into DNA and the resulting cDNA were synthesized (GeneArt or Twist Biosciences) and then cloned into heavy chain expression vectors as fusion proteins with human IgGl backbones expression vectors as fusion proteins to human C-kappa.
  • Light chain (LC) and heavy chain (HC) plasmids were then co-transfected into HEK293 cells and purified after 7 days from supernatants by standard methods for antibody purification.
  • Table 11 Summary of expressed monovalent anti-BCMA variants The protein concentration of purified constructs was determined by measuring the optical density (OD) at 280 nm, using the mass extinction coefficient calculated on the basis of the amino acid sequence according to Pace, et al., Protein Science, 1995, 4, 2411-1423. Purity and molecular weight of the proteins were analyzed by CE-SDS in the presence and absence of a reducing agent using a LabChipGXII (Perkin Elmer).
  • the binding kinetics of the monovalent humanized BCMA antibody variants to human BCMA and to cynomolgus BCMA were investigated by surface plasmon resonance (SPR) using a BIACORE T200 instrument (GE Healthcare). All experiments were performed at 25° C using HBS-P Buffer (10 mM HEPES, 150 mM NaCl pH 7.4, 0.05% surfactant P20) as running buffer and as dilution buffer.
  • Anti-BCMA antibodies were captured on the surface for 30 s at a flow rate of 5 pl/min leading to a capturing response of 50-200 RU.
  • a dilution series of the antigen human BCMA Fc homodimer (R&D Systems) or cynomolgus BCMA Fc homodimer (R&D Systems), respectively
  • the dissociation phase was monitored for 300-600 sec by washing with running buffer.
  • the surface was regenerated by injecting 5 mM NaOH (freshly prepared) for 2 x 30 s.
  • the KD values for the monovalent constructs including the 29 preferred BCMA variants are shown in Table 12 below.
  • the antibodies P1AG5080, P1AG5072, P1AG5028, P1AG5031, P1AG5063 and P1AG5036 (4 BCMA 54 variants and 2 BCMA E04 variants) were selected as the molecules with the lowest potential T-cell epitopes.
  • Pl AG5072 and Pl AG5031 were choosen as BCMA 54 variants and Pl AG5063 and Pl AG5036 were selected as the BCMA E04 variant antibodies to be included in the bispecific antibodies.
  • Fc fragments contained either the “knob” (S354C/T366W mutations, numbering according to Kabat EU index) or “hole” mutations (Y349C/T366S/L368A/Y407V mutations according to Kabat EU index) to avoid mispairing of the heavy chains.
  • “knob” S354C/T366W mutations, numbering according to Kabat EU index
  • “hole” mutations Y349C/T366S/L368A/Y407V mutations according to Kabat EU index
  • FIG. 13 A schematic illustration of the BCMA targeting 4-1BBL trimer-containing antigen binding molecule is shown in Figure IB.
  • Table 13 summarizes specific antigen binding molecules made, their identifiers and the sequences of the heavy chains (Fcl knob / fusion protein 2 and Fc2 hole) and light chains (LC and fusion protein 1).
  • Table 13 Summary of expressed anti-BCMA-4-lBBL antigen binding molecules
  • Proteins were purified from cell culture supernatants referring to standard protocols. In brief, Fc containing proteins were purified from cell culture supernatants by Protein A-affinity chromatography (equilibration buffer: 20 mM sodium citrate, 20 mM sodium phosphate, pH 7.5 or PBS; elution buffer: 20 mM, 25 mM or 50 mM sodium citrate, pH 3.0). Elution was achieved at pH 3.0 followed by immediate pH neutralization of the sample.
  • the protein was concentrated by centrifugation (Millipore Amicon® ULTRA- 15, #UFC903096), and aggregated protein was separated from monomeric protein by size exclusion chromatography in 20 mM histidine, 140 mM sodium chloride, pH 6.0.
  • Determination of the aggregate content was performed by HPLC chromatography at 25°C using analytical size-exclusion column (TSKgel G3000 SW XL or UP-SW3000, Tosoh Bioscience) equilibrated in running buffer (200 mM KH2PO4, 250 mM KC1 pH 6.2, 0.02% NaN 3 ).
  • Table 14 Summary of the production and purification of BCMA targeting 4-1BBL trimer- containing antigen binding molecules 2.3 Biophysical and biochemical characterization of BCMA targeting 4-1BBL trimer- containing antigen binding molecules
  • the aggregation temperature (T agg ) of the tested BCMA-4-1BBL constructs Pl AG7397 and Pl AG7422 was favorable as compared to the constructs Pl AG7409 and Pl AG7400, however the aggregation temperature for all constructs was considered sufficiently high for further development.
  • the apparent hydrophobicity of the bispecific antibodies was assessed by hydrophobic interaction chromatography (HIC) as relative retention time compared to hydrophobicity standards (90 % of immunoglobulins in IVIG preparation have a relative retention time ⁇ 0.35).
  • HIC hydrophobic interaction chromatography
  • 20 pg of sample was injected onto a HIC-Ether-5PW (Tosoh) column equilibrated with 25 mM Na-phosphate, 1.5 M ammonium sulfate, pH 7.0. Elution was performed with a linear gradient from 0 to 100% buffer B (25 mM Na-phosphate, pH 7.0) within 60 minutes. Retention times were then compared to protein standards with known hydrophobicity (e.g. Avastin). All constructs possess a higher hydrophobicity than a typical antibody.
  • FcRn affinity chromatography FcRn was expressed, purified and biotinylated as described (Schlothauer et al., MAbs 2013, 5(4), 576-86).
  • the prepared receptor was added to streptavidin-sepharose (GE Healthcare).
  • streptavidin-sepharose GE Healthcare
  • the resulting FcRn-sepharose matrix was packed in a column housing.
  • the column was equilibrated with 20 mM 2-(N-morpholine)- ethanesulfonic acid (MES) and 140 mM NaCl, pH 5.5 (eluent A) at a 0.5 ml/min flow rate.
  • MES 2-(N-morpholine)- ethanesulfonic acid
  • Heparin affinity was determined by injecting 30-50 pg of sample onto a TSKgel Heparin- 5PW (Tosoh) column equilibrated with 50 mM Tris, pH 7.4. Elution was performed with a linear gradient from 0 to 100% buffer B (50 mM Tris, IM NaCl, pH 7.4 mM) within 37 minutes. Retention times were compared to protein standards with known affinities. The expected values for the retention times and the measured retention times for particular BCMA-4-1BBL constructs are shown in Table 15.
  • Biotinylated human BCMA and 4-1BB, as well as biotinylated anti-hu IgG were immobilized on a Series S Sensor Chip SA (GE Healthcare, #29104992), resulting in surface densities of at least 1000 resonance units (RU).
  • BCMA-4-1BBL constructs with a concentration of 2 pg/ml were injected for 30 s at a flow rate of 5 pl/min, and dissociation was monitored for 120 s. The surface was regenerated by injecting 10 mM glycine buffer, pH 1.5, for 60 s. Bulk refractive index differences were corrected by subtracting blank injections and by subtracting the response obtained from a blank control flow cell. For evaluation, the binding response 5 seconds after injection end was taken.
  • the BCMA and 4-1BB binding was divided by the anti-hu IgG response (the signal (RU) obtained upon capture of the BCMA-4-1BBL constructs on the immobilized anti-hu IgG antibody).
  • the relative binding activity was calculated by referencing each temperature stressed sample to the corresponding, non-stressed sample. As shown in Table 16, all BCMA-4-1BBL constructs showed a stabile binding upon stress to BCMA and 4-1BB.
  • the BCMA-41BBL antigen binding molecules displayed a lower stability in the in vitro assessment compared to classical antibodies or bispecific antibodies. However, the data are in the range of other fusion proteins that are currently tested in clinical trials and thus considered acceptable.
  • Alnuctamab is a BCMA x CD3 bispecific antibody in a 2+1 format, based on an IgGl Fc with L234A/L235A/P329G (EU numbering) mutations.
  • the sequences are identified in the International Non-Proprietary Nomenclature List (Recommended INN: List 85; WHO Drug Information, Vol. 35, No. 1, 2021).
  • Alnuctamab comprises an amino acid sequence of SEQ ID NO: 191, two amino acid sequences of SEQ ID NO: 192, an amino acid sequence of SEQ ID NO: 193 and amino acid sequence of SEQ ID NO: 194 (2+1 format).
  • Elranatamab is a BCMA x CD3 bispecific antibody in a 1+1 format. The sequences are identified in the International Non-Proprietary Nomenclature List (Recommended INN: List 87, WHO Drug Information, Vol. 36, No. 1, 2022). Elranatamab comprises an amino acid sequence of SEQ ID NO: 195, an amino acid sequence of SEQ ID NO: 196, an amino acid sequence of SEQ ID NO: 197 and amino acid sequence of SEQ ID NO: 198.
  • Alnuctamab (Pl AF0105)
  • the DNA sequences encoding the variable heavy and light chain regions of the respective binding domains were cloned into mammalian expression vectors using conventional cloning techniques.
  • Antibodies were generated by transient transfection of Expi293F cells. Cells were seeded in Expi293 media (Gibco, #1435101) at a density of 2.5 x 10 6 /mL.
  • Expression plasmids and ExpiFectamine (Gibco, ExpiFectamine transfection kit, #13385544) were separately mixed in OptiMEM (Gibco, #11520386).
  • Elranatamab (P1AH5054) was produced and purified by Proteros according to their standard methods and protocols.
  • the quantification of Fc containing constructs in supernatants was performed by Protein A - HPLC on an Agilent HPLC System with UV detector. Supernatants are injected on POROS 20 A (Applied Biosystems), washed with 10 mM Tris, 50 mM Glycine, 100 mM NaCl, pH 8.0 and eluted in the same buffer at pH 2.0. Titers were quantified by measuring absorption at 280 nm, and subsequently calculating the protein concentration by comparing the elution peak area (under the curve) of the analyte with a reference standard curve.
  • Proteins were purified from filtered cell culture supernatants referring to standard protocols.
  • Fc containing proteins were purified from cell culture supernatants by Protein A-affinity chromatography (equilibration buffer: 20 mM sodium citrate, 20 mM sodium phosphate, pH 7.5; elution buffer: 20 mM sodium citrate, pH 3.0). Elution was achieved at pH 3.0 followed by immediate pH neutralization of the sample.
  • the protein was concentrated by centrifugation using Millipore Amicon® ULTRA- 15 (Merck, #UFC903096), and aggregated protein was separated from monomeric protein by size exclusion chromatography in 20 mM histidine, 140 mM sodium chloride, pH 6.0.
  • the concentrations of purified proteins were determined by measuring the absorption at 280 nm using the mass extinction coefficient calculated on the basis of the amino acid sequence according to Pace, et al., Protein Science, 1995, 4, 2411-1423. Purity and molecular weight of the proteins were analyzed by CE-SDS in the presence and absence of a reducing agent using a LabChipGXII or LabChip GX Touch (Perkin Elmer) (Perkin Elmer).
  • Teclistamab is a BCMA x CD3 bispecific antibody with an IgG4-F234A/L235A/S228P (EU numbering) Fc. The sequences are identified in the International Non-Proprietary Nomenclature List (Recommended INN: List 82, WHO Drug Information, Vol. 33, No. 3, 2019). It was obtained from a Supplier (FarmaMondo, Lot Nr. AT1334P1). Teclistamab comprises an amino acid sequence of SEQ ID NO: 199, an amino acid sequence of SEQ ID NO: 200, an amino acid sequence of SEQ ID NO: 201 and amino acid sequence of SEQ ID NO: 202.
  • Lentiviral particles were prepared by transiently cotransfecting HEK 293-derived viral production cells (Gibco, #A35347) with transfer plasmid and lentiviral packaging mix (pRSV-Rev, pCgpV, and pCMV-VSV-G) using the LV-MAX Transfection Kit (Gibco, # A35346) according to the manufacturer's protocol.
  • Viral supernatants were harvested 48 h after transfection, filtered through a 0.45 -pm low protein binding filter and stored at -80°C until use.
  • 5 x 10 4 CHO-K1 (ATCC CRL-9618) cells were seeded per well in a 24-well plate.
  • the culture medium was replaced with 300 pL of purified lentiviral supernatant and 100 pL of fresh culture medium DMEM/F-12 (Gibco, #11320033) supplemented with 10% fetal bovine serum (Gibco, #16140063) and 1% GlutaMAX Supplement (Gibco; #31331-028).
  • the infectious medium was further supplemented with 2.5 pL of TransDuxTM reagent and 100 pL of MAX Enhancer (SBI; # LV860A-1). The cells were then incubated for 24 hours at 37 °C. After the incubation period, the viral medium was discarded and the cells were subsequently maintained in fresh culture medium.
  • the culture medium was supplemented with 6 pg/mL puromycin (Invivogen; #ant-pr-l).
  • the cells exhibiting human BCMA surface expression were isolated by BD FACSAria III cell sorter (BD Biosciences) and subsequently cultured to generate stable clones. Following a 4-week stability test, the surface expression and its stability were verified by flow cytometry analysis using mouse PE-conjugated anti-human BCMA (BioLegend, #357503).
  • the stable CHO transfectants (parental cell line CHO-kl ATCC #CCL-61) were cultured in DMEM/F-12 (Gibco, #10565018) supplemented with 10% fetal bovine serum (Gibco, #16140063 or Sigma-Aldrich F4135) and 1% GlutaMAX Supplement (Gibco; #31331-028), including 6 pg/ml puromycin (Invivogen; #ant-pr-l).
  • Adherent CHO cells were detached using Cell Dissociation Buffer (Gibco, #13151014) or trypsin (Gibco by ThermoFisher Scientific, TrypLETMExpress Enzyme #2605-010), counted and checked for viability. All subsequent steps were performed at 4°C.
  • CHO-huBCMA cells were re-suspended in FACS buffer (PBS, 2% Fetal Bovine Serum; 1% 0.5 M EDTA pH 8; 0.25% NaNs Sodium azide) at 1 Mio cells per ml.
  • FACS buffer PBS, 2% Fetal Bovine Serum; 1% 0.5 M EDTA pH 8; 0.25% NaNs Sodium azide
  • 0.1 Mio cells were plated per well of a round-bottom 96-well-plate and washed with 150 pl cold FACS buffer per well once.
  • Cells were stained in a total volume of 50 pl per well and increasing concentrations of the indicated BCMA-4-1BBL antigen binding molecules (0.48 pM - 2000 nM) for 30 minutes at 4°C. Afterwards, the cells were centrifuged and washed with 150 pl FACS buffer twice.
  • CHO transfectants were resuspended in PBS (Gibco by ThermoFisher Scientific, #20012050) and counted. Live-dead staining of target cells was performed by incubation of cells with 1 : 1000 diluted Zombie Aqua Viability dye (BioLegend #42310277143) in PBS at 1.5 Mio cells per ml for 10 minutes in the dark, followed by a two washing steps with PBS and centrifugation at 400 xg at 4°C for 4 minutes.
  • PBS Gibco by ThermoFisher Scientific, #20012050
  • Live-dead staining of target cells was performed by incubation of cells with 1 : 1000 diluted Zombie Aqua Viability dye (BioLegend #42310277143) in PBS at 1.5 Mio cells per ml for 10 minutes in the dark, followed by a two washing steps with PBS and centrifugation at 400 xg at 4°C for 4 minutes.
  • CHO-K1 cells were adjusted to 1.5 Mio cells per ml in PBS and 40 pl were seeded per well of a 384-U bottom well plates (ThermoFisher Scientific #264573). Plates were centrifuged once more at 400 xg at 4°C for 4 minutes and 20 pl supernatant was removed.
  • Cells were stained in a total volume of 20 40 pl per well and by adding 20 pl of 2x concentrated increasing concentrations of the indicated dilutions of BCMA-4-1BBL antigen binding molecules (final concentrations ranged from 0.008 - to 125 nM) for 30 minutes at 4°C in the dark. Afterwards, the cells were centrifuged and washed with 40 pl PBS buffer twice.
  • Binding curves and ECso values were obtained using GraphPadPrism6.
  • the data as measured for various BCMA-4-1BBL antigen binding molecules and controls (for instance “2nd antibody only refers to samples containing only the fluorophore labeled secondary antibody) are shown in Figures 3C to 3H.
  • the Jurkat-NFKB-luc2_4-lBB Reporter Cell Line was developed by Promega in collaboration with Roche Diagnostics GmbH and is stably transfected with two plasmids encoding human 4-1BB and a NFKB-driven luciferase reporter gene.
  • the cell line was grown in RPMI1640 medium supplemented with 10% FCS, 25 mM HEPES (Thermofisher), 2 mM GlutaMax, 0.1 mM non-essential amino acid (Thermofisher), and 1 mM sodium pyruvate.
  • the medium was supplemented with 400 pg/ml of Hygromycin B and 600pg/mL of Geneticin (Sigma-Aldrich).
  • Jurkat cells were cultured twice per week to maintain a density between 0.2 - 1.0 xlO 6 cells/ml.
  • Jurkat-NFkB-luc2_4-lBB cells were resuspended in PBS at 1.0 xlO 6 cells/ml.
  • 0.1 xlO 6 cells per well were seeded into a 96-round- bottom-well plate and stained with a fixable viability dye (LIVE/DEADTM Fixable Near-IR Dead Cell Stain Kit (APC/Cy7), L34976 MolecularProbes, 1 :1000 diluted in PBS) for 20 min at 4°C.
  • a fixable viability dye LIVE/DEADTM Fixable Near-IR Dead Cell Stain Kit (APC/Cy7)
  • the cells were washed with cold FACS buffer (PBS, 2% Fetal Bovine Serum; 1% 0.5m EDTA pH 8; 0.25% NaNs Sodium azide (20%)) twice and then stained with PE-conjugated secondary antibody (PE-AffiniPure F(ab')2 Fragment Goat Anti-Human IgG, Fey Fragment Specific; Jackson Immunoresearch, 109-116-170) that was diluted 1/100 in cold FACS buffer, for another 30 min at 4°C. After two final washing steps, cells were fixed with 1% PFA for 20 min at RT. Flow cytometric acquisition was performed on a custom-designed BD Biosciences Fortessa and analyzed using BD Diva.
  • PE-AffiniPure F(ab')2 Fragment Goat Anti-Human IgG, Fey Fragment Specific; Jackson Immunoresearch, 109-116-170 PE-AffiniPure F(ab')2 Fragment Goat Anti-
  • BCMA targeting 4-1 BBL trimer-containing antigen binding molecules were able to bind human BCMA (Fig. 2A and 3A) as well as to human 4- IBB (Fig. 2B and 3B) in a concentration-dependent manner.
  • the BCMA-4-1BBL constructs showed a significantly stronger binding to human BCMA than the construct P1AH1062 (BCMA 5D5 LM4) as prepared according to WO 2021/118246 Al.
  • P1AH1062 is a bivalent BCMA antibody that comprises two scFv fragments binding to 4-1BB at its C-terminus.
  • P1AH1062 comprises two similar heavy chains of SEQ ID NO:89 and two light chains of SEQ ID NO:90. Binding to human 4- 1BB was comparable for all constructs (Fig. 2B and 3B).
  • the ECso values are listed in Table 17 below. Table 17: ECso values (nM) for binding of the indicated antigen binding molecules to either human 4-1BB or BCMA, expressed on cells
  • the bispecific antigen binding molecules tested comprised the trimeric 4- 1BBL and the BCMA binder BCMA (54_2a2a) or BCMA (E04_lalf). Since one of the relapse mechanisms in MM can be non-truncating, missense mutations or in-frame deletions in the extracellular domain of BCMA, the above mentioned molecules were compared head-to-head to well described BCMA-targeted CD3 T cell engagers, namely Teclistamab, Alnuctamab and Elranatamab (Lee et al., Nature Medicine 2023, 29, 2295-2306).
  • BCMA-targeting molecules The binding properties of the various BCMA-targeting molecules are summarized in Table 17A. Both BCMA-targeted 4-1BBL bispecific molecules, as well as Alnuctamab, were able to bind to the wt and to all mutated forms of human BCMA in a concentration-dependent manner. In contrast, Elranatamab displayed a significant reduction of binding to the point mutation R27P, which translated into a weak binding signal at the highest concentrations only. Teclistamab was not able to bind to the point mutation R27P and the S30del. Efficient binding to BCMA is a crucial requisite for the therapeutic activity of BCMA-targeted bispecific molecules, suggesting an advantage for molecules who are not affected by point mutations in the ECD of BCMA.
  • the activity of the targeted BCMA-4-1BBL molecules was assessed in a Jurkat-NFKB- Iuc2_4-1BB Reporter assay, where the molecules simultaneously bind to human 4-1BB on Jurkat-NFKB-luc2_4-lBB cells and BCMA expressed on the indicated MM cell lines leading to hyperclustering of 4- IBB and thereby receptor activation. Subsequent induction of corresponding signaling pathways results in the activation of NFKB which induces the expression of firefly luciferase. The activity of the luciferase reporter is measured by adding luciferase substrate and luminescence readout. 2.
  • BCMA-4-1BBL In another read-out, the functionality of BCMA-4-1BBL was evaluated in a PBMC coculture assay in presence of BCMA-expressing MM cell lines and a fixed concentration of a GPRC5D TCB providing the simultaneous 1st signal for T-cell activation.
  • BCMA-4-1BBL was added at a fixed concentration to different concentrations of a FcRH5- targeted CD3 engager (FcRH5 x CD3).
  • FcRH5 x CD3 bispecific antibodies are for instance disclosed in WO 2016/205520 Al. Read-outs were upregulation of surface activation markers on T cells and lysis of tumor cells, as indicated.
  • NCI-H929 cells were cultivated in RPMI1640 (Gibco) supplemented with 10% FCS (PAN-biotech), 2 mM L-glutamine (Sigma-Aldrich), 1 mM sodium pyruvate (Thermofisher), and 50pM 2-Mercaptoethanol (Thermofisher). Cells were cultured twice per week to maintain a density between 0.5 - 2.0 xlO 6 cells/ml.
  • Jurkat IL2 reporter and Jurkat NF- KB/4-1BB reporter cell lines were grown in RPMI1640 medium supplemented with 10% FCS, 25 mM HEPES (Thermofisher), 2 mM L-glutamine, 0.1 mM non-essential amino acid (Thermofisher), and 1 mM sodium pyruvate.
  • the medium was supplemented with 400 pg/ml of Hygromycin B and 600pg/mL of Geneticin (Sigma-Aldrich) for Jurkat NFKB/4- 1BB reporter cell line.
  • Jurkat cells were cultured twice per week to maintain a density between 0.1 - 0.5 xlO 6 cells/ml.
  • the target (NCI-H929) and effector (Jurkat NFKB/4-1BB reporter) cells were harvested and re-suspended in assay medium (Jurkat cell medium without antibiotics) to obtain a cell density of 6 xlO 6 cells/ml for the target cells and 2 xlO 6 cells/ml for the effector cells. Then, the cells were mixed at a ratio E:T 1 :3, and 20 pl of effector-target cells mixture were plated per well of a white-walled 384-flat bottom well plate (353988 FalconTM 384-Well White Flat-Bottom Tissue Culture Treated Microplate).
  • the assay plates were incubated for 5 min at room temperature before adding 20pl of the ONE-Glo solution (Promega). Furthermore, plates were centrifuged for 1 min at 350g and incubated for 10 min at room temperature in the dark to reach complete lysis of the cells. Luminescence was measured (read: 1 s per well) by using the Tecan SparklOM.
  • the target NCLH929 cell line expressing high levels of BCMA was mixed at the ratio 1 :3 (E:T) with the effector Jurkat NFKB reporter cell line that induces 4-1BB receptor- mediated signaling induces luminescence via the NFKB signaling pathway. Then, titrated (600.0- 0.02 nM) BCMA-4-1BBL antigen binding molecules were added and luminescence was measured 4 hrs later. Results showed that all tested BCMA-4-1BBL antigen binding molecules induced T cell activation in a dose-dependent manner (Fig. 4A). Two molecules P1AG7409 and Pl AG7422 outperformed other variants and the molecule comprising BCMA antibody PR (P1AF7814) (Fig.A-C).
  • Table 18 EC50 values (nM) and Emax (%) for T cell activation as measured in the NFKB/4-1BB Reporter cell assay
  • Target Cells NCI-H929 & NCI-H929 BCMAko, BCMA-expressing CHO-kl transfectants or MOLP-2, as indicated respectively.
  • NCI-H929 (ATCC® CRL-9068TM) is a human multiple myeloma cell line that expresses BCMA.
  • BCMA knockout variant of the NCI-H929 cell line (generated using CRISPR/Cas9 technology) was tested as well.
  • the cells were cultivated in RPMI 1640 (GibcoTM 31870074) supplemented with 10% FCS (GibcoTM 16140-071), 10 mM HEPES (GibcoTM 15630056), 2 mM GlutaMAX-I (GibcoTM 35050-038), 1 mM sodium pyruvate (GibcoTM 11360039), and 50 pM 2-Mercapto-ethanol (GibcoTM 31350010). Cells were passaged 2-3 times per week by adding fresh medium to maintain a density between 0.5xl0 6 /ml and 2.5xl0 6 /ml. Cells were incubated at 37 °C with 5% CO2.
  • the target cells were harvested, counted and re-suspended in assay medium (RPMI 1640 GibcoTM 31870074 w/ HEPES w/GlutaMax plus 10% FCS, Sigma-Aldrich #F4135).
  • the stable CHO transfectants (parental cell line CHO-kl ATCC #CCL-61) were cultured in DMEM/F-12 (Gibco, #10565018) supplemented with 10% fetal bovine serum (Gibco, #16140063 or Sigma-Aldrich F4135) and 1% GlutaMAX Supplement (Gibco; #31331-028), including 6 g/ml puromycin (Invivogen; #ant-pr-l).
  • Adherent CHO cells were detached using trypsin (Gibco by ThermoFisher Scientific, TrypLETMExpress Enzyme #2605-010).
  • Target cells were centrifuged at 300 xg for 5 minutes, resuspended in PBS and counted and checked for viability using Cedex HiRes Analyzer.
  • Target cells were centrifuged at 300 xg for 5 minutes, PBS was removed except for 1 ml and pellet was not disturbed for the irradiation of the target cells for 1.49 minutes (5000 Rad, 50 Gy) using a RS 2000 Irradiator (RadSource). Afterwards cells were resuspended in PBS for subsequent counting using Cedex HiRes Analyzer.
  • the irradiated target cells were adjusted to 1.2 Mio cells per ml in assay medium (RPMI 1640 GibcoTM 72400-21 w/ HEPES w/GlutaMax plus 10% FCS, Sigma-Aldrich #F4135).
  • MOLP-2 (DSMZ ACC607) is a human multiple myeloma cell line that expresses e.g. BCMA, GPRC5D and FcRH5.
  • the cells were cultured in RPMI 1640 with HEPES and GlutaMax (GibcoTM 72400-21) supplemented with 20% FCS. Cells were passaged 2 times per week by adding fresh medium to maintain a density between 0.3xl0 6 /ml and lxl0 6 /ml. Cells were incubated at 37 °C with 5% CO2. For the assay, MOLP-2 cells were counted and checked for viability.
  • Assay medium was added (RPMI 1640 GibcoTM 72400- 21 w/ HEPES w/GlutaMax plus 10% FCS, Sigma-Aldrich #F4135), cells were centrifuged at 280 xg for 5 minutes, counted and checked for viability and adjusted to 1.2 Mio cells per ml in assay medium (RPMI 1640 GibcoTM 72400-21 w/ HEPES w/GlutaMax plus 10% FCS, Sigma- Aldrich #F4135).
  • PBMC peripheral blood mononuclear cells
  • PBMCs The interphase consisting of the PBMCs was collected and washed several times with PBS. PBMCs were resuspended in Freezing medium (80023 -IB I) at 40-67 Mio cells/ml and frozen using a Cell Freezing Container (CLS432002 Corning) at -80°C over night and then transferred to nitrogen vapor phase for storage.
  • Freezing medium 80023 -IB I
  • CHS432002 Corning Cell Freezing Container
  • PBMCs were stored in nitrogen vapor phase and thawed on the day of the assay. Cells were counted and then labeled with Cell Proliferation Dye eFluorTM 450 (65-0842-90, eBioscienceTM ). Briefly, PBMCs were washed once with DPBS (Gibco), supernatant was discarded and cells resuspended to 2 Mio cells per well using DPBS. 10 ml of the cell suspension was added to 50ml-falcon tubes and then 10 ml of a 10 pM concentrated Cell Proliferation Dye eFluorTM 450 was added while carefully vortexing (final dye concentration was 5 pM).
  • DPBS Gibco
  • 10 ml of the cell suspension was added to 50ml-falcon tubes and then 10 ml of a 10 pM concentrated Cell Proliferation Dye eFluorTM 450 was added while carefully vortexing (final dye concentration was 5 pM).
  • human PBMCs were thawed and washed with PBS, including a centrifugation at 300 xg for 15 minutes at room temperature.
  • CFSE CellTrace CFSE dye (Invitrogen via ThermoFischer Scientific, #C34554) was diluted in room temperature PBS (2 mM stock concentration) and cells were incubated at a final concentration of 0.1 pM for 15 minutes at 37°C in a waterbath. 20 ml medium containing 10 % FCS were added and the suspension was centrifuged at 300 xg for 15 minutes.
  • the cells were resuspended in assay medium (RPMI 1640 GibcoTM 72400-2 w/ HEPES w/GlutaMax plus 10% FCS, Sigma- Aldrich #F4135) at a concentration of 1.2 Mio cells per ml.
  • assay medium RPMI 1640 GibcoTM 72400-2 w/ HEPES w/GlutaMax plus 10% FCS, Sigma- Aldrich #F4135
  • GPRC5D-TCB 50 pl of fixed concentration (0.32 pM) GPRC5D-TCB (P1AE6625) was added to the plate, reaching the final volume of 200 pl per well.
  • target, and effector cells were treated with GPRC5D- TCB alone to indicate the baseline.
  • a control with target and effector cells was prepared in which no antibody was added (untreated).
  • Assay medium was used to reach the final volume (200 pl) for the control wells. Assay plates were centrifuged for 1 min at 350 g and incubated for 4 days at 37°C in a humidified CO2 incubator.
  • 50 pl (0.06 Mio) of the respective CHO-hBCMA variant or parental (BCMA-negative) CHO-kl and 50 pl (0.06 Mio) eFluor450-labeled PBMCs were plated per well in 96-well flat bottom plates (TPP, #92096) resulting in a 1 : 1 effector to target cell ratio.
  • 50 pl of a fixed concentration (final concentration of 90 pM) anti-CD3 IgG (clone SP34-1, BD Biosciences 551916) was added to the plate.
  • BCMA-4-1BBL antigen binding molecules were added to the plate in triplicates, covering a final concentration of 3.84 pM to 300 nM, with a final volume of 200 pl per well.
  • a control was plated, containing target and effector cells with anti-CD3 IgG alone to determine the baseline effects induced by the first signal provider only.
  • a control with target and effector cells was prepared in which no antibody was added (untreated).
  • Assay medium was used to reach the final volume (200 pl) for the control wells. Assay plates were centrifuged for 1 min at 350 g and incubated for 4 days at 37°C in a humidified CO2 incubator.
  • 50 pl (0.06 Mio) FarRed-labeled MOLP-2 and 50 pl (0.06 Mio) CFSE- labeled PBMCs were plated per well in 96-well round bottom plates (TPP, # 92097) resulting in a 1 : 1 effector to target cell ratio.
  • 50 pl of different doses of FcRH5 x CD3 were added (final concentration range of 0.03 pM to 32 nM).
  • 50 pl of assay medium and to others 50 pl of a fixed concentration of 10 nM of BCMA-4-1BBL antigen binding molecules were added (final volume of 200 pl per well).
  • a control was plated, containing target and effector cells with 10 nM BCMA-4-1BBL alone.
  • a control with target and effector cells was prepared in which no antibody was added (untreated).
  • Assay medium was used to reach the final volume (200 pl) for the control wells. Assay plates were centrifuged for 1 min at 350 g and then incubated for 4 days at 37°C in a humidified CO2 incubator.
  • FACS antibody mix (BUV737 anti-human CD4, clone SK3 from BD Biosciences, BV785 anti-human CD8, clone SKI, BV605 anti-human CD25, clone BC96, PE anti-human CD137, clone 4B4-1, PE/Dazzle594 anti-human CD3, clone OKT3, all but antihuman CD4 from BioLegend and pre-diluted in FACS Buffer) were added per well and cells were incubated for 30 minutes at 4°C in the dark.
  • FACS antibody mix (BUV737 anti-human CD4, clone SK3 from BD Biosciences, BV785 anti-human CD8, clone SKI, BV605 anti-human CD25, clone BC96, PE anti-human CD137, clone 4B4-1, PE/Dazzle594 anti-human CD3, clone OKT3, all but antihuman CD4 from BioLegend and pre-diluted in FACS Buffer
  • FSC-A/SSC-A In order to determine tumor cell lysis of MOLP-2 cells, a pre-gate in FSC-A/SSC-A channel was set to include the larger tumor cells and exclude lymphocytes as well as counting beads. Next was gated for singlets (FSC-H, FSC-A) and from these for FarRed positive/CD3 negative cells. Then Zombie UV positive, dead cells were gated. The dead cell count per pl was calculated by dividing the cell count from this gate with the bead count (separate gate in FSC-A/SSC-A) multiplied by the counting bead concentration.
  • Table 19 summarizes the ECso values, as well as Emax values derived from the data shown in Fig. 5A as well as results obtained with 1-3 additional donors. ECso values were calculated using GraphPadPrism6.
  • Table 19 ECso values (nM) and Efficacy of CD25 upregulation on CD8 T cells
  • the functional activity of the bispecific BCMA-4-1BBL molecules P1AG7397 and P1AG7400 was tested in combination with an anti-CD3 IgG as the first signal provider and in presence of CHO transfectants expressing either the wildtype or mutated forms of human BCMA (see also Example 3, binding to transfectants).
  • both BCMA-4-1BBL molecules display a similar concentration-dependent boosting of T cell activation on top of the CD3 IgG-mediated T cell activation (as illustrated by the upregulation of CD25 on CD8 T cells) in presence of either the mutated or the wildtype BCMA expressed on CHO transfectants ( Figures 5C to 5H, Table 19A).
  • the difference in the maximal activity for the wt versus the mutated BCMA transfectants is due to different expression levels of the human BCMA wt and variants on the transfectants. This data supports the broader use of BCMA-4- 1BBL also in patients harboring one of the tested BCMA point mutations without expecting any significant loss of activity.
  • Table 19A ECso values (nM) for T cell activation as measured by flow cytometry and detection of CD25 on CD8 T cells
  • the therapeutic efficacy of the bispecific BCMA-4-1BBL antigen binding molecules was tested in combination therapy with GPRC5D-TCB in heparinized primary MM patient bone marrow aspirate (BMA) samples obtained within the first 48 hours after extraction.
  • MM PCs MM plasma cells
  • a fixed concentration of a GPRC5D-CD3 bispecific molecule GPRC5D TCB, 1 or 10 nM as indicated
  • a TCB isotype respectively an untargeted 4-1BBL molecule was added.
  • Sterile PBS was added up to 1 mL.
  • Cells were centrifuged at 540 g for 5 min and erythrocytes were lysed for 15 minutes according to standard methods. Cells were centrifuged at 800 g for 10 minutes, washed with sterile PBS once and incubated at room temperature for 20 minutes with maleimide to stain dead versus living cells. Cells were washed with 12 ml of PBS, including 0.09% of NaN? and 0.5 % of BSA to remove unbound maleimide. Thereafter, cell pellets were resuspended in 500 pL PBS and filtered through 5 ml polystyrene Round-bottom tubes with cell-strainer cap to discard cell clots and remove potential membrane aggregates.
  • Table 20 Antibody combination used for the analysis of pre-treatment sample
  • Table 21 Antibody combination used to determine MM-PC lysis and effector cell activation
  • BCMA-4-1BBL antigen binding molecules was tested in combination therapy with GPRC5D-TCB using frozen and thawed primary MM bone marrow mononuclear cells (BMMNCs) as described below.
  • StemSpan SFEMII StemSpan SFEMII (StemCell) medium, including 20 % human serum, 55 M P-mercaptoethanol (Gibco cat# 11528926) and 100 U/ml penicillin and 100 pg/ml streptomycin (Gibco, lOOx stock).
  • 3 Mio cells were plated per well of a 12-well-plate, including 100 ng/mLof recombinant human IL-6 and stored in the incubator at 37°C, 5 % CO2 for 24 hours.
  • Samples were washed twice with sterile PBS and stained as follows: First, a live/dead staining was performed for 20 minutes at room temperature in the dark, using a NIR dye (ThermoFisher). After one washing step, human TruStain Fcx Blocking was added in FACS buffer (PBS with 2% Fetal Bovine Serum, 1% 0.5 M EDTA pH 8, 0.25% Na ? Sodium azide) and cells were incubated for another 10 minutes at room temperature (RT) in the dark prior to addition of the respective antibody mix (see Table 25).
  • FACS buffer PBS with 2% Fetal Bovine Serum, 1% 0.5 M EDTA pH 8, 0.25% Na ? Sodium azide
  • Table 23 Percent of tumor cell lysis, respective Up-regulation of the activation marker CD25 or the degranulation marker CD107a on CD8 + and CD4 + T cells upon incubation of primary MM BM aspirate samples with the indicated molecules for 96 hours, as assessed by flow cytometry This could be demonstrated as well with another primary MM patient BM aspirate sample, as depicted in Figures 7A to 7E and Table 24.
  • boosting of TCB-mediated lysis of primary malignant MM plasma cells or T cell activation could be observed in presence of 4.4 nM and higher concentrations of the BCMA-4-1BBL molecules Pl AG7409 and Pl AG7400, but no significant lysis could be observed in presence of the untargeted 4-1BBL at concentrations of up to even 40 and 120 nM.
  • Table 24 Percent of tumor cell lysis, respective Up-regulation of the activation marker CD25 on CD8 + and CD4 + T cells upon incubation of primary MM BM aspirate samples with the indicated molecules for 96 hours, as assessed by flow cytometry
  • Table 25 Percent of tumor cell lysis, respective Up-regulation of the activation marker CD25 on CD8 + and CD4 + T cells upon incubation of primary MM BM aspirate samples with the indicated molecules for 96 hours, as assessed by flow cytometry
  • Table 26 Increased lysis of primary malignant MM plasma cells upon incubation of primary MM BM MNCs with BCMA-4-1BBL (P1AG7400) for 96 hours, as assessed by flow cytometry
  • Human NCI-H929 cells obtained from Roche Nutley were cultured in RPMI1640 high glucose medium containing 10% FCS, 2 mM L-Glutamine, 10 mM HEPES and 1 mM Sodiumpyruvate (37 °C at 5 % CO2).
  • 50 microliters cell suspension 2.5 xlO 6 cells
  • 50 pl Matrigel subcutaneously in the right flank of anaesthetized, humanized NSG mice.
  • Mouse model Humanized NSG mice were provided by Jackson Laboratories, Sacramento USA. For engraftment, animals were irradiated (140cGy) and injected with CD34 + cord blood cells (9xl0 4 cells) from healthy donors (hematopoietic stem cells; HSC). After arrival animals were maintained for one week to get accustomed to new environment and for observation. Mice were maintained under specific pathogen-free conditions with daily cycles of 12 h light /12 h darkness according to committed guidelines (GV-Solas; Felasa; TierschG). Continuous health monitoring was carried out on a regular basis. Experimental study protocol was reviewed and approved by the local government (ROB-55.2-2532. Vet_03-20-170).
  • Pl AG7400 was tested in different doses (40, 4 and 0.4 mg/kg) in combination with GPRC5D x CD3 (0.05 mg/kg Pl AE6625) and compared to the GPRC5D x CD3 monotherapy.
  • P1AG7400 was injected 24 hours after GPRC5D x CD3.
  • the GPRC5D x CD3 monotherapy induces strong tumor growth inhibition in the NCI-H929 model ( Figures 11A to 11F). However, tumors start to relapse after the 4th treatment cycle (Table 29). All three doses of Pl AG7400 (40 and 10 mg/kg) inhibit the tumor regrowth.
  • day 64 5 7 and 4 responders were left in the Pl AG7400 40, 4 and 0.4 mg/kg combination groups, respectively. In the GPRC5D x CD3 monotherapy group no responders were left.
  • mice carrying the human FcRn instead of the mouse FcRn are considered more predictive for the clearance in human than in wild-type mice (C57/B16).
  • Serum samples were analyzed using an immunoassay with anti-human FCpan (CH2) or kCH capture and detection reagents. As shown in Figure 12 and Table 30, all tested BCMA- 4-1BBL antigen binding molecules have a similar plasma concentration-time profiles and clearance values ranging between 4 to 7 mL/kg/day in these mouse strains.
  • CH2 anti-human FCpan
  • kCH capture and detection reagents As shown in Figure 12 and Table 30, all tested BCMA- 4-1BBL antigen binding molecules have a similar plasma concentration-time profiles and clearance values ranging between 4 to 7 mL/kg/day in these mouse strains.
  • the Cell Microarray Technology (Charles River Laboratories) was used to screen for potential off-target binding interactions.
  • BCMA-4-1BBL agonistic antigen binding molecules were screened for binding against fixed HEK293 cells expressing 6019 individual full-length human plasma membrane proteins and cell surface-tethered human secreted proteins, as well as a further 397 human heterodimers. Fluorescent images of the spotted cells were analyzed using ImageQuant software (GE healthcare, Version 8.2).
  • Table 31 reports the results of the screen as strong, medium, weak or no interaction after visual inspection of the spots intensity.
  • MAPPs Major histocompatibility complex-II (MHC-II)-Associated Peptide Proteomics (MAPPs) is a mass spectrometry-based approach to identify and relatively quantitate naturally processed and presented MHC-II-associated peptides that can potentially activate T cells and contribute to the immunogenicity of a drug.
  • PBMCs Peripheral blood mononuclear cells
  • Ficoll-Paque PLUS GE Healthcare Europe GmbH, Glattbrugg, Switzerland
  • Monocytes were isolated by positive immunoselection using anti-CD14-coated microbeads and a magnetic separator (MACS, Miltenyi Biotech, Bergisch Gladbach, Germany).
  • CD14 + cells were then cultured at a concentration of 0.3 x 10 6 cells/mL in 100mm ultra-low attachment culture dishes (Coming Inc., Corning, NY, USA) in serum-free Cellgro medium containing 1% GlutaMAX, 1% penicillin/streptomycin.
  • Monocytes were differentiated into immature DCs with 50 ng/mL of GM-CSF and 5 ng/mL of IL-4 for 5 days at 37 °C with 5% CO2 before being challenged with a test protein at 50 pg/mL in the presence of 1 pg/mL of lipopolysaccharide (LPS) from Salmonella abortus equi (Sigma-Aldrich Chemie GmbH, Buchs, Switzerland) for 24 h.
  • LPS lipopolysaccharide
  • Mature DCs were harvested, washed with phosphate-buffered saline (PBS) and the cell pellets were frozen at -80 °C prior to subsequent immunoprecipitation.
  • PBS phosphate-buffered saline
  • HLA-DR-Presented Peptides Cell pellets were lysed in 20 mM Tris-buffer solution pH 7.8 containing 1% (v/v) Triton X-100 and protease inhibitors (Roche Diagnostics GmbH, Mannheim, Germany) for 1 h at 4 °C on a ThermoMixer at 1100 rpm.
  • the HLA-DR immune complexes were isolated by immunoprecipitation using biotin-conjugated anti-human HLA-DR antibodies (clone L243, RayBiotech). Lysates were incubated with the antibody on a rotator overnight at 4°C.
  • MHC-II peptide preparations obtained from about 3 x 10 6 human monocyte-derived DCs (moDCs) per sample were separated on a nanocapillary liquid chromatography system (UltiMate 3000 RSLC, Thermo Scientific, CA, USA) using self-packed fused-silica C18 reversed phase column (75 pm i.d. x 170 mm, ReproSil-Pur C18-AQ, 3 pm, Dr.
  • DataMAPPs is a Roche-created data analysis tool to help visualising otherwise complex mass spectrometry-derived data in the form of a heat map.
  • the program is publicly available at https://www.R-project.org/ and can be executed with a standard R installation. Please see reference (Steiner et al. 2020) for an extensive description of the package.
  • DataMAPPs is invoked after processing the LC-MS/MS data with the PEAKS software and exporting results in a suitable tabular format.
  • the dataMAPPs processing pipeline consists of (1) data import and consistency check: sample annotation and peptide quantification (PEAKS output) files are read into memory and checked for consistency.
  • Cutoffs can be modified by the user after inspecting a collection of QC plots, which allows for a suitable, data set-specific processing while being able to rerun the procedure in a reproducible way; (3) data normalisation: peptide abundance (based on peak area) is normalised based on an adjusted version of the GRSN (global rank-invariant set normalisation) procedure. (4) replicate aggregation: technical replicates (i.e. samples run for the same donor, same treatment, same dose) can be averaged to retain information on all peptides that were detected in at least one of the replicates; (5) peptide mapping: antibody-associated peptides are mapped on the tested biologic’s protein amino acid sequences.
  • peptides with neighbouring amino acid positions are binned to distinct epitope clusters (hotspots), whose abundance reflects the summed intensities of each of the constitutive MHC-II peptides;
  • data export and visualisation the dataMAPPs workflow contains standard functionalities to generate several heatmap plots (epitope cluster or individual peptide level, per antibody or a global experiment summary) for a quick visualisation and comparison of the results
  • Pl AG7422 revealed one binding cluster which contains any non-germline residues. In total 3/10 donors (35%) presented a potential immunogenic T cell epitope that could contribute to the immunogenicity of the compound.
  • Pl AG7422 revealed two binding clusters. Among them, two clusters (Cl and C2) contained non-germline residues with frequencies of 1/10 and 3/10, respectively. In total 4/10 donors (40%) presented a potential immunogenic T cell epitope that could contribute to the immunogenicity of the compound.
  • T cell activation is an important part of the immune response to therapeutic proteins and is usually required for the development of anti -drug antibodies in the clinic.
  • the DC-T cell assay was used to assess the capacity of four BCMA-4-1BBL antigen binding molecules: Pl AG7409, P1AG7400, P1AG7397 and P1AG7422, to induce CD4 + T cells upon presentation of T cell epitopes by APCs.
  • KLH Keyhole limpet haemocyanin
  • Avastin® bevacizumab
  • Monocytes were isolated from frozen PBMC samples by magnetic bead selection and differentiated into immature DC (iDC) using GM-CSF and IL-4. iDC were then harvested, washed and loaded with each individual test protein/peptide for 4 hours at 37°C. A DC maturation cocktail containing TNFa and IL-ip was then added for a further 40-42 hours to activate/mature the DC (mDC).
  • the expression of key DC surface markers (CD11c, CD14, CD40, CD80, CD83, CD86, CD209 and HLA-DR) at both the immature and mature stage were assessed by flow cytometry to ensure the DC were activated prior to T cell interaction.
  • the mDCs were then co-cultured with autologous CD4 + T cells (isolated by magnetic bead selection) for 6 days at 37°C, 5% CO2 in a humidified atmosphere.
  • autologous monocytes were isolated from PBMC using magnetic bead selection and loaded with the selected protein/peptide that were initially used to load the DC.
  • the monocytes were added to anti-ZFNy pre-coated FluoroSpot plates (Mabtech) along with the corresponding DC:CD4 co-culture in quadruplicate.
  • the FluoroSpot plates were incubated for 40-42 hours at 37°C, 5% CO2 in a humidified atmosphere. After incubation the FluoroSpot plates were developed using an in-house procedure and the spotforming cells (SFC) per well assessed for each cytokine in each test condition.
  • SFC spotforming cells
  • Data analysis Data management and statistical analysis has been performed in the R programming language (https://www.R-project.org/, v. 3.6.1). Data are transformed to a log2 scale and a Generalized linear model (GLM) is applied to quantify SI (fold change and 95% CI). Adjustments are applied to the dataset (exponential type of heteroscedasticity adjusted, gaussian noise injection at low end of SFU scale, linear regression and extrapolation of each SI to a blank value of 0) and QC plot are generated (DC differentiation markers, reproducibility on compound and donor level, relative stimulation of donors).
  • GLM Generalized linear model
  • the Stimulation Index is calculated for each test condition in each donor (ratio between SFU/well and the matched blank). A positive donor response is counted if at least 2-fold SI change is established with p ⁇ 0.05 (non-adjusted p- value from GLM). The number of positive donor responses to a treatment within the 30 healthy donor cohort gives the response rate relative to this treatment. Results: The DC used in this assay were of high quality and expressed high levels of the T cell co-stimulatory molecules required for the activation of T cells.
  • BCMA-4-1BBL antigen binding molecules Pl AG7400 and Pl AG739 were associated with a low risk of sequence-related immunogenicity for CD4 + T cell response (below the threshold of 10% as described in Siegel et al, Pharmaceutics 2022, 14(12), 2672), whereas P1AG740 and P1AG7422 showed an incidence of T-cell activation (IFN-y release) above the 10% threshold.
  • BCMA-4- 1BBL antigen binding molecules can be ranked as follows, from the lowest risk of immunogenicity to the highest risk: Pl AG7400, Pl AG7397, Pl AG7409 and Pl AG7422.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne de nouveaux anticorps humanisés qui se lient à l'antigène de maturation des lymphocytes B (BCMA), et des molécules de liaison à l'antigène immunostimulatrices compromettant ces anticorps BCMA, en particulier des molécules de liaison à l'antigène contenant un trimère 4-1 BBL ciblant BCMA, des procédés pour leur production, ainsi que leur utilisation dans le traitement du cancer.
EP24730639.2A 2023-06-01 2024-05-29 Molécules de liaison à l'antigène immunostimulatrices se liant spécifiquement à bcma Pending EP4720121A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP23176584 2023-06-01
EP23189804 2023-08-04
PCT/EP2024/064692 WO2024246086A1 (fr) 2023-06-01 2024-05-29 Molécules de liaison à l'antigène immunostimulatrices se liant spécifiquement à bcma

Publications (1)

Publication Number Publication Date
EP4720121A1 true EP4720121A1 (fr) 2026-04-08

Family

ID=91375792

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24730639.2A Pending EP4720121A1 (fr) 2023-06-01 2024-05-29 Molécules de liaison à l'antigène immunostimulatrices se liant spécifiquement à bcma

Country Status (6)

Country Link
EP (1) EP4720121A1 (fr)
JP (1) JP2026519560A (fr)
CN (1) CN121219321A (fr)
AR (1) AR132805A1 (fr)
TW (1) TW202502811A (fr)
WO (1) WO2024246086A1 (fr)

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2808353C2 (de) 1977-04-18 1984-01-19 Hitachi Metals, Ltd., Tokyo Ohrring
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0590058B1 (fr) 1991-06-14 2003-11-26 Genentech, Inc. ANTICORP HUMANISE specifique pour heregulin
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
CA2372813A1 (fr) 1992-02-06 1993-08-19 L.L. Houston Proteine fixatrice biosynthetique pour marqueur du cancer
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
CA2307166A1 (fr) 1997-10-31 1999-05-14 Genentech, Inc. Compositions renfermant des glycoformes de glycoproteine et methodes afferentes
WO1999029888A1 (fr) 1997-12-05 1999-06-17 The Scripps Research Institute Humanisation d'anticorps murins
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
EP1332209B1 (fr) 2000-09-08 2009-11-11 Universität Zürich Groupes de proteines a domaines de repetition comprenant des modules de repetition
EP1423510A4 (fr) 2001-08-03 2005-06-01 Glycart Biotechnology Ag Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
CA2531238C (fr) 2003-07-04 2015-02-24 Affibody Ab Polypeptides presentant une affinite de liaison pour le recepteur 2 du facteur de croissance epidermique humain (her2)
WO2005019255A1 (fr) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteines de la lipocaline lacrymale
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
BRPI0417302A (pt) 2003-12-05 2007-03-06 Compound Therapeutics Inc inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
WO2005100402A1 (fr) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anticorps anti-p-selectine
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
BRPI0607315B1 (pt) 2005-02-07 2022-05-17 Roche Glycart Ag Molécula de ligação ao antígeno anti-egfr humanizada e seus usos, composição farmacêutica, e método para detectar a presença de egfr em uma amostra
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
EP1958957A1 (fr) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprenant un partie caractéristique des protéines appellées "Knottins"
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
EP3663318A1 (fr) 2008-01-07 2020-06-10 Amgen Inc. Procédé de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
PE20171512A1 (es) 2010-08-13 2017-10-20 Roche Glycart Ag Anticuerpos anti-fap
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
EP2714737A1 (fr) 2011-05-27 2014-04-09 Glaxo Group Limited Protéines de liaison à bcma (cd269/tnfrsf17)
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
AR095374A1 (es) * 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
JP6829194B2 (ja) 2014-10-24 2021-02-10 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｖｈ−ｖｌドメイン間角度に基づく抗体ヒト化の方法
US10323094B2 (en) 2015-06-16 2019-06-18 Genentech, Inc. Humanized and affinity matured antibodies to FcRH5 and methods of use
CN118580364A (zh) * 2019-11-06 2024-09-03 西雅图免疫公司 制导和导航控制蛋白及其制备和使用方法
CN114829405B (zh) 2019-12-10 2025-07-18 爱必乐生物公司 抗bcma/抗4-1bb双特异性抗体及其用途
WO2023088889A1 (fr) * 2021-11-16 2023-05-25 Apogenix Ag Ligand cd137

Also Published As

Publication number Publication date
CN121219321A (zh) 2025-12-26
JP2026519560A (ja) 2026-06-16
AR132805A1 (es) 2025-07-30
WO2024246086A1 (fr) 2024-12-05
TW202502811A (zh) 2025-01-16

Similar Documents

Publication Publication Date Title
US12565530B2 (en) Combination therapy with targeted 4-1BB (CD137) agonists/anti-FAP binding domain and anti-CEA/anti-CD3 bispecific antibody
US12240911B2 (en) Bispecific antibodies specific for OX40
EP3359568B1 (fr) Anticorps bispécifiques avec tétravalence pour un récepteur de tnf costimulant
US20200223925A1 (en) Tumor-targeted superagonistic cd28 antigen binding molecules
EP3898682A1 (fr) Molécules de liaison à l'antigène cd28 agonistes de ciblage de tumeurs
WO2021198333A1 (fr) Molécules bispécifiques de liaison à l'antigène ciblant ox40 et fap
WO2019086500A2 (fr) Anticorps 2 + 1 bispécifiques (contorsbodies)
EP2961773B1 (fr) Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t
EP4172203A1 (fr) Molécules bispécifiques de liaison à l'antigène anti-cd3/anti-cd28
EP3765489A1 (fr) Combinaison thérapeutique d'agonistes de 4-1 bb avec des anticorps anti-cd20
WO2023117834A1 (fr) Anticorps anti-ltbr agonistes et anticorps bispécifiques comprenant ceux-ci
EP3601346A1 (fr) Molécule bispécifique de liaison à l'antigène pour un récepteur de co-stimulation du tnf
WO2020260326A1 (fr) Nouveaux anticorps anti-icos et molécules de liaison à un antigène ciblant les tumeurs les comprenant
WO2022243261A1 (fr) Molécules de liaison à l'antigène cd40 agonistes ciblant cea
WO2024246086A1 (fr) Molécules de liaison à l'antigène immunostimulatrices se liant spécifiquement à bcma
WO2024246083A1 (fr) Anticorps bispécifiques ciblant bcma et cd28
HK40129589A (en) Bispecific antibodies targeting bcma and cd28
HK40128377A (en) Immunostimulatory antigen binding molecules that specifically bind to bcma
HK40059020A (en) Tumor-targeted superagonistic cd28 antigen binding molecules

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260102

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR